<?xml version="1.0"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2014//EN" "http://www.ncbi.nlm.nih.gov/corehtml/query/DTD/pubmed_140101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25142580</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1098-5514</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of virology</Title>
                <ISOAbbreviation>J. Virol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Recombinant AAV utilizes cell-specific infectious entry mechanisms.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">JVI.01971-14</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Understanding the entry and trafficking mechanism(s) of rAAV into host cells can lead to evolution in capsid and vector design and delivery methods, resulting in enhanced transduction and therapeutic gene expression. Variability of findings regarding the early entry pathway of rAAV supports the possibility that rAAV, like other viruses, can utilize more than one infectious entry pathway. We tested whether inhibition of macropinocytosis impacted rAAV transduction of HeLa cells as compared to hepatocellular carcinoma cell lines. We found that macropinocytosis inhibitor cytochalasin-D blocked rAAV transduction of HeLa cells (&gt;2-fold), but enhanced (10-fold) transduction in HepG2 and Huh7 lines. Similar results were obtained with another macropinocytosis inhibitor 5-(N-Ethyl-N-isopropyl) amiloride (EIPA). The augmented transduction was neither due to viral binding nor promoter activity, affected multiple rAAV serotypes (rAAV2, rAAV2-R585E, and rAAV8), and influenced both single stranded and self-complementary virions to comparable extents. Follow-up studies using CDC42 inhibitor ML141 and p21-activated kinase 1 (PAK1) siRNA knockdown also resulted in enhanced HepG2 transduction. Microscopy revealed that macropinocytosis inhibition correlated with expedited nuclear entry of the rAAV virions into HepG2 cells. Enhancement of hepatocellular rAAV transduction extended to the mouse liver in vivo (4-fold enhancement), but inversely blocked heart tissue transduction (13-fold). This evidence of host cell-specific rAAV entry pathways confers a potent means for controlling and enhancing vector delivery, and could help unify the divergent accounts of rAAV cellular entry mechanisms.</AbstractText>
                <AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">There is a recognized need for improved rAAV vector targeting strategies that result in delivery of fewer total particles, averting untoward toxicity and/or an immune response against the vector. A critical step in rAAV transduction is entry and early trafficking through the host cellular machinery - the mechanisms of which are under continued study. However, should the early entry and trafficking mechanisms of rAAV differ across virus serotype or be dependent on host cell environment, this could expand our ability to target particular cells and tissue for selective transduction. Thus the observation that inhibiting macropinocytosis leads to cell-specific enhancement or inhibition of rAAV transduction that extends to the organismic level exposes a new means of modulating vector targeting.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Weinberg</LastName>
                    <ForeName>Marc S</ForeName>
                    <Initials>MS</Initials>
                    <Affiliation>Gene Therapy Center.</Affiliation>
                </Author>
                <Author>
                    <LastName>Nicolson</LastName>
                    <ForeName>Sarah</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Gene Therapy Center Department of Pharmacology.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bhatt</LastName>
                    <ForeName>Aadra P</ForeName>
                    <Initials>AP</Initials>
                    <Affiliation>Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, North Carolina, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>McLendon</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Gene Therapy Center.</Affiliation>
                </Author>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>Chengwen</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Gene Therapy Center.</Affiliation>
                </Author>
                <Author>
                    <LastName>Samulski</LastName>
                    <ForeName>R Jude</ForeName>
                    <Initials>RJ</Initials>
                    <Affiliation>Gene Therapy Center Department of Pharmacology rjs@med.unc.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Virol</MedlineTA>
            <NlmUniqueID>0113724</NlmUniqueID>
            <ISSNLinking>0022-538X</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">JVI.01971-14</ArticleId>
            <ArticleId IdType="doi">10.1128/JVI.01971-14</ArticleId>
            <ArticleId IdType="pubmed">25142580</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25142552</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1365-2249</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical and experimental immunology</Title>
                <ISOAbbreviation>Clin. Exp. Immunol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Immunotherapy with B-cell epitopes ameliorates inflammatory responses in Balb/c mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1111/cei.12442</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Osmotin, a protein from pathogenesis related family (PR-5) has been identified as an allergen based on in silico and in vitro studies. In the present study, three B-cell epitopes of osmotin with single and double amino acid modifications were studied for immunotherapy in a murine model. The single modification peptides (P-1-1, P-2-1 and P-3-1) and double modification peptides (P-1-2, P-2-2 and P-3-2) showed significantly lower IgE binding with patients' sera as compared to osmotin (p&lt;0.01). These peptides showed reduced IgE binding as compared to the unmodified peptides (B-cell epitopes) P-1, P-2 and P-3. Among the modified peptides, four P-2-1, P-3-1, P-2-2 and P-3-2 showed significant reduction in IgE binding and were used for immunotherapy in mice. The sera of mice group treated with peptides showed significant increase in IgG2a level and a significant decrease in IgE and IgG1 levels (p&lt;0.05). The mice that received peptide immunotherapy showed a shift from a Th2 to Th1 type where IFN-??, IL-10 levels were elevated with significant increase in groups treated with peptides P-3-1 and P-3-2 (p&lt;0.05). There was reduction in the IL-4 and IL-5 levels in bronchoalveolar lavage fluid (BALF) in peptides treated mice groups. Total cell count and eosinophil count in BALF of the peptide treated groups was also reduced as compared to the PBS treated group. Lung histology showed significant reduction in cellular infiltrate in mice treated with P-2-2 and P-3-2 as compared to PBS. In conclusion, peptides P-2-2 and P-3-2 lowered inflammatory responses and induced Th1 response in mice.</AbstractText>
                <CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Sharma</LastName>
                    <ForeName>Prerna</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Allergy and Immunology Section, CSIR- Institute of Genomics and Integrative Biology, Delhi, India; Department of Biotechnology, University of Pune, Ganeshkhind, Pune., India.</Affiliation>
                </Author>
                <Author>
                    <LastName>Gaur</LastName>
                    <ForeName>Shailendra Nath</ForeName>
                    <Initials>SN</Initials>
                </Author>
                <Author>
                    <LastName>Arora</LastName>
                    <ForeName>Naveen</ForeName>
                    <Initials>N</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Clin Exp Immunol</MedlineTA>
            <NlmUniqueID>0057202</NlmUniqueID>
            <ISSNLinking>0009-9104</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Osmotin</Keyword>
            <Keyword MajorTopicYN="N">epitopes</Keyword>
            <Keyword MajorTopicYN="N">immunotherapy</Keyword>
            <Keyword MajorTopicYN="N">mice</Keyword>
            <Keyword MajorTopicYN="N">peptides</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cei.12442</ArticleId>
            <ArticleId IdType="pubmed">25142552</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25142524</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1742-5662</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>11</Volume>
                    <Issue>99</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Oct</Month>
                        <Day>6</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of the Royal Society, Interface / the Royal Society</Title>
                <ISOAbbreviation>J R Soc Interface</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Modelling biological behaviours with the unified modelling language: an immunological case study and critique.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1098/rsif.2014.0704</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">20140704</ELocationID>
            <Abstract>
                <AbstractText>We present a framework to assist the diagrammatic modelling of complex biological systems using the unified modelling language (UML). The framework comprises three levels of modelling, ranging in scope from the dynamics of individual model entities to system-level emergent properties. By way of an immunological case study of the mouse disease experimental autoimmune encephalomyelitis, we show how the framework can be used to produce models that capture and communicate the biological system, detailing how biological entities, interactions and behaviours lead to higher-level emergent properties observed in the real world. We demonstrate how the UML can be successfully applied within our framework, and provide a critique of UML's ability to capture concepts fundamental to immunology and biology more generally. We show how specialized, well-explained diagrams with less formal semantics can be used where no suitable UML formalism exists. We highlight UML's lack of expressive ability concerning cyclic feedbacks in cellular networks, and the compounding concurrency arising from huge numbers of stochastic, interacting agents. To compensate for this, we propose several additional relationships for expressing these concepts in UML's activity diagram. We also demonstrate the ambiguous nature of class diagrams when applied to complex biology, and question their utility in modelling such dynamic systems. Models created through our framework are non-executable, and expressly free of simulation implementation concerns. They are a valuable complement and precursor to simulation specifications and implementations, focusing purely on thoroughly exploring the biology, recording hypotheses and assumptions, and serve as a communication medium detailing exactly how a simulation relates to the real biology.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Read</LastName>
                    <ForeName>Mark</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Electronics, University of York, York YO10 5GW, UK mark.read@sydney.edu.au.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Andrews</LastName>
                    <ForeName>Paul S</ForeName>
                    <Initials>PS</Initials>
                    <Affiliation>Department of Computer Science, University of York, York YO10 5GW, UK.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Timmis</LastName>
                    <ForeName>Jon</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of Electronics, University of York, York YO10 5GW, UK.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kumar</LastName>
                    <ForeName>Vipin</ForeName>
                    <Initials>V</Initials>
                    <Affiliation>Torrey Pines Institute for Molecular Studies, San Diego, CA 92121, USA.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>J R Soc Interface</MedlineTA>
            <NlmUniqueID>101217269</NlmUniqueID>
            <ISSNLinking>1742-5662</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">computational biology</Keyword>
            <Keyword MajorTopicYN="N">diagrammatic modelling</Keyword>
            <Keyword MajorTopicYN="N">immunology</Keyword>
            <Keyword MajorTopicYN="N">modelling and simulation</Keyword>
            <Keyword MajorTopicYN="N">unified modelling language</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">rsif.2014.0704</ArticleId>
            <ArticleId IdType="doi">10.1098/rsif.2014.0704</ArticleId>
            <ArticleId IdType="pubmed">25142524</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25142466</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1477-9129</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Development (Cambridge, England)</Title>
                <ISOAbbreviation>Development</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Histone H3.3 regulates dynamic chromatin states during spermatogenesis.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">dev.106450</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The histone variant H3.3 is involved in diverse biological processes, including development, transcriptional memory and transcriptional reprogramming, as well as diseases, including most notably malignant brain tumors. Recently, we developed a knockout mouse model for the H3f3b gene, one of two genes encoding H3.3. Here, we show that targeted disruption of H3f3b results in a number of phenotypic abnormalities, including a reduction in H3.3 histone levels, leading to male infertility, as well as abnormal sperm and testes morphology. Additionally, null germ cell populations at specific stages in spermatogenesis, in particular spermatocytes and spermatogonia, exhibited increased rates of apoptosis. Disruption of H3f3b also altered histone post-translational modifications and gene expression in the testes, with the most prominent changes occurring at genes involved in spermatogenesis. Finally, H3f3b null testes also exhibited abnormal germ cell chromatin reorganization and reduced protamine incorporation. Taken together, our studies indicate a major role for H3.3 in spermatogenesis through regulation of chromatin dynamics.</AbstractText>
                <CopyrightInformation>?? 2014. Published by The Company of Biologists Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Yuen</LastName>
                    <ForeName>Benjamin T K</ForeName>
                    <Initials>BT</Initials>
                    <Affiliation>Department of Cell Biology and Human Anatomy, Shriners Hospital For Children Northern California, Sacramento, CA 95817, USA Genome Center, University of California Davis School of Medicine, Shriners Hospital For Children Northern California, Sacramento, CA 95817, USA Institute of Pediatric Regenerative Medicine, Shriners Hospital For Children Northern California, Sacramento, CA 95817, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bush</LastName>
                    <ForeName>Kelly M</ForeName>
                    <Initials>KM</Initials>
                    <Affiliation>Department of Cell Biology and Human Anatomy, Shriners Hospital For Children Northern California, Sacramento, CA 95817, USA Genome Center, University of California Davis School of Medicine, Shriners Hospital For Children Northern California, Sacramento, CA 95817, USA Institute of Pediatric Regenerative Medicine, Shriners Hospital For Children Northern California, Sacramento, CA 95817, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Barrilleaux</LastName>
                    <ForeName>Bonnie L</ForeName>
                    <Initials>BL</Initials>
                    <Affiliation>Department of Cell Biology and Human Anatomy, Shriners Hospital For Children Northern California, Sacramento, CA 95817, USA Genome Center, University of California Davis School of Medicine, Shriners Hospital For Children Northern California, Sacramento, CA 95817, USA Institute of Pediatric Regenerative Medicine, Shriners Hospital For Children Northern California, Sacramento, CA 95817, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Cotterman</LastName>
                    <ForeName>Rebecca</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Department of Cell Biology and Human Anatomy, Shriners Hospital For Children Northern California, Sacramento, CA 95817, USA Genome Center, University of California Davis School of Medicine, Shriners Hospital For Children Northern California, Sacramento, CA 95817, USA Institute of Pediatric Regenerative Medicine, Shriners Hospital For Children Northern California, Sacramento, CA 95817, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Knoepfler</LastName>
                    <ForeName>Paul S</ForeName>
                    <Initials>PS</Initials>
                    <Affiliation>Department of Cell Biology and Human Anatomy, Shriners Hospital For Children Northern California, Sacramento, CA 95817, USA Genome Center, University of California Davis School of Medicine, Shriners Hospital For Children Northern California, Sacramento, CA 95817, USA Institute of Pediatric Regenerative Medicine, Shriners Hospital For Children Northern California, Sacramento, CA 95817, USA knoepfler@ucdavis.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Development</MedlineTA>
            <NlmUniqueID>8701744</NlmUniqueID>
            <ISSNLinking>0950-1991</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">dev.106450</ArticleId>
            <ArticleId IdType="doi">10.1242/dev.106450</ArticleId>
            <ArticleId IdType="pubmed">25142466</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25142465</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1477-9129</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Development (Cambridge, England)</Title>
                <ISOAbbreviation>Development</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Prostaglandin D2 acts through the Dp2 receptor to influence male germ cell differentiation in the foetal mouse testis.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">dev.103408</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Through intercellular signalling, the somatic compartment of the foetal testis is able to program primordial germ cells to undergo spermatogenesis. Fibroblast growth factor 9 and several members of the transforming growth factor ?? superfamily are involved in this process in the foetal testis, counteracting the induction of meiosis by retinoic acid and activating germinal mitotic arrest. Here, using in vitro and in vivo approaches, we show that prostaglandin D2 (PGD2), which is produced through both L-Pgds and H-Pgds enzymatic activities in the somatic and germ cell compartments of the foetal testis, plays a role in mitotic arrest in male germ cells by activating the expression and nuclear localization of the CDK inhibitor p21(Cip1) and by repressing pluripotency markers. We show that PGD2 acts through its Dp2 receptor, at least in part through direct effects in germ cells, and contributes to the proper differentiation of male germ cells through the upregulation of the master gene Nanos2. Our data identify PGD2 signalling as an early pathway that acts in both paracrine and autocrine manners, and contributes to the differentiation of germ cells in the foetal testis.</AbstractText>
                <CopyrightInformation>?? 2014. Published by The Company of Biologists Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Moniot</LastName>
                    <ForeName>Brigitte</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Genetic and Development department, Institute of Human Genetics, CNRS UPR1142, Montpellier 34094, Cedex 05, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ujjan</LastName>
                    <ForeName>Safdar</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Genetic and Development department, Institute of Human Genetics, CNRS UPR1142, Montpellier 34094, Cedex 05, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Champagne</LastName>
                    <ForeName>Julien</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Genetic and Development department, Institute of Human Genetics, CNRS UPR1142, Montpellier 34094, Cedex 05, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hirai</LastName>
                    <ForeName>Hiroyuki</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Department of Advanced Technology and Development, BML, Matoba, Kawagoe, Saitama 350-1101, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Aritake</LastName>
                    <ForeName>Kosuke</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Department of Molecular Behavioral Biology, Osaka Bioscience Institute, Osaka 565-0874, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Nagata</LastName>
                    <ForeName>Kinya</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Department of Advanced Technology and Development, BML, Matoba, Kawagoe, Saitama 350-1101, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Dubois</LastName>
                    <ForeName>Emeric</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Plateforme MGX, Functional Genomic Institute, CNRS UMR 5203 - INSERM U 661, Montpellier 34094, Cedex 05, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Nidelet</LastName>
                    <ForeName>Sabine</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Plateforme MGX, Functional Genomic Institute, CNRS UMR 5203 - INSERM U 661, Montpellier 34094, Cedex 05, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Nakamura</LastName>
                    <ForeName>Masataka</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Human Gene Sciences Center, Tokyo Medical and Dental University, Yushima, Bunkyo-ku, Tokyo 113-8510, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Urade</LastName>
                    <ForeName>Yoshihiro</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Molecular Behavioral Biology, Osaka Bioscience Institute, Osaka 565-0874, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Poulat</LastName>
                    <ForeName>Francis</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Genetic and Development department, Institute of Human Genetics, CNRS UPR1142, Montpellier 34094, Cedex 05, France francis.poulat@igh.cnrs.fr brigitte.boizet@igh.cnrs.fr.</Affiliation>
                </Author>
                <Author>
                    <LastName>Boizet-Bonhoure</LastName>
                    <ForeName>Brigitte</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Genetic and Development department, Institute of Human Genetics, CNRS UPR1142, Montpellier 34094, Cedex 05, France francis.poulat@igh.cnrs.fr brigitte.boizet@igh.cnrs.fr.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Development</MedlineTA>
            <NlmUniqueID>8701744</NlmUniqueID>
            <ISSNLinking>0950-1991</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">dev.103408</ArticleId>
            <ArticleId IdType="doi">10.1242/dev.103408</ArticleId>
            <ArticleId IdType="pubmed">25142465</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25142464</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1477-9129</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Development (Cambridge, England)</Title>
                <ISOAbbreviation>Development</ISOAbbreviation>
            </Journal>
            <ArticleTitle>SirT1 is required in the male germ cell for differentiation and fecundity in mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">dev.110627</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Sirtuins are NAD(+)-dependent deacylases that regulate numerous biological processes in response to the environment. SirT1 is the mammalian ortholog of yeast Sir2, and is involved in many metabolic pathways in somatic tissues. Whole body deletion of SirT1 alters reproductive function in oocytes and the testes, in part caused by defects in central neuro-endocrine control. To study the function of SirT1 specifically in the male germ line, we deleted this sirtuin in male germ cells and found that mutant mice had smaller testes, a delay in differentiation of pre-meiotic germ cells, decreased spermatozoa number, an increased proportion of abnormal spermatozoa and reduced fertility. At the molecular level, mutants do not have the characteristic increase in acetylation of histone H4 at residues K5, K8 and K12 during spermiogenesis and demonstrate corresponding defects in the histone to protamine transition. Our findings thus reveal a germ cell-autonomous role of SirT1 in spermatogenesis.</AbstractText>
                <CopyrightInformation>?? 2014. Published by The Company of Biologists Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Bell</LastName>
                    <ForeName>Eric L</ForeName>
                    <Initials>EL</Initials>
                    <Affiliation>Massachusetts Institute of Technology, Department of Biology, Glenn Laboratory for the Science of Aging, Cambridge, MA 02139, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Nagamori</LastName>
                    <ForeName>Ippei</ForeName>
                    <Initials>I</Initials>
                    <Affiliation>Center for Epigenetics and Metabolism, Department of Biological Chemistry, University of California, Irvine, CA 92697, USA Osaka University, Graduate School of Medicine, Osaka 565-0871, Japan.</Affiliation>
                </Author>
                <Author>
                    <LastName>Williams</LastName>
                    <ForeName>Eric O</ForeName>
                    <Initials>EO</Initials>
                    <Affiliation>Massachusetts Institute of Technology, Department of Biology, Glenn Laboratory for the Science of Aging, Cambridge, MA 02139, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Del Rosario</LastName>
                    <ForeName>Amanda M</ForeName>
                    <Initials>AM</Initials>
                    <Affiliation>Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bryson</LastName>
                    <ForeName>Bryan D</ForeName>
                    <Initials>BD</Initials>
                    <Affiliation>Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA Massachusettes Institute of Technology, Department of Biological Engineering, Cambridge, MA 02139, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Watson</LastName>
                    <ForeName>Nicki</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>W. M. Keck Microscopy Facility Whitehead Institute, Cambridge, MA 02139, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>White</LastName>
                    <ForeName>Forest M</ForeName>
                    <Initials>FM</Initials>
                    <Affiliation>Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA Massachusettes Institute of Technology, Department of Biological Engineering, Cambridge, MA 02139, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Sassone-Corsi</LastName>
                    <ForeName>Paolo</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Center for Epigenetics and Metabolism, Department of Biological Chemistry, University of California, Irvine, CA 92697, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Guarente</LastName>
                    <ForeName>Leonard</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Massachusetts Institute of Technology, Department of Biology, Glenn Laboratory for the Science of Aging, Cambridge, MA 02139, USA Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA leng@mit.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Development</MedlineTA>
            <NlmUniqueID>8701744</NlmUniqueID>
            <ISSNLinking>0950-1991</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">dev.110627</ArticleId>
            <ArticleId IdType="doi">10.1242/dev.110627</ArticleId>
            <ArticleId IdType="pubmed">25142464</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25142463</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1477-9129</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>19</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Development (Cambridge, England)</Title>
                <ISOAbbreviation>Development</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Tbx1 controls the morphogenesis of pharyngeal pouch epithelia through mesodermal Wnt11r and Fgf8a.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">dev.111740</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The pharyngeal pouches are a segmental series of epithelial structures that organize the embryonic vertebrate face. In mice and zebrafish that carry mutations in homologs of the DiGeorge syndrome gene TBX1, a lack of pouches correlates with severe craniofacial defects, yet how Tbx1 controls pouch development remains unclear. Using mutant and transgenic rescue experiments in zebrafish, we show that Tbx1 functions in the mesoderm to promote the morphogenesis of pouch-forming endoderm through wnt11r and fgf8a expression. Consistently, compound losses of wnt11r and fgf8a phenocopy tbx1 mutant pouch defects, and mesoderm-specific restoration of Wnt11r and Fgf8a rescues tbx1 mutant pouches. Time-lapse imaging further reveals that Fgf8a acts as a Wnt11r-dependent guidance cue for migrating pouch cells. We therefore propose a two-step model in which Tbx1 coordinates the Wnt-dependent epithelial destabilization of pouch-forming cells with their collective migration towards Fgf8a-expressing mesodermal guideposts.</AbstractText>
                <CopyrightInformation>?? 2014. Published by The Company of Biologists Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Choe</LastName>
                    <ForeName>Chong Pyo</ForeName>
                    <Initials>CP</Initials>
                    <Affiliation>Broad California Institute of Regenerative Medicine Center, Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Crump</LastName>
                    <ForeName>J Gage</ForeName>
                    <Initials>JG</Initials>
                    <Affiliation>Broad California Institute of Regenerative Medicine Center, Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA gcrump@usc.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Development</MedlineTA>
            <NlmUniqueID>8701744</NlmUniqueID>
            <ISSNLinking>0950-1991</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">dev.111740</ArticleId>
            <ArticleId IdType="doi">10.1242/dev.111740</ArticleId>
            <ArticleId IdType="pubmed">25142463</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25142413</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1521-4141</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>European journal of immunology</Title>
                <ISOAbbreviation>Eur. J. Immunol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Conditional ablation of NKp46(+) cells using a novel Ncr1(greenCre) mouse strain: NK cells are essential for protection against pulmonary B16 metastases.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1002/eji.201444643</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">To study gene functions specifically in NKp46+ cells we developed novel Cre mice allowing for conditional gene targeting in cells expressing Ncr1 (encoding NKp46). We generated transgenic Ncr1(greenCre) mice carrying an EGFPcre fusion under the control of a proximal Ncr1 promoter that faithfully directed EGFPcre expression to NKp46(+) cells from lymphoid and non-lymphoid tissues. This approach allowed for direct detection of Cre-expressing NKp46(+) cells via their GFP signature by flow cytometry and histology. Cre was functional as evidenced by the NKp46(+) cell-specific expression of RFP in Ncr1(greenCre) ROSA-RFP reporter mice. We generated Ncr1(greenCre) Il2rg(fl/fl) mice that lack NKp46(+) cells in an otherwise intact hematopoietic environment. Il2rg encodes the common gamma chain (??c ), which is an essential receptor subunit for cytokines (IL-2, -4, -7, -9, -15, and -21) that stimulate lymphocyte development and function. In Ncr1(greenCre) Il2rg(fl/fl) mice, NK cells are severely reduced and the few remaining NKp46(+) cells escaping ??c deletion failed to express GFP. Using this new NK cell-deficient model, we demonstrate that the homeostasis of NKp46(+) cells from all tissues (including the recently described intraepithelial ILC1 subset) requires Il2rg. Finally, Ncr1(greenCre) Il2rg(fl/fl) mice are unable to reject B16 lung metastases demonstrating the essential role of NKp46(+) cells in anti-melanoma immune responses. This article is protected by copyright. All rights reserved.</AbstractText>
                <CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Merzoug</LastName>
                    <ForeName>Leila Ben</ForeName>
                    <Initials>LB</Initials>
                    <Affiliation>Institut Pasteur, Unit?? d'Immunit?? Inn??e, D??partement d'Immunologie, Paris, France; Institut Pasteur, INSERM U668, Paris, France; Univ. Paris Diderot, Sorbonne Paris Cit??, Cellule Pasteur, Paris, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Marie</LastName>
                    <ForeName>Solenne</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author>
                    <LastName>Satoh-Takayama</LastName>
                    <ForeName>Naoko</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author>
                    <LastName>Lesjean</LastName>
                    <ForeName>Sarah</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author>
                    <LastName>Albanesi</LastName>
                    <ForeName>Marcello</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author>
                    <LastName>Luche</LastName>
                    <ForeName>Herv??</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author>
                    <LastName>Fehling</LastName>
                    <ForeName>Hans J??rg</ForeName>
                    <Initials>HJ</Initials>
                </Author>
                <Author>
                    <LastName>Di Santo</LastName>
                    <ForeName>James P</ForeName>
                    <Initials>JP</Initials>
                </Author>
                <Author>
                    <LastName>Vosshenrich</LastName>
                    <ForeName>Christian A J</ForeName>
                    <Initials>CA</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Eur J Immunol</MedlineTA>
            <NlmUniqueID>1273201</NlmUniqueID>
            <ISSNLinking>0014-2980</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Innate immunity</Keyword>
            <Keyword MajorTopicYN="N">NK cells</Keyword>
            <Keyword MajorTopicYN="N">NKp46+ cells</Keyword>
            <Keyword MajorTopicYN="N">Transgenic mouse model</Keyword>
            <Keyword MajorTopicYN="N">tumor immunology</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1002/eji.201444643</ArticleId>
            <ArticleId IdType="pubmed">25142413</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25142403</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1365-2249</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical and experimental immunology</Title>
                <ISOAbbreviation>Clin. Exp. Immunol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Impact of suppressing ROR??t in ameliorating central nervous system autoimmunity.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1111/cei.12441</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Multiple Sclerosis (MS) is an immune-mediated chronic CNS disease affecting over 400,000 people in the USA. Myelin-reactive CD4 T cells play critical roles in the formation of acute inflammatory lesions and disease progression in MS and experimental autoimmune encephalomyelitis (EAE), a well-defined mouse model for MS. Current MS therapies are only partially effective, making it necessary to develop more effective therapies that specifically target pathogenic myelin-specific CD4 T cells for MS treatment. While suppressing T-bet, the key transcription in Th1 cells, has been demonstrated to be beneficial in prevention and treatment of EAE, the therapeutic potential of ROR??t, the key transcription factor for Th17 cells, has not been well-characterized. In this study, we characterized the correlation between ROR??t expression and other factors affecting T cell encephalitogenicity and evaluated the therapeutic potential of targeting ROR??t by siRNA inhibition of ROR??t. Our data showed that ROR??t expression correlates with IL-17 production, but not with the encephalitogenicity of myelin-specific CD4 T cells. IL-23, a cytokine that enhances encephalitogenicity, does not enhance ROR??t expression significantly. Additionally, GM-CSF levels, which correlate with the encephalitogenicity of different myelin-specific CD4 T cell populations, do not correlate with ROR??t. More importantly, inhibiting ROR??t expression in myelin-specific CD4 T cells with a siRNA does not significantly reduce disease severity in adoptively transferred EAE. Thus, ROR??t is unlikely to be a more effective therapeutic target for ameliorating pathogenicity of encephalitogenic CD4 T cells.</AbstractText>
                <CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Yang</LastName>
                    <ForeName>Yuhong</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Winger</LastName>
                    <ForeName>Ryan</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author>
                    <LastName>Lee</LastName>
                    <ForeName>Priscilla W</ForeName>
                    <Initials>PW</Initials>
                </Author>
                <Author>
                    <LastName>Nuro-Gyina</LastName>
                    <ForeName>Patrick K</ForeName>
                    <Initials>PK</Initials>
                </Author>
                <Author>
                    <LastName>Minc</LastName>
                    <ForeName>Alexa</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author>
                    <LastName>Larson</LastName>
                    <ForeName>Michelle</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Yue</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author>
                    <LastName>Pei</LastName>
                    <ForeName>Wei</ForeName>
                    <Initials>W</Initials>
                </Author>
                <Author>
                    <LastName>Rieser</LastName>
                    <ForeName>Elizabeth</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author>
                    <LastName>Racke</LastName>
                    <ForeName>Michael K</ForeName>
                    <Initials>MK</Initials>
                </Author>
                <Author>
                    <LastName>Lovett-Racke</LastName>
                    <ForeName>Amy E</ForeName>
                    <Initials>AE</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Clin Exp Immunol</MedlineTA>
            <NlmUniqueID>0057202</NlmUniqueID>
            <ISSNLinking>0009-9104</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">EAE</Keyword>
            <Keyword MajorTopicYN="N">Multiple Sclerosis</Keyword>
            <Keyword MajorTopicYN="N">ROR??t</Keyword>
            <Keyword MajorTopicYN="N">T cell encephalitogenicity</Keyword>
            <Keyword MajorTopicYN="N">transcription factor</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cei.12441</ArticleId>
            <ArticleId IdType="pubmed">25142403</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25142379</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1558-6804</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Stem cell reviews</Title>
                <ISOAbbreviation>Stem Cell Rev</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Medaka Oct4 is Essential for Pluripotency in Blastula Formation and ES Cell Derivation.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The origin and evolution of molecular mechanisms underlying cellular pluripotency is a fundamental question in stem cell biology. The transcription factor Oct4 or Pou5f1 identified in mouse features pluripotency expression and activity in the inner cell mass and embryonic stem (ES) cells. Pou2 identified in zebrafish is the non-mammalian homolog prototype of mouse Oct4. The genes oct4 and pou2 have reportedly evolved by pou5 gene duplication in the common ancestor of vertebrates. Unlike mouse oct4, however, zebrafish pou2 lacks pluripotency expression and activity. Whether the presence of pluripotency expression and activity is specific for mammalian Oct4 or common to the ancestor of vertebrate Oct4 and Pou2 proteins has remained to be determined. Here we report that Oloct4, the medaka oct4/pou2, is essential for early embryogenesis and pluripotency maintenance. Oloct4 exists as a single copy gene and is orthologous to pou2 by sequence and chromosome synteny. Oloct4 expression occurs in early embryos, germ stem cells and ES cells like mouse oct4 but also in the brain and tail bud like zebrafish pou2. Importantly, OlOct4 depletion caused blastula lethality or blockage. We show that Oloct4 depletion abolishes ES cell derivation from midblastula embryos. Thus, Oloct4 has pluripotency expression and is essential for early embryogenesis and pluripotency maintenance. Our results demonstrate the conservation of pluripotency expression and activity in vertebrate Oct4 and Pou2 proteins. The finding that Oloct4 combines the features of mouse oct4 and zebrafish pou2 in expression and function suggests that Oloct4 might represent the ancestral prototype of vertebrate oct4 and pou2 genes.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Rong</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Department of Biological Sciences, National University of Singapore, 14 Science Drive 4, Singapore, 117543, Singapore.</Affiliation>
                </Author>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>Mingyou</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>Zhendong</ForeName>
                    <Initials>Z</Initials>
                </Author>
                <Author>
                    <LastName>Hong</LastName>
                    <ForeName>Ni</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author>
                    <LastName>Xu</LastName>
                    <ForeName>Hongyan</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author>
                    <LastName>Hong</LastName>
                    <ForeName>Yunhan</ForeName>
                    <Initials>Y</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Stem Cell Rev</MedlineTA>
            <NlmUniqueID>101255952</NlmUniqueID>
            <ISSNLinking>1550-8943</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12015-014-9523-2</ArticleId>
            <ArticleId IdType="pubmed">25142379</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25142335</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1471-2164</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>15</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>BMC genomics</Title>
                <ISOAbbreviation>BMC Genomics</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The genome of Eimeria falciformis - reduction and specialization in a single host apicomplexan parasite.</ArticleTitle>
            <Pagination>
                <MedlinePgn>696</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The phylum Apicomplexa comprises important unicellular human parasites such as Toxoplasma and Plasmodium. Eimeria is the largest and most diverse genus of apicomplexan parasites and some species of the genus are the causative agent of coccidiosis, a disease economically devastating in poultry. We report a complete genome sequence of the mouse parasite Eimeria falciformis. We assembled and annotated the genome sequence to study host-parasite interactions in this understudied genus in a model organism host.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The genome of E. falciformis is 44 Mb in size and contains 5,879 predicted protein coding genes. Comparative analysis of E. falciformis with Toxoplasma gondii shows an emergence and diversification of gene families associated with motility and invasion mainly at the level of the Coccidia. Many rhoptry kinases, among them important virulence factors in T. gondii, are absent from the E. falciformis genome. Surface antigens are divergent between Eimeria species. Comparisons with T. gondii showed differences between genes involved in metabolism, N-glycan and GPI-anchor synthesis. E. falciformis possesses a reduced set of transmembrane transporters and we suggest an altered mode of iron uptake in the genus Eimeria.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Reduced diversity of genes required for host-parasite interaction and transmembrane transport allow hypotheses on host adaptation and specialization of a single host parasite. The E. falciformis genome sequence sheds light on the evolution of the Coccidia and helps to identify determinants of host-parasite interaction critical for drug and vaccine development.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Heitlinger</LastName>
                    <ForeName>Emanuel</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author>
                    <LastName>Spork</LastName>
                    <ForeName>Simone</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author>
                    <LastName>Lucius</LastName>
                    <ForeName>Richard</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author>
                    <LastName>Dieterich</LastName>
                    <ForeName>Christoph</ForeName>
                    <Initials>C</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>BMC Genomics</MedlineTA>
            <NlmUniqueID>100965258</NlmUniqueID>
            <ISSNLinking>1471-2164</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>1</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">1471-2164-15-696</ArticleId>
            <ArticleId IdType="doi">10.1186/1471-2164-15-696</ArticleId>
            <ArticleId IdType="pubmed">25142335</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25142306</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1523-4681</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research</Title>
                <ISOAbbreviation>J. Bone Miner. Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Natural large-scale regeneration of rib cartilage in a mouse model.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1002/jbmr.2326</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The clinical need for methods to repair and regenerate large cartilage and bone lesions persists. One way to make new headway is to study skeletal regeneration when it occurs naturally. Cartilage repair is typically slow and incomplete. However, an exception to this observation can be found in the costal cartilages where complete repair has been reported in humans but the cellular and molecular mechanisms have not yet been characterized. In this study, we establish a novel animal model for cartilage repair using the mouse rib costal cartilage. We then use this model to test the hypothesis that the perichondrium, the dense connective tissue that surrounds the cartilage, is a tissue essential for repair. Our results show that full replacement of the resected cartilage occurs quickly (within 1-2 months) and properly differentiates, but that repair occurs only in the presence of the perichondrium. We then provide evidence that the rib perichondrium contains a special niche that houses chondrogenic progenitors that possess qualities particularly suited for mediating repair. Label-retaining cells can be found within the perichondrium that can give rise to new chondrocytes. Furthermore, the perichondrium proliferates and thickens during the healing period, and when ectopically placed can generate new cartilage. In conclusion, we have successfully established a model for hyaline cartilage repair in the mouse rib which should be useful for gaining a more detailed understanding of cartilage regeneration and ultimately for developing methods to improve cartilage and bone repair in other parts of the skeleton. ?? 2014 American Society for Bone and Mineral Research.</AbstractText>
                <CopyrightInformation>?? 2014 American Society for Bone and Mineral Research.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Srour</LastName>
                    <ForeName>Marissa K</ForeName>
                    <Initials>MK</Initials>
                    <Affiliation>Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, Keck School of Medicine, University of Southern California, 1425 San Pablo St., BCC 407, Los Angeles, CA 90033.</Affiliation>
                </Author>
                <Author>
                    <LastName>Fogel</LastName>
                    <ForeName>Jennifer L</ForeName>
                    <Initials>JL</Initials>
                </Author>
                <Author>
                    <LastName>Yamaguchi</LastName>
                    <ForeName>Kent T</ForeName>
                    <Initials>KT</Initials>
                </Author>
                <Author>
                    <LastName>Montgomery</LastName>
                    <ForeName>Aaron P</ForeName>
                    <Initials>AP</Initials>
                </Author>
                <Author>
                    <LastName>Izuhara</LastName>
                    <ForeName>Audrey K</ForeName>
                    <Initials>AK</Initials>
                </Author>
                <Author>
                    <LastName>Misakian</LastName>
                    <ForeName>Aaron L</ForeName>
                    <Initials>AL</Initials>
                </Author>
                <Author>
                    <LastName>Lam</LastName>
                    <ForeName>Stephanie</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author>
                    <LastName>Lakeland</LastName>
                    <ForeName>Daniel L</ForeName>
                    <Initials>DL</Initials>
                </Author>
                <Author>
                    <LastName>Urata</LastName>
                    <ForeName>Mark M</ForeName>
                    <Initials>MM</Initials>
                </Author>
                <Author>
                    <LastName>Lee</LastName>
                    <ForeName>Janice S</ForeName>
                    <Initials>JS</Initials>
                </Author>
                <Author>
                    <LastName>Mariani</LastName>
                    <ForeName>Francesca V</ForeName>
                    <Initials>FV</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Bone Miner Res</MedlineTA>
            <NlmUniqueID>8610640</NlmUniqueID>
            <ISSNLinking>0884-0431</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Cartilage repair</Keyword>
            <Keyword MajorTopicYN="N">chondroctyes</Keyword>
            <Keyword MajorTopicYN="N">chondrogenic progenitors</Keyword>
            <Keyword MajorTopicYN="N">perichondrium</Keyword>
            <Keyword MajorTopicYN="N">segmental defect</Keyword>
            <Keyword MajorTopicYN="N">stem cells</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>4</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jbmr.2326</ArticleId>
            <ArticleId IdType="pubmed">25142306</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25142300</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1521-4141</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>European journal of immunology</Title>
                <ISOAbbreviation>Eur. J. Immunol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>IL-15-dependent CD8(+) CD122(+) T cells ameliorate experimental autoimmune encephalomyelitis by modulating IL-17 production by CD4(+) T cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1002/eji.201444675</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Interleukin-15 (IL-15) is an inflammatory cytokine whose role in autoimmune diseases has not been fully elucidated. Th17 cells have been shown to play critical roles in experimental autoimmune encephalomyelitis (EAE) models. In this study, we demonstrate that blockade of IL-15 signaling by TM??-1 mAb treatment aggravated EAE severity. The key mechanism was not NK-cell depletion but depletion of CD8(+) CD122(+) T cells. Adoptive transfer of exogenous CD8(+) CD122(+) T cells to TM??-1-treated mice rescued animals from severe disease. Moreover, transfer of pre-activated CD8(+) CD122(+) T cells prevented EAE development and significantly reduced IL-17 secretion. Na??ve effector CD4(+) CD25(-) T cells cultured with either CD8(+) CD122(+) T cells from wild-type mice or IL-15 transgenic mice displayed lower frequencies of IL-17A production with lower amounts of IL-17 in the supernatants when compared with production by effector CD4(+) CD25(-) T cells cultured alone. Addition of a neutralizing antibody to IL-10 led to recovery of IL-17A production in Th17 cultures. Furthermore, co-culture of CD8(+) CD122(+) T cells with effector CD4(+) T cells inhibited their proliferation significantly, suggesting a regulatory function for IL-15 dependent CD8(+) CD122(+) T cells. Taken together, these observations suggest that IL-15, acting through CD8(+) CD122(+) T cells, has a negative regulatory role in reducing IL-17 production and Th17-mediated EAE inflammation. This article is protected by copyright. All rights reserved.</AbstractText>
                <CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Ping</LastName>
                    <ForeName>Yu</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bamford</LastName>
                    <ForeName>Richard</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author>
                    <LastName>Waldmann</LastName>
                    <ForeName>Thomas A</ForeName>
                    <Initials>TA</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Eur J Immunol</MedlineTA>
            <NlmUniqueID>1273201</NlmUniqueID>
            <ISSNLinking>0014-2980</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">CD8+CD122+ T cells</Keyword>
            <Keyword MajorTopicYN="N">Experimental autoimmune encephalomyelitis</Keyword>
            <Keyword MajorTopicYN="N">Interleukin-15</Keyword>
            <Keyword MajorTopicYN="N">Interleukin-17</Keyword>
            <Keyword MajorTopicYN="N">Multiple sclerosis</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1002/eji.201444675</ArticleId>
            <ArticleId IdType="pubmed">25142300</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25142285</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1365-2141</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>British journal of haematology</Title>
                <ISOAbbreviation>Br. J. Haematol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Stimulation of invariant natural killer T cells by ??-Galactosylceramide activates the JAK-STAT pathway in endothelial cells and reduces angiogenesis in the 5T33 multiple myeloma model.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1111/bjh.13092</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Tumour pathogenesis in multiple myeloma (MM) correlates with a high vascular index. Therefore, targeting angiogenesis is an important therapeutic tool to reduce MM progression. This study aimed to investigate the role of invariant natural killer T (iNKT) cells in angiogenesis and the mechanisms behind the stimulation by ??-Galactosylceramide (??-GalCer). We have previously found that ??-GalCer could increase the survival of 5T33MM mice and here we demonstrate that ??-GalCer reduces the microvessel density. We performed both in vivo and in vitro angiogenic assays to confirm this observation. We found that conditioned medium of ??-GalCer stimulated iNKT cells reduced neovascularization in the chick chorioallantoic membrane and in matrigel plug assays. Moreover, we observed a reduction in proliferation, migration and network formation and an induction of apoptosis upon exposure of murine endothelial cell lines to this conditioned medium. We furthermore observed that the JAK-STAT signaling pathway was highly activated in endothelial cells in response to stimulated iNKT cells, indicating the possible role of IFN-?? in the anti-angiogenic process. In conclusion, these results highlight the possibility of recruiting iNKT cells to target MM and angiogenesis. This gives a rationale for combining immunotherapy with conventional anti-tumour treatments in view of increasing their therapeutic potential.</AbstractText>
                <CopyrightInformation>?? 2014 John Wiley &amp; Sons Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Nur</LastName>
                    <ForeName>Haneen</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Department of Haematology and Immunology, Myeloma Centre Brussels, Vrije Universiteit Brussel (VUB), Brussels, Belgium; Department of Biology, Faculty of Science and Technology, Hebron University, Hebron, Palestine.</Affiliation>
                </Author>
                <Author>
                    <LastName>Rao</LastName>
                    <ForeName>Luigia</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author>
                    <LastName>Frassanito</LastName>
                    <ForeName>Maria Antonia</ForeName>
                    <Initials>MA</Initials>
                </Author>
                <Author>
                    <LastName>De Raeve</LastName>
                    <ForeName>Hendrik</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author>
                    <LastName>Ribatti</LastName>
                    <ForeName>Domenico</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author>
                    <LastName>Mfopou</LastName>
                    <ForeName>Josu?? Kunjom</ForeName>
                    <Initials>JK</Initials>
                </Author>
                <Author>
                    <LastName>Van Valckenborgh</LastName>
                    <ForeName>Els</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author>
                    <LastName>De Bruyne</LastName>
                    <ForeName>Elke</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author>
                    <LastName>Vacca</LastName>
                    <ForeName>Angelo</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author>
                    <LastName>Vanderkerken</LastName>
                    <ForeName>Karin</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author>
                    <LastName>Menu</LastName>
                    <ForeName>Eline</ForeName>
                    <Initials>E</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Br J Haematol</MedlineTA>
            <NlmUniqueID>0372544</NlmUniqueID>
            <ISSNLinking>0007-1048</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">JAK-STAT pathway</Keyword>
            <Keyword MajorTopicYN="N">MM-induced angiogenesis</Keyword>
            <Keyword MajorTopicYN="N">invariant natural killer T cells</Keyword>
            <Keyword MajorTopicYN="N">multiple myeloma</Keyword>
            <Keyword MajorTopicYN="N">??-Galactosylceramide</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>9</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bjh.13092</ArticleId>
            <ArticleId IdType="pubmed">25142285</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25142233</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1423-0380</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine</Title>
                <ISOAbbreviation>Tumour Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Immunization with a novel chimeric peptide representing B and T cell epitopes from HER2 extracellular domain (HER2 ECD) for breast cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Because of direct stimulating immune system against disease, vaccination or active immunotherapy is preferable compared to passive immunotherapy. For this purpose, a newly designed chimeric peptide containing epitopes for both B and T cells from HER2 ECD subdomain III was proposed. To evaluate the effects of the active immunization, a discontinuous B cell epitope peptide was selected based on average antigenicity by bioinformatics analysis. The selected peptide was collinearly synthesized as a chimera with a T helper epitope from the protein sequence of measles virus fusion (208-302) using the GPSL linker. Three mice were immunized with the chimeric peptide. Reactive antibodies with HER2 protein in ELISA and immunofluorescence assays with no cross-reactivity were generated. The 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) assay indicated that the anti-peptide sera had inhibitory effects on proliferation of SK-BR-3 cells. Hence, the newly designed, discontinuous chimeric peptide representing B and T cell epitopes from subdomain III of HER2-ECD can form the basis for future vaccines design, where these data can be applied for monoclonal antibody production targeting the distinct epitope of HER2 receptor compared to the two broadly used anti-HER2 monoclonal antibodies, Herceptin and pertuzumab.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Mahdavi</LastName>
                    <ForeName>Manijeh</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Pharmaceutical Biotechnology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran, mahdavi@pharm.mui.ac.ir.</Affiliation>
                </Author>
                <Author>
                    <LastName>Keyhanfar</LastName>
                    <ForeName>Mehrnaz</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author>
                    <LastName>Jafarian</LastName>
                    <ForeName>Abbas</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author>
                    <LastName>Mohabatkar</LastName>
                    <ForeName>Hassan</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author>
                    <LastName>Rabbani</LastName>
                    <ForeName>Mohammad</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Tumour Biol</MedlineTA>
            <NlmUniqueID>8409922</NlmUniqueID>
            <ISSNLinking>1010-4283</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13277-014-2503-y</ArticleId>
            <ArticleId IdType="pubmed">25142233</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25142225</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1475-2840</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>13</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cardiovascular diabetology</Title>
                <ISOAbbreviation>Cardiovasc Diabetol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Cardiac contractile function and mitochondrial respiration in diabetes-related mouse models.</ArticleTitle>
            <Pagination>
                <MedlinePgn>118</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">BackgroundPathophysiological processes underlying diabetic-related cardiomyopathies are complex. Mitochondria dysfunction is often described as a cause of cardiac impairment but its extent may depend on the type of experimental diabetes. Here we proposed to compare drug- or diet-induced models of diabetes in terms of metabolic features, cardiac and mitochondrial functions.MethodsMice were fed with regular chow or fat-enriched diet. After three weeks, they received either citrate or streptozotocin injections for five consecutive days. Metabolic parameters, myocardial contractile function and mitochondrial respiration were measured after three more weeks. Fat mass volumes were assessed by magnetic resonance imaging. Oral glucose tolerance test, insulin tolerance test, triglyceride and adipocytokine quantification were evaluated to establish metabolic profiles. Cardiac function was assessed ex vivo onto a Langendorff column. Isolated cardiac mitochondria respiration was obtained using high-resolution oxygraphy.ResultsMice fed with the fat-enriched regimen presented abdominal obesity, increased blood glucose, elevated leptin level, glucose intolerance, and insulin resistance. Mice treated with streptozotocin, independently of the regimen, lost their capacity to release insulin in response to glucose ingestion. Mice fed with regular chow diet and injected with streptozotocin developed cardiac dysfunction without mitochondrial respiration defect. However, both groups of high-fat diet fed mice developed cardiac alterations associated with reduction in mitochondrial oxygen consumption, despite an increase in mitochondrial biogenesis signalling.ConclusionsWe explored three animal models mimicking type 1 and 2 diabetes. While cardiac dysfunction was present in the three groups of mice, mitochondrial respiration impairment was only obvious in models reproducing features of type 2 diabetes.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Marciniak</LastName>
                    <ForeName>Camille</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author>
                    <LastName>Marechal</LastName>
                    <ForeName>Xavier</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author>
                    <LastName>Montaigne</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author>
                    <LastName>Neviere</LastName>
                    <ForeName>Remi</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author>
                    <LastName>Lancel</LastName>
                    <ForeName>Steve</ForeName>
                    <Initials>S</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Cardiovasc Diabetol</MedlineTA>
            <NlmUniqueID>101147637</NlmUniqueID>
            <ISSNLinking>1475-2840</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">s12933-014-0118-7</ArticleId>
            <ArticleId IdType="doi">10.1186/s12933-014-0118-7</ArticleId>
            <ArticleId IdType="pubmed">25142225</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25142218</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1366-5928</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Xenobiotica; the fate of foreign compounds in biological systems</Title>
                <ISOAbbreviation>Xenobiotica</ISOAbbreviation>
            </Journal>
            <ArticleTitle>In vitro and in vivo metabolism of (14)C-AZ11, a novel inhibitor of bacterial DNA gyrase/type II topoisomerase.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1-13</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Abstract 1.???(2R,4S,4aS)-11-Fluoro-2,4-dimethyl-8-((S)-4-methyl-2-oxooxazolidin-3-yl)-2,4,4a,6-tetrahydro-1H,1'H-spiro [isoxazolo[4,5-g][1,4]oxazino[4,3-a]quinoline-5,5'-pyrimidine]-2',4',6'(3'H)-trione (AZ11) is a novel mode-of-inhibition bacterial topoisomerase inhibitor that entered preclinical development for the treatment of Gram-positive bacteria infection. 2.???The in vitro biotransformation studies of AZ11 using mouse, rat, dog and human hepatocytes showed low-intrinsic clearance in all species attributed to microsomal metabolism. 3.???After a single intravenous administration of [(14)C]AZ11 in bile duct cannulated rats, the mean percentage of dose recovered in rat urine, bile and feces was approximately 18, 36 and 42%, respectively. Unchanged AZ11 recovered in rat urine and bile was less than 9% of the dose, indicating that AZ11 underwent extensive metabolism in rats. 4.???The most abundant in vivo metabolite detected in urine and bile was M1 formed via ring opening on the piperidine and morpholine rings accounting for 20% of the administered dose. The major fecal metabolite was M5, which accounted for approximately 32% of administered dose. M5 was not formed when AZ11 incubated with rat intestinal microsomes and cytosol but was formed when incubated with fresh rat feces, suggesting that unchanged AZ11 was directly excreted into gut lumen where M5 formed as an intestinal microflora-mediated product. This process could have significant impact on bioavailability or exposure of AZ11 in rat.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Guo</LastName>
                    <ForeName>Jian</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department of DMPK and.</Affiliation>
                </Author>
                <Author>
                    <LastName>Joubran</LastName>
                    <ForeName>Camil</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author>
                    <LastName>Luzietti</LastName>
                    <ForeName>Ricardo A</ForeName>
                    <Initials>RA</Initials>
                    <Suffix>Jr</Suffix>
                </Author>
                <Author>
                    <LastName>Zhou</LastName>
                    <ForeName>Fei</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author>
                    <LastName>Basarab</LastName>
                    <ForeName>Gregory S</ForeName>
                    <Initials>GS</Initials>
                </Author>
                <Author>
                    <LastName>Vishwanathan</LastName>
                    <ForeName>Karthick</ForeName>
                    <Initials>K</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Xenobiotica</MedlineTA>
            <NlmUniqueID>1306665</NlmUniqueID>
            <ISSNLinking>0049-8254</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">AZ11</Keyword>
            <Keyword MajorTopicYN="N">excretion</Keyword>
            <Keyword MajorTopicYN="N">mass spectrometry</Keyword>
            <Keyword MajorTopicYN="N">metabolism</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.3109/00498254.2014.952799</ArticleId>
            <ArticleId IdType="pubmed">25142218</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25142214</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1527-3350</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Hepatology (Baltimore, Md.)</Title>
                <ISOAbbreviation>Hepatology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Chronic passive venous congestion drives hepatic fibrogenesis via sinusoidal thrombosis and mechanical forces.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1002/hep.27387</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Chronic passive hepatic congestion (congestive hepatopathy) leads to hepatic fibrosis; however the mechanisms involved in this process are not well understood. We developed a murine experimental model of congestive hepatopathy through partial ligation of the inferior vena cava (pIVCL). C57BL/6 and transgenic mice overexpressing tissue factor pathway inhibitor (SM22?? -TFPI) were subjected to pIVCL or SHAM. Liver and blood samples were collected and analyzed in immunohistochemical, morphometric, real-time polymerase chain reaction and western blot assays. Hepatic fibrosis and portal pressure were significantly increased after pIVCL concurrent with hepatic stellate cell (HSC) activation. Liver stiffness, as assessed by magnetic resonance elastography, correlated with portal pressure and preceded fibrosis in our model. Hepatic sinusoidal thrombosis as evidenced by fibrin deposition was demonstrated both in mice after pIVCL as well as in humans with congestive hepatopathy. Warfarin treatment and TFPI overexpression both had a protective effect on fibrosis development and HSC activation after pIVCL. In vitro studies show that congestion stimulates HSC fibronectin (FN) fibril assembly through direct effects of thrombi as well as by virtue of mechanical strain. Pretreatment with either Mab13 or Cytochalasin-D, to inhibit ??-integrin or actin polymerization, respectively, significantly reduced fibrin and stretch induced FN fibril assembly. Conclusion: Chronic hepatic congestion leads to sinusoidal thrombosis and strain, which in turn promote hepatic fibrosis. These studies mechanistically link congestive hepatopathy to hepatic fibrosis. (Hepatology 2014;).</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 American Association for the Study of Liver Diseases.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Simonetto</LastName>
                    <ForeName>Douglas A</ForeName>
                    <Initials>DA</Initials>
                    <Affiliation>Gastroenterology Research Unit, Mayo Clinic, Rochester, MN.</Affiliation>
                </Author>
                <Author>
                    <LastName>Yang</LastName>
                    <ForeName>Hui-Yin</ForeName>
                    <Initials>HY</Initials>
                </Author>
                <Author>
                    <LastName>Yin</LastName>
                    <ForeName>Meng</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author>
                    <LastName>deAssuncao</LastName>
                    <ForeName>Thiago M</ForeName>
                    <Initials>TM</Initials>
                </Author>
                <Author>
                    <LastName>Kwon</LastName>
                    <ForeName>Jung Hee</ForeName>
                    <Initials>JH</Initials>
                </Author>
                <Author>
                    <LastName>Hilsher</LastName>
                    <ForeName>Moira</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author>
                    <LastName>Pan</LastName>
                    <ForeName>Shuchong</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author>
                    <LastName>Yang</LastName>
                    <ForeName>Liu</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author>
                    <LastName>Bi</LastName>
                    <ForeName>Yan</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author>
                    <LastName>Beyder</LastName>
                    <ForeName>Arthur</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author>
                    <LastName>Cao</LastName>
                    <ForeName>Sheng</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author>
                    <LastName>Simari</LastName>
                    <ForeName>Robert D</ForeName>
                    <Initials>RD</Initials>
                </Author>
                <Author>
                    <LastName>Ehman</LastName>
                    <ForeName>Richard</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author>
                    <LastName>Kamath</LastName>
                    <ForeName>Patrick S</ForeName>
                    <Initials>PS</Initials>
                </Author>
                <Author>
                    <LastName>Shah</LastName>
                    <ForeName>Vijay H</ForeName>
                    <Initials>VH</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Hepatology</MedlineTA>
            <NlmUniqueID>8302946</NlmUniqueID>
            <ISSNLinking>0270-9139</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Congestive hepatopathy</Keyword>
            <Keyword MajorTopicYN="N">Extracellular Matrix</Keyword>
            <Keyword MajorTopicYN="N">fibronectin fibril assembly</Keyword>
            <Keyword MajorTopicYN="N">hepatic stellate cell</Keyword>
            <Keyword MajorTopicYN="N">mechanical stretch</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.27387</ArticleId>
            <ArticleId IdType="pubmed">25142214</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25142202</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1521-4141</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>European journal of immunology</Title>
                <ISOAbbreviation>Eur. J. Immunol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Bone morphogenetic protein 4 inhibits liposaccharide-induced inflammation in the airway.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1002/eji.201344287</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Bone morphogenetic protein 4 (BMP4) is a multifunctional growth factor that belongs to the TGF-?? super-family. The role of BMP4 in lung diseases is not fully understood. Here, we demonstrate that BMP4 was upregulated in lungs undergoing liposaccharide (LPS)-induced inflammation, and in airway epithelial cells treated with LPS or TNF-??. BMP4 mutant (BMP4(+/-) ) mice presented with more severe lung inflammation in response to LPS or Pseudomonas aruginosa, and lower bacterial load compared with that in BMP4(+/+) mice. Knockdown of BMP4 by siRNA increased LPS and TNF-??-induced IL-8 expression in 16HBE human airway epithelial cells and in primary human bronchial epithelial cells. Similarly, peritoneal macrophages from BMP4(+/-) mice produced greater levels of TNF-?? and KC upon LPS treatment compared with cells from BMP4(+/+) mice. Administration of exogenous BMP4 attenuated the upregulation of TNF-??, IL-8 or KC induced by LPS and/or TNF-?? in airway epithelial cells, and peritoneal macrophages. Finally, partial deficiency of BMP4 in BMP4(+/-) mice protected the animals from restrictive lung function reduction upon chronic LPS exposure. These results indicate that BMP4 plays an important anti-inflammatory role, controlling the strength and facilitating the resolution of acute lung inflammation; yet, BMP4 also contributes to lung function impairment during chronic lung inflammation. This article is protected by copyright. All rights reserved.</AbstractText>
                <CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>Zhengtu</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Disease, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Jian</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Yan</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author>
                    <LastName>Jiang</LastName>
                    <ForeName>Hua</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author>
                    <LastName>Xu</LastName>
                    <ForeName>Xiaoming</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Chenting</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>Defu</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author>
                    <LastName>Xu</LastName>
                    <ForeName>Chuyi</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Kedong</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author>
                    <LastName>Qi</LastName>
                    <ForeName>Yafei</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author>
                    <LastName>Gong</LastName>
                    <ForeName>Xuefang</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author>
                    <LastName>Tang</LastName>
                    <ForeName>Chun</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author>
                    <LastName>Zhong</LastName>
                    <ForeName>Nanshan</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author>
                    <LastName>Lu</LastName>
                    <ForeName>Wenju</ForeName>
                    <Initials>W</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Eur J Immunol</MedlineTA>
            <NlmUniqueID>1273201</NlmUniqueID>
            <ISSNLinking>0014-2980</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">BMP4</Keyword>
            <Keyword MajorTopicYN="N">LPS</Keyword>
            <Keyword MajorTopicYN="N">Pseudomonas aruginosa</Keyword>
            <Keyword MajorTopicYN="N">airway inflammation</Keyword>
            <Keyword MajorTopicYN="N">and lung function</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>11</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>3</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1002/eji.201344287</ArticleId>
            <ArticleId IdType="pubmed">25142202</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25142190</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1601-5215</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>26</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Acta neuropsychiatrica</Title>
                <ISOAbbreviation>Acta Neuropsychiatr</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effects of acute administration of mazindol on brain energy metabolism in adult mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>146-54</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1017/neu.2013.43</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Mazindol is a sympathomimetic amine, widely used as an anorectic agent in the treatment of obesity. This drug causes psychostimulant effects because of its pharmacological profile similar to amphetamine, acting like a monoamine reuptake inhibitor. However, the mechanisms underlying the action of mazindol are still not clearly understood.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Swiss mice received a single acute administration of mazindol (0.25, 1.25 and 2.5 mg/kg, ip) or saline. After 2 h, the animals were killed by decapitation; the brain was removed and used for the evaluation of activities of mitochondrial respiratory chain complexes, Krebs cycle enzymes and creatine kinase.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Acute administration of mazindol decreased complex I activity only in the hippocampus. Complex IV activity was increased in the cerebellum (2.5 mg/kg) and cerebral cortex (0.25 mg/kg). Citrate synthase activity was increased in the cerebellum (1.25 mg/kg) and cerebral cortex (1.25 mg/kg), and creatine kinase activity was increased in the cerebellum (1.25 mg/kg).</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">We suggest that the inhibition of complex I in the hippocampus only and activation of complex IV, citrate synthase and creatine kinase occurs because of a stimulus effect of mazindol in the central nervous system, which causes a direct impairment on energy metabolism.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Gon??alves</LastName>
                    <ForeName>Cinara Ludvig</ForeName>
                    <Initials>CL</Initials>
                    <Affiliation>1 Laborat??rio de Bioenerg??tica, Programa de P??s-gradua????o em Ci??ncias da Sa??de, Universidade do Extremo Sul Catarinense, Crici??ma, SC, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Scaini</LastName>
                    <ForeName>Giselli</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>1 Laborat??rio de Bioenerg??tica, Programa de P??s-gradua????o em Ci??ncias da Sa??de, Universidade do Extremo Sul Catarinense, Crici??ma, SC, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rezin</LastName>
                    <ForeName>Gislaine Tezza</ForeName>
                    <Initials>GT</Initials>
                    <Affiliation>1 Laborat??rio de Bioenerg??tica, Programa de P??s-gradua????o em Ci??ncias da Sa??de, Universidade do Extremo Sul Catarinense, Crici??ma, SC, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jeremias</LastName>
                    <ForeName>Isabela Casagrande</ForeName>
                    <Initials>IC</Initials>
                    <Affiliation>1 Laborat??rio de Bioenerg??tica, Programa de P??s-gradua????o em Ci??ncias da Sa??de, Universidade do Extremo Sul Catarinense, Crici??ma, SC, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bez</LastName>
                    <ForeName>Gisele Daiane</ForeName>
                    <Initials>GD</Initials>
                    <Affiliation>1 Laborat??rio de Bioenerg??tica, Programa de P??s-gradua????o em Ci??ncias da Sa??de, Universidade do Extremo Sul Catarinense, Crici??ma, SC, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Daufenbach</LastName>
                    <ForeName>Juliana Felipe</ForeName>
                    <Initials>JF</Initials>
                    <Affiliation>1 Laborat??rio de Bioenerg??tica, Programa de P??s-gradua????o em Ci??ncias da Sa??de, Universidade do Extremo Sul Catarinense, Crici??ma, SC, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gomes</LastName>
                    <ForeName>Lara Mezari</ForeName>
                    <Initials>LM</Initials>
                    <Affiliation>1 Laborat??rio de Bioenerg??tica, Programa de P??s-gradua????o em Ci??ncias da Sa??de, Universidade do Extremo Sul Catarinense, Crici??ma, SC, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ferreira</LastName>
                    <ForeName>Gabriela Kozuchovski</ForeName>
                    <Initials>GK</Initials>
                    <Affiliation>1 Laborat??rio de Bioenerg??tica, Programa de P??s-gradua????o em Ci??ncias da Sa??de, Universidade do Extremo Sul Catarinense, Crici??ma, SC, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zugno</LastName>
                    <ForeName>Alexandra Ioppi</ForeName>
                    <Initials>AI</Initials>
                    <Affiliation>2 Instituto Nacional de Ci??ncia e Tecnologia Translacional em Medicina, Porto Alegre, RS, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Streck</LastName>
                    <ForeName>Emilio Luiz</ForeName>
                    <Initials>EL</Initials>
                    <Affiliation>1 Laborat??rio de Bioenerg??tica, Programa de P??s-gradua????o em Ci??ncias da Sa??de, Universidade do Extremo Sul Catarinense, Crici??ma, SC, Brazil.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Acta Neuropsychiatr</MedlineTA>
            <NlmUniqueID>9612501</NlmUniqueID>
            <ISSNLinking>0924-2708</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0924270813000434</ArticleId>
            <ArticleId IdType="doi">10.1017/neu.2013.43</ArticleId>
            <ArticleId IdType="pubmed">25142190</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25142164</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1572-994X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Virus genes</Title>
                <ISOAbbreviation>Virus Genes</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Characterization of the biological properties and complete genome sequence analysis of a cattle-derived rabies virus isolate from the Guangxi province of southern China.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">In this study, a street rabies virus isolate, GXHXN, was obtained from the brain of one rabid cattle in Guangxi province of southern China. To characterize the biological properties of GXHXN, we first evaluated its pathogenicity using 4-week-old adult mice. GXHXN was highly pathogenic with a short incubation period and course of disease. Its LD50 of 10(-6.86)/mL is significantly higher than the LD50 of 10(-5.19)/mL of GXN119, a dog-derived rabies virus isolate. It also displayed a higher neurotropism index than the rRC-HL strain. However, the relative neurotropism index of GXHXN was slightly lower than that of GXN119. Analyzing antigenicity using anti-N and anti-G monoclonal antibodies (MAbs), all tested anti-N MAbs reacted similarly to GXHXN, CVS, and rRC-HL, but the reaction of anti-N MAbs to GXHXN was slightly different from GXN119. Moreover, 2/11 tested anti-G mAbs showed weaker reactivity to GXHXN than rRC-HL, whereas 4/11 showed stronger reactivity to GXHXN than CVS and GXN119, indicating that the structures of G might differ. In order to understand its genetic variation and evolution, the complete GXHXN genome sequence was determined and compared with the known 12 isolates from other mammals. A total of 42 nucleotide substitutions were found in the full-length genome, including 15 non-synonymous mutations. The G gene accounts for the highest nucleotide substitution rate of 0.70??% in ORF and an amino acid substitution rate of 0.95??%. Phylogenetic trees based on the complete genome sequence as well as the N and G gene sequences from 37 known rabies isolates from various mammals demonstrated that the GXHXN is closely related to the BJ2011E isolate from a horse in Beijing, the WH11 isolate from a donkey in Hubei, and isolates from dogs in the Fujian and Zhejiang provinces. These findings will be helpful in exploring the molecular mechanisms underlying interspecies transmission and the genetic variation of the rabies virus in different mammal species.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Tang</LastName>
                    <ForeName>Hai-Bo</ForeName>
                    <Initials>HB</Initials>
                    <Affiliation>The Key Laboratory of Ministry of Education for Microbial and Plant Genetic Engineering, State Key Laboratory for Conservation and Utilization of Subtropical Agro-bioresources, Guangxi University, Nanning, 530004, Guangxi, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Lu</LastName>
                    <ForeName>Zhuan-Ling</ForeName>
                    <Initials>ZL</Initials>
                </Author>
                <Author>
                    <LastName>Zhong</LastName>
                    <ForeName>Yi-Zhi</ForeName>
                    <Initials>YZ</Initials>
                </Author>
                <Author>
                    <LastName>He</LastName>
                    <ForeName>Xiao-Xia</ForeName>
                    <Initials>XX</Initials>
                </Author>
                <Author>
                    <LastName>Zhong</LastName>
                    <ForeName>Tao-Zhen</ForeName>
                    <Initials>TZ</Initials>
                </Author>
                <Author>
                    <LastName>Pan</LastName>
                    <ForeName>Yan</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author>
                    <LastName>Wei</LastName>
                    <ForeName>Xian-Kai</ForeName>
                    <Initials>XK</Initials>
                </Author>
                <Author>
                    <LastName>Luo</LastName>
                    <ForeName>Yang</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author>
                    <LastName>Liao</LastName>
                    <ForeName>Su-Huan</ForeName>
                    <Initials>SH</Initials>
                </Author>
                <Author>
                    <LastName>Minamoto</LastName>
                    <ForeName>Nobuyuki</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author>
                    <LastName>Luo</LastName>
                    <ForeName>Ting Rong</ForeName>
                    <Initials>TR</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Virus Genes</MedlineTA>
            <NlmUniqueID>8803967</NlmUniqueID>
            <ISSNLinking>0920-8569</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11262-014-1108-2</ArticleId>
            <ArticleId IdType="pubmed">25142164</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25142145</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1078-0432</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical cancer research : an official journal of the American Association for Cancer Research</Title>
                <ISOAbbreviation>Clin. Cancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">clincanres.1339.2014</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Purpose: Immunomodulatory mAbs can treat cancer, but cures are rare except for small tumors. Our objective was to explore whether the therapeutic window increases by combining mAbs with different modes of action and injecting them into tumors. Experimental Design: Combinations of mAbs to CD137/PD-1/CTLA4 or CD137/PD-1/CTLA4/CD19 were administrated intratumorally to mice with syngeneic tumors (B16 and SW1 melanoma, TC1 lung carcinoma), including tumors with a mean surface of ~80mm2. Survival and tumor growth were assessed. Immunological responses were evaluated using flow cytometry and qRT-PCR. 2 Results: Over 50% of tumor-bearing mice had complete regression and long-term survival after tumor injection with mAbs recognizing CD137/PD-1/CTLA4/CD19 with similar responses in 3 models. Intratumoral injection was more efficacious than i.p. injection to cause rejection also of untreated tumors in the same mice. The 3 mAb combination could also induce regression but was less efficacious. There were few side-effects and therapy resistant tumors were not observed. Transplanted tumor cells rapidly caused a Th2 response with increased CD19 cells. Successful therapy shifted this response to the Th1 phenotype with decreased CD19 cells and increased numbers of long term memory CD8 effector cells and T cells making IFN?? and TNF??. Conclusion: Intratumoral injection of mAbs recognizing CD137/PD-1/CTLA4/CD19 can eradicate established tumors and reverse a Th2 response with tumor-associated CD19 cells to Th1 immunity while a combination lacking anti-CD19 is less effective. There are several human cancers where a similar approach may provide clinical benefit.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014, American Association for Cancer Research.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Dai</LastName>
                    <ForeName>Min</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Pathology, University of Washington.</Affiliation>
                </Author>
                <Author>
                    <LastName>Yip</LastName>
                    <ForeName>Yuen Yee</ForeName>
                    <Initials>YY</Initials>
                    <Affiliation>Pathology, University of Washington.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hellstrom</LastName>
                    <ForeName>Ingegerd</ForeName>
                    <Initials>I</Initials>
                    <Affiliation>Pathology, University of Washington.</Affiliation>
                </Author>
                <Author>
                    <LastName>Hellstrom</LastName>
                    <ForeName>Karl Erik</ForeName>
                    <Initials>KE</Initials>
                    <Affiliation>Department of Pathology, University of Washington Harborview Medical Center hellsk@u.washington.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Clin Cancer Res</MedlineTA>
            <NlmUniqueID>9502500</NlmUniqueID>
            <ISSNLinking>1078-0432</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">1078-0432.CCR-14-1339</ArticleId>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-14-1339</ArticleId>
            <ArticleId IdType="pubmed">25142145</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25142140</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1476-5462</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Gene therapy</Title>
                <ISOAbbreviation>Gene Ther.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>High and prolonged sulfamidase secretion by the liver of MPS-IIIA mice following hydrodynamic tail vein delivery of antibiotic-free pFAR4 plasmid vector.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1038/gt.2014.75</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Mucopolysaccharidosis type IIIA (MPS-IIIA) or Sanfilippo A syndrome is a lysosomal storage genetic disease that results from the deficiency of the N-sulfoglucosamine sulfohydrolase (SGSH) protein, a sulfamidase required for the degradation of heparan sulfate glycosaminoglycans (GAGs). The accumulation of these macromolecules leads to somatic organ pathologies, severe neurodegeneration and death. To assess a novel gene therapy approach based on prolonged secretion of the missing enzyme by the liver, mediated by hydrodynamic gene delivery, we first compared a kanamycin and an antibiotic-free expression plasmid vector, called pFAR4. Thanks to the reduced vector size, pFAR4 derivatives containing either a ubiquitous or a liver-specific promoter mediated a higher reporter gene expression level than the control plasmid. Hydrodynamic delivery of SGSH-encoding pFAR4 into MPS-IIIA diseased mice led to high serum levels of sulfamidase protein that was efficiently taken up by neighboring organs, as shown by the correction of GAG accumulation. A similar reduction in GAG content was also observed in the brain, at early stages of the disease. Thus, this study contributes to the effort towards the development of novel biosafe non-viral gene vectors for therapeutic protein expression in the liver, and represents a first step towards an alternative gene therapy approach for the MPS-IIIA disease.Gene Therapy advance online publication, 21 August 2014; doi:10.1038/gt.2014.75.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Quiviger</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>1] Unit?? de Technologies Chimiques et Biologiques pour la Sant??, Facult?? de Pharmacie, Universit?? Paris Descartes, Paris, France [2] Ecole Nationale Sup??rieure de Chimie de Paris, Chimie Paristech, Paris, France [3] CNRS, UMR8258, Paris, France [4] Inserm, U1022, Paris, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Arfi</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>1] Unit?? de Technologies Chimiques et Biologiques pour la Sant??, Facult?? de Pharmacie, Universit?? Paris Descartes, Paris, France [2] Ecole Nationale Sup??rieure de Chimie de Paris, Chimie Paristech, Paris, France [3] CNRS, UMR8258, Paris, France [4] Inserm, U1022, Paris, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Mansard</LastName>
                    <ForeName>D</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>1] Unit?? de Technologies Chimiques et Biologiques pour la Sant??, Facult?? de Pharmacie, Universit?? Paris Descartes, Paris, France [2] Ecole Nationale Sup??rieure de Chimie de Paris, Chimie Paristech, Paris, France [3] CNRS, UMR8258, Paris, France [4] Inserm, U1022, Paris, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Delacotte</LastName>
                    <ForeName>L</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>1] Unit?? de Technologies Chimiques et Biologiques pour la Sant??, Facult?? de Pharmacie, Universit?? Paris Descartes, Paris, France [2] Ecole Nationale Sup??rieure de Chimie de Paris, Chimie Paristech, Paris, France [3] CNRS, UMR8258, Paris, France [4] Inserm, U1022, Paris, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Pastor</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>1] Unit?? de Technologies Chimiques et Biologiques pour la Sant??, Facult?? de Pharmacie, Universit?? Paris Descartes, Paris, France [2] Ecole Nationale Sup??rieure de Chimie de Paris, Chimie Paristech, Paris, France [3] CNRS, UMR8258, Paris, France [4] Inserm, U1022, Paris, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Scherman</LastName>
                    <ForeName>D</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>1] Unit?? de Technologies Chimiques et Biologiques pour la Sant??, Facult?? de Pharmacie, Universit?? Paris Descartes, Paris, France [2] Ecole Nationale Sup??rieure de Chimie de Paris, Chimie Paristech, Paris, France [3] CNRS, UMR8258, Paris, France [4] Inserm, U1022, Paris, France.</Affiliation>
                </Author>
                <Author>
                    <LastName>Marie</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>1] Unit?? de Technologies Chimiques et Biologiques pour la Sant??, Facult?? de Pharmacie, Universit?? Paris Descartes, Paris, France [2] Ecole Nationale Sup??rieure de Chimie de Paris, Chimie Paristech, Paris, France [3] CNRS, UMR8258, Paris, France [4] Inserm, U1022, Paris, France.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Gene Ther</MedlineTA>
            <NlmUniqueID>9421525</NlmUniqueID>
            <ISSNLinking>0969-7128</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>8</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">gt201475</ArticleId>
            <ArticleId IdType="doi">10.1038/gt.2014.75</ArticleId>
            <ArticleId IdType="pubmed">25142140</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25142138</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1476-5462</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Gene therapy</Title>
                <ISOAbbreviation>Gene Ther.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Overexpression of X-Linked Inhibitor of Apoptotic Protein (XIAP) reduces age-related neuronal degeneration in the mouse cochlea.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1038/gt.2014.77</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Previously, we showed that age-related hearing loss (AHL) was delayed in C57BL6 mice overexpressing X-Linked Inhibitor of Apoptotic Protein (XIAP), and the delayed AHL was associated with attenuated hair cell (HC) loss in XIAP-overexpressing mice. Similar to other reports, the HC loss in aged mice was restricted to the basal turn in this previous study, and occurred slightly at the apical end of the cochlea, showing considerably less spread than the frequency region of hearing loss. In the present study, we examined whether and how AHL is related to the degeneration of neuronal innervation of the cochlea and whether the overexpression of XIAP exerts a protective effect against age-related degeneration in both afferent and efferent cochlear neurites. In contrast to HC loss, degeneration of both afferent and efferent neurites spread to the middle turns of the cochlea. Moreover, XIAP-overexpressing mice lost fewer HC afferent dendrites and efferent axons, as well as fewer spiral ganglion neurons between 3 and???14 months of age in comparison with wild-type littermates. The results suggest that age-related degeneration of cochlear neurites may be independent of HC loss. Further, the inhibition of apoptosis by XIAP appears to reduce degeneration of both afferent and efferent cochlear neurites.Gene Therapy advance online publication, 21 August 2014; doi:10.1038/gt.2014.77.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Ruan</LastName>
                    <ForeName>Q</ForeName>
                    <Initials>Q</Initials>
                    <Affiliation>1] Department and Research Institute of Otolaryngology, The Sixth Affiliated Hospital of Shanghai Jiaotong University, Shanghai, People's Republic of China [2] Research Center of Aging and Medicine, Shanghai Key Laboratory of Clinical Geriatrics, Huadong Hospital, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zeng</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department and Research Institute of Otolaryngology, The Sixth Affiliated Hospital of Shanghai Jiaotong University, Shanghai, People's Republic of China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Otolaryngology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Z</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>Department and Research Institute of Otolaryngology, The Sixth Affiliated Hospital of Shanghai Jiaotong University, Shanghai, People's Republic of China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Yu</LastName>
                    <ForeName>Z</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>Research Center of Aging and Medicine, Shanghai Key Laboratory of Clinical Geriatrics, Huadong Hospital, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Research Center of Aging and Medicine, Shanghai Key Laboratory of Clinical Geriatrics, Huadong Hospital, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.</Affiliation>
                </Author>
                <Author>
                    <LastName>He</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Department and Research Institute of Otolaryngology, The Sixth Affiliated Hospital of Shanghai Jiaotong University, Shanghai, People's Republic of China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Bance</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>1] Division of Otolaryngology, Department of Surgery, Dalhousie University, Halifax, Nova Scotia, Canada [2] Department of Anatomy and Neurobiology, Dalhousie University, Halifax, Nova Scotia, Canada.</Affiliation>
                </Author>
                <Author>
                    <LastName>Robertson</LastName>
                    <ForeName>G</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>1] Division of Otolaryngology, Department of Surgery, Dalhousie University, Halifax, Nova Scotia, Canada [2] Department of Psychiatry and Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada.</Affiliation>
                </Author>
                <Author>
                    <LastName>Yin</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department and Research Institute of Otolaryngology, The Sixth Affiliated Hospital of Shanghai Jiaotong University, Shanghai, People's Republic of China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>1] Department and Research Institute of Otolaryngology, The Sixth Affiliated Hospital of Shanghai Jiaotong University, Shanghai, People's Republic of China [2] Division of Otolaryngology, Department of Surgery, Dalhousie University, Halifax, Nova Scotia, Canada [3] School of Human Communication Disorders, Dalhousie University, Halifax, Nova Scotia, Canada.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Gene Ther</MedlineTA>
            <NlmUniqueID>9421525</NlmUniqueID>
            <ISSNLinking>0969-7128</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">gt201477</ArticleId>
            <ArticleId IdType="doi">10.1038/gt.2014.77</ArticleId>
            <ArticleId IdType="pubmed">25142138</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25142115</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1521-4095</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>26</Volume>
                    <Issue>32</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Advanced materials (Deerfield Beach, Fla.)</Title>
                <ISOAbbreviation>Adv. Mater. Weinheim</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Imaging: upconversion nanoparticles as a contrast agent for photoacoustic imaging in live mice (adv. Mater. 32/2014).</ArticleTitle>
            <Pagination>
                <MedlinePgn>5632</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/adma.201470220</ELocationID>
            <Abstract>
                <AbstractText>Photoacoustic imaging has evolved as a promising deep-tissue optical imaging modality. On page 5633, Y. Zhao and co-workers demonstrate the inclusion complex of NaYF4 :Yb(3+) ,Er(3+) upconversion nanoparticles with ??-cyclodextrin in aqueous conditions that exhibits luminescence quenching when excited at 980 nm. This non-radiative relaxation leads to photoacoustic signal enhancement in vivo, showing high capability of the material for photoacoustic imaging.</AbstractText>
                <CopyrightInformation>?? 2014 WILEY-VCH Verlag GmbH &amp; Co. KGaA, Weinheim.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Maji</LastName>
                    <ForeName>Swarup Kumar</ForeName>
                    <Initials>SK</Initials>
                    <Affiliation>Division of Chemistry and Biological Chemistry, School of Physical and Mathematical Sciences, Nanyang Technological University, 21 Nanyang Link, 637371, Singapore.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sreejith</LastName>
                    <ForeName>Sivaramapanicker</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Joseph</LastName>
                    <ForeName>James</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lin</LastName>
                    <ForeName>Manjing</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>He</LastName>
                    <ForeName>Tingchao</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tong</LastName>
                    <ForeName>Yan</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sun</LastName>
                    <ForeName>Handong</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yu</LastName>
                    <ForeName>Sidney Wing-Kwong</ForeName>
                    <Initials>SW</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhao</LastName>
                    <ForeName>Yanli</ForeName>
                    <Initials>Y</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Germany</Country>
            <MedlineTA>Adv Mater</MedlineTA>
            <NlmUniqueID>9885358</NlmUniqueID>
            <ISSNLinking>0935-9648</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Er3+</Keyword>
            <Keyword MajorTopicYN="N">NaYF4:Yb3+</Keyword>
            <Keyword MajorTopicYN="N">contrast agent</Keyword>
            <Keyword MajorTopicYN="N">live mice</Keyword>
            <Keyword MajorTopicYN="N">photoacoustic imaging</Keyword>
            <Keyword MajorTopicYN="N">upconversion nanoparticles</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1002/adma.201470220</ArticleId>
            <ArticleId IdType="pubmed">25142115</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25142111</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1521-4141</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>European journal of immunology</Title>
                <ISOAbbreviation>Eur. J. Immunol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>microRNA management of NK-cell developmental and functional programs.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1002/eji.201444798</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">NK cells are innate lymphoid cells that are critical for host defense against infection, and mediate anti-tumor responses. MicroRNAs (miRNAs) are a large family of small non-coding RNAs that target the 3'UTR of mRNAs, thereby attenuating protein translation. The expression of miRNAs within human peripheral blood and mouse splenic NK cells has been cataloged, with the majority of the miRNA sequence pool represented in the top 60 most abundantly expressed miRNAs. Global miRNA deficiency within NK cells has confirmed their critical role in NK-cell biology, including defects in NK-cell development and altered functionality. Studies using gain- and loss-of-function of individual miRNAs in NK cells have demonstrated the role of specific miRNAs in regulating NK-cell development, maturation, and activation. miRNAs also regulate fundamental NK-cell processes including cytokine production, cytotoxicity, and proliferation. This review provides an update on the intrinsic miRNA regulation of NK cells, including miRNA expression profiles, as well as their impact on NK-cell biology. Additional profiling is needed to better understand miRNA expression within NK-cell developmental intermediates, subsets, tissues, and in the setting of disease. Furthermore, key open questions in the field as well as technical challenges in the study of miRNAs in NK cells are highlighted. This article is protected by copyright. All rights reserved.</AbstractText>
                <CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Leong</LastName>
                    <ForeName>Jeffrey W</ForeName>
                    <Initials>JW</Initials>
                    <Affiliation>Washington University School of Medicine, Department of Medicine, Division of Oncology, St. Louis, MO, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Sullivan</LastName>
                    <ForeName>Ryan P</ForeName>
                    <Initials>RP</Initials>
                </Author>
                <Author>
                    <LastName>Fehniger</LastName>
                    <ForeName>Todd A</ForeName>
                    <Initials>TA</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Eur J Immunol</MedlineTA>
            <NlmUniqueID>1273201</NlmUniqueID>
            <ISSNLinking>0014-2980</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">NK cell</Keyword>
            <Keyword MajorTopicYN="N">activation</Keyword>
            <Keyword MajorTopicYN="N">development</Keyword>
            <Keyword MajorTopicYN="N">lymphocyte</Keyword>
            <Keyword MajorTopicYN="N">microRNA</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>31</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1002/eji.201444798</ArticleId>
            <ArticleId IdType="pubmed">25142111</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25142097</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1601-5215</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>26</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Acta neuropsychiatrica</Title>
                <ISOAbbreviation>Acta Neuropsychiatr</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Chronic oral carbamazepine treatment elicits mood-stabilising effects in mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>29-34</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1017/neu.2013.23</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The underlying biology of bipolar disorder and the mechanisms by which effective medications induce their therapeutic effects are not clear. Appropriate use of animal models are essential to further understand biological mechanisms of disease and treatment, and further understanding the therapeutic mechanism of mood stabilisers requires that clinically relevant administration will be effective in animal models. The clinical regimens for mood-stabilising drugs include chronic oral administration; however, much of the work with animal models includes acute administration via injection. An effective chronic and oral administration of the prototypic mood stabiliser lithium was already established and the present study was designed to do the same for the mood stabiliser carbamazepine.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Mice were treated for 3 weeks with carbamazepine in food. ICR mice were treated with 0.25%, 0.5% and 0.75%, and C57bl/6 mice with 0.5% and 0.75%, carbamazepine in food (w/w, namely, 2.5, 5.0 or 7.5 g/kg food). Mice were then tested for spontaneous activity, forced swim test (FST), tail suspension test (TST) and amphetamine-induced hyperactivity.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Oral carbamazepine administration resulted in dose-dependent blood levels reaching 3.65 ??g/ml at the highest dose. In ICR mice, carbamazepine at the 0.5% dose had no effect on spontaneous activity, but significantly reduced immobility in the TST by 27% and amphetamine-induced hyperactivity by 28%. In C57bl/6 mice, carbamazepine at the 0.75% dose reduced immobility time in the FST by 26%.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These results demonstrate a behaviourally effective oral and chronic regimen for carbamazepine with mood stabilising-like activity in a standard model for mania-like behaviour and two standard models for depression-like behaviour.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kara</LastName>
                    <ForeName>Nirit Z</ForeName>
                    <Initials>NZ</Initials>
                    <Affiliation>1 School of Behavioral Sciences, Tel Aviv-Yaffo Academic College, Tel-Aviv, Israel.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Karpel</LastName>
                    <ForeName>Orit</ForeName>
                    <Initials>O</Initials>
                    <Affiliation>2 Department of Clinical Biochemistry, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beersheba, Israel.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Toker</LastName>
                    <ForeName>Lilach</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>2 Department of Clinical Biochemistry, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beersheba, Israel.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Agam</LastName>
                    <ForeName>Galila</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>2 Department of Clinical Biochemistry, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beersheba, Israel.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Belmaker</LastName>
                    <ForeName>Robert H</ForeName>
                    <Initials>RH</Initials>
                    <Affiliation>3 Department of Psychiatry Research Unit, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beersheba, Israel.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Einat</LastName>
                    <ForeName>Haim</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>1 School of Behavioral Sciences, Tel Aviv-Yaffo Academic College, Tel-Aviv, Israel.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Acta Neuropsychiatr</MedlineTA>
            <NlmUniqueID>9612501</NlmUniqueID>
            <ISSNLinking>0924-2708</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0924270813000239</ArticleId>
            <ArticleId IdType="doi">10.1017/neu.2013.23</ArticleId>
            <ArticleId IdType="pubmed">25142097</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25142082</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2045-2322</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>4</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Scientific reports</Title>
                <ISOAbbreviation>Sci Rep</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Microneedle-mediated immunization of an adenovirus-based malaria vaccine enhances antigen-specific antibody immunity and reduces anti-vector responses compared to the intradermal route.</ArticleTitle>
            <Pagination>
                <MedlinePgn>6154</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/srep06154</ELocationID>
            <Abstract>
                <AbstractText>Substantial effort has been placed in developing efficacious recombinant attenuated adenovirus-based vaccines. However induction of immunity to the vector is a significant obstacle to its repeated use. Here we demonstrate that skin-based delivery of an adenovirus-based malaria vaccine, HAdV5-PyMSP142, to mice using silicon microneedles induces equivalent or enhanced antibody responses to the encoded antigen, however it results in decreased anti-vector responses, compared to intradermal delivery. Microneedle-mediated vaccine priming and resultant induction of low anti-vector antibody titres permitted repeated use of the same adenovirus vaccine vector. This resulted in significantly increased antigen-specific antibody responses in these mice compared to ID-treated mice. Boosting with a heterologous vaccine; MVA-PyMSP142 also resulted in significantly greater antibody responses in mice primed with HAdV5-PyMSP142 using MN compared to the ID route. The highest protection against blood-stage malaria challenge was observed when a heterologous route of immunization (MN/ID) was used. Therefore, microneedle-mediated immunization has potential to both overcome some of the logistic obstacles surrounding needle-and-syringe-based immunization as well as to facilitate the repeated use of the same adenovirus vaccine thereby potentially reducing manufacturing costs of multiple vaccines. This could have important benefits in the clinical ease of use of adenovirus-based immunization strategies.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Carey</LastName>
                    <ForeName>John B</ForeName>
                    <Initials>JB</Initials>
                    <Affiliation>School of Pharmacy, University College Cork, Cork, Ireland.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vrdoljak</LastName>
                    <ForeName>Anto</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>School of Pharmacy, University College Cork, Cork, Ireland.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>O'Mahony</LastName>
                    <ForeName>Conor</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>The Tyndall National Institute, University College Cork, Cork, Ireland.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hill</LastName>
                    <ForeName>Adrian V S</ForeName>
                    <Initials>AV</Initials>
                    <Affiliation>The Jenner Institute, University of Oxford, Oxford, UK.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Draper</LastName>
                    <ForeName>Simon J</ForeName>
                    <Initials>SJ</Initials>
                    <Affiliation>The Jenner Institute, University of Oxford, Oxford, UK.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Moore</LastName>
                    <ForeName>Anne C</ForeName>
                    <Initials>AC</Initials>
                    <Affiliation>1] School of Pharmacy, University College Cork, Cork, Ireland [2] Dept. of Pharmacology and Therapeutics, University College Cork, Cork, Ireland.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Sci Rep</MedlineTA>
            <NlmUniqueID>101563288</NlmUniqueID>
            <ISSNLinking>2045-2322</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>04</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">srep06154</ArticleId>
            <ArticleId IdType="doi">10.1038/srep06154</ArticleId>
            <ArticleId IdType="pubmed">25142082</ArticleId>
            <ArticleId IdType="pmc">PMC4139947</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25142063</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1471-4159</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of neurochemistry</Title>
                <ISOAbbreviation>J. Neurochem.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Lardy brains make Parkinson's disease mice worse.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1111/jnc.12843</ELocationID>
            <AuthorList>
                <Author>
                    <LastName>Cookson</LastName>
                    <ForeName>Mark R</ForeName>
                    <Initials>MR</Initials>
                    <Affiliation>Cell Biology and Gene Expression Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>EDITORIAL</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Neurochem</MedlineTA>
            <NlmUniqueID>2985190R</NlmUniqueID>
            <ISSNLinking>0022-3042</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jnc.12843</ArticleId>
            <ArticleId IdType="pubmed">25142063</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25142058</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2047-9980</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>3</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of the American Heart Association</Title>
                <ISOAbbreviation>J Am Heart Assoc</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Activation of endothelial transient receptor potential c3 channel is required for small conductance calcium-activated potassium channel activation and sustained endothelial hyperpolarization and vasodilation of cerebral artery.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1161/JAHA.114.000913</ELocationID>
            <ELocationID EIdType="pii" ValidYN="Y">e000913</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Transient receptor potential C3 (TRPC3) has been demonstrated to be involved in the regulation of vascular tone through endothelial cell (EC) hyperpolarization and endothelium-dependent hyperpolarization-mediated vasodilation. However, the mechanism by which TRPC3 regulates these processes remains unresolved. We tested the hypothesis that endothelial receptor stimulation triggers rapid TRPC3 trafficking to the plasma membrane, where it provides the source of Ca(2+) influx for small conductance calcium-activated K(+) (SKCa) channel activation and sustained EC hyperpolarization.</AbstractText>
                <AbstractText Label="METHODS AND RESULTS" NlmCategory="RESULTS">Pressurized artery studies were performed with isolated mouse posterior cerebral artery. Treatment with a selective TRPC3 blocker (Pyr3) produced significant attenuation of endothelium-dependent hyperpolarization-mediated vasodilation and endothelial Ca(2+) response (EC-specific Ca(2+) biosensor) to intraluminal ATP. Pyr3 treatment also resulted in a reduced ATP-stimulated global Ca(2+) and Ca(2+) influx in primary cultures of cerebral endothelial cells. Patch-clamp studies with freshly isolated cerebral ECs demonstrated 2 components of EC hyperpolarization and K(+) current activation in response to ATP. The early phase was dependent on intermediate conductance calcium-activated K(+) channel activation, whereas the later sustained phase relied on SKC a channel activation. The SKC a channel-dependent phase was completely blocked with TRPC3 channel inhibition or in ECs of TRPC3 knockout mice and correlated with increased trafficking of TRPC3 (but not SKC a channel) to the plasma membrane.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We propose that TRPC3 dynamically regulates SKC a channel activation through receptor-dependent trafficking to the plasma membrane, where it provides the source of Ca(2+) influx for sustained SKC a channel activation, EC hyperpolarization, and endothelium-dependent hyperpolarization-mediated vasodilation.</AbstractText>
                <CopyrightInformation>?? 2014 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kochukov</LastName>
                    <ForeName>Mikhail Y</ForeName>
                    <Initials>MY</Initials>
                    <Affiliation>Department of Anesthesiology, Baylor College of Medicine, Houston, TX (M.Y.K., A.B., S.P.M.).</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Balasubramanian</LastName>
                    <ForeName>Adithya</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Anesthesiology, Baylor College of Medicine, Houston, TX (M.Y.K., A.B., S.P.M.).</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Abramowitz</LastName>
                    <ForeName>Joel</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Division of Intramural Research, National Institute of Environmental Health Sciences Research, Triangle Park, NC (J.A., L.B.).</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Birnbaumer</LastName>
                    <ForeName>Lutz</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Division of Intramural Research, National Institute of Environmental Health Sciences Research, Triangle Park, NC (J.A., L.B.).</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Marrelli</LastName>
                    <ForeName>Sean P</ForeName>
                    <Initials>SP</Initials>
                    <Affiliation>Department of Anesthesiology, Baylor College of Medicine, Houston, TX (M.Y.K., A.B., S.P.M.) Department of Physiology and Biophysics and Graduate Program in Physiology, Cardiovascular Sciences Track, Baylor College of Medicine, Houston, TX (S.P.M.).</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>J Am Heart Assoc</MedlineTA>
            <NlmUniqueID>101580524</NlmUniqueID>
            <ISSNLinking>2047-9980</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">cerebrovascular circulation</Keyword>
            <Keyword MajorTopicYN="N">endothelium</Keyword>
            <Keyword MajorTopicYN="N">endothelium???derived factors</Keyword>
            <Keyword MajorTopicYN="N">ion channels</Keyword>
            <Keyword MajorTopicYN="N">vasculature</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">jah3649</ArticleId>
            <ArticleId IdType="doi">10.1161/JAHA.114.000913</ArticleId>
            <ArticleId IdType="pubmed">25142058</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25142032</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1746-6148</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>10</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>BMC veterinary research</Title>
                <ISOAbbreviation>BMC Vet. Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Recombinant porcine epidermal growth factor-secreting.</ArticleTitle>
            <Pagination>
                <MedlinePgn>171</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">BackgroundEpidermal growth factor (EGF) is an important growth factor in regulation of cell proliferation, differentiation, survival and apoptosis. Studies showed that food-grade Lactococcus lactis (L. lactis) and NICE expression system have superior performance in exogenous protein expression. This study aimed to construct and express porcine EGF (pEGF), and use L. lactis as vehicle for producing and delivering pEGF. Furthermore, investigating biological activity of pEGF and exploring applications feasibility of combination effects of L. lactis and pEGF on early weaned piglets?? production.ResultsA recombinant Lactococcus lactis which produced and secreted pEGF at 1000 ng/ml in culture supernatant was generated. Secreted pEGF was a fully biologically active protein, as demonstrated by its capacity to stimulate L929 mouse fibroblast cell line proliferation in vitro. For in vivo study, forty piglets were randomly allocated to control, antibiotic control, empty vector-expressing L. lactis (LL-EV) and pEGF-secreting L. lactis (LL-pEGF). After 14 d of rearing, final body weight and average daily gain in LL-pEGF were greater (P &lt; 0.05, 8.95 vs. 8.37 kg, 206.1 vs. 157.7 g/day, respectively) than those in control, but no significant differences between LL-pEGF, LL-EV and antibiotic control. Overall period average daily feed intake was higher in LL-pEGF, LL-EV and antibiotic control than in control (P &lt; 0.05, 252.9, 255.6, 250.0, 207.3 g/day, respectively). No significant difference was observed on ADFI/ADG. LL-pEGF increased villous height in the duodenum, jejunum and ileum than in control and LL-EV (P &lt; 0.05). Sucrase in the 3 intestinal segments, aminopeptidase A in the duodenum and Jejunum, aminopeptidase N and dipeptidase IV in the duodenum in LL-pEGF were higher than those in control (P &lt; 0.05). Furthermore, Escherichia coli and Enterococcus counts decreased in the ileum and Lactobacillus increased in the ileum and cecum digesta in LL-pEGF compare with the control (P &lt; 0.05). Lactobacillus increased in the cecum in LL-EV compared with control and antibiotic control (P &lt; 0.05).ConclusionWe have generated a recombinant Lactococcus lactis which produced and secreted fully biologically active porcine EGF. Oral administration of pEGF-secreting L. lactis had beneficial effects on intestinal health and performance of early-weaned piglets.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Dingyue</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author>
                    <LastName>Xu</LastName>
                    <ForeName>Shengyu</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author>
                    <LastName>Lin</LastName>
                    <ForeName>Yan</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author>
                    <LastName>Fang</LastName>
                    <ForeName>Zhengfeng</ForeName>
                    <Initials>Z</Initials>
                </Author>
                <Author>
                    <LastName>Che</LastName>
                    <ForeName>Lianqiang</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author>
                    <LastName>Xue</LastName>
                    <ForeName>Bai</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author>
                    <LastName>Wu</LastName>
                    <ForeName>De</ForeName>
                    <Initials>D</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>BMC Vet Res</MedlineTA>
            <NlmUniqueID>101249759</NlmUniqueID>
            <ISSNLinking>1746-6148</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>11</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">s12917-014-0171-1</ArticleId>
            <ArticleId IdType="doi">10.1186/s12917-014-0171-1</ArticleId>
            <ArticleId IdType="pubmed">25142032</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25142024</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1930-739X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Obesity (Silver Spring, Md.)</Title>
                <ISOAbbreviation>Obesity (Silver Spring)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>High-fat diet reduces neuroprotection of isoflurane post-treatment: Role of carboxyl-terminal modulator protein-Akt signaling.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1002/oby.20879</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">High-fat diet (HFD) contributes to the increased prevalence of obesity and hyperlipidemia in young adults, a possible cause for their recent increase in stroke. Isoflurane post-treatment provides neuroprotection. Isoflurane post-treatment induced neuroprotection in HFD-fed mice was determined.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Six-week old CD-1 male mice were fed HFD or regular diet (RD) for 5 or 10 weeks. Their hippocampal slices (400 ??m) were subjected to oxygen-glucose deprivation (OGD). Some slices were exposed to isoflurane for 30 min immediately after OGD. Some mice had a 90-min middle cerebral arterial occlusion and were post-treated with 2% isoflurane for 30 min.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">OGD time-dependently induced cell injury. This injury was dose-dependently reduced by isoflurane. The effect was apparent at 1% or 2% isoflurane in RD-fed mice but required 3% isoflurane in HFD-fed mice. HFD influenced the isoflurane effects in DG. OGD increased carboxyl-terminal modulator protein (CTMP), an Akt inhibitor, and decreased Akt signaling. Isoflurane reduced these effects. LY294002, an Akt activation inhibitor, attenuated the isoflurane effects. HFD increased CTMP and reduced Akt signaling. Isoflurane improved neurological outcome in the RD-fed mice but not in the HFD-fed mice.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">HFD attenuated isoflurane post-treatment-induced neuroprotection possibly because of decreased prosurvival Akt signaling.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 The Obesity Society.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Yu</LastName>
                    <ForeName>Hai</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Department of Anesthesiology, University of Virginia, Charlottesville, Virginia, 22908, USA; Department of Anesthesiology and Translational Neuroscience Center, West China Hospital, Sichuan University, Chengdu, 610041, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Deng</LastName>
                    <ForeName>Jiao</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author>
                    <LastName>Zuo</LastName>
                    <ForeName>Zhiyi</ForeName>
                    <Initials>Z</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Obesity (Silver Spring)</MedlineTA>
            <NlmUniqueID>101264860</NlmUniqueID>
            <ISSNLinking>1930-7381</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>2</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>5</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1002/oby.20879</ArticleId>
            <ArticleId IdType="pubmed">25142024</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25142022</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1527-3350</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Hepatology (Baltimore, Md.)</Title>
                <ISOAbbreviation>Hepatology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Targeting mitochondria with methylene blue protects mice against acetaminophen-induced liver injury.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1002/hep.27385</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Acetaminophen (APAP) overdose is the most frequent cause of drug-induced liver injury in the Western world. Previous studies with mouse models have revealed that impairment of mitochondrial respiration is an early event in the pathogenesis, but the exact mechanisms have remained unclear, and therapeutic approaches to specifically target mitochondria have been insufficiently explored. Here, we found that the reactive oxidative metabolite of APAP, N-acetyl-p-benzoquinoneimine (NAPQI), caused the selective inhibition of mitochondrial complex II activity by &gt;90% in both mouse hepatic mitochondria and yeast-derived complexes reconstituted into nanoscale model membranes, as well as the decrease of succinate-driven ATP biosynthesis rates. Based on these findings we hypothesized that methylene blue (MB), a mitochondria-permeant redox-active compound that can act as an alternative electron carrier, protects against APAP-induced hepatocyte injury. We found that MB (???3 ??M) readily accepted electrons from NAPQI-altered, succinate-energized complex II and transferred them to cytochrome c, restoring ATP biosynthesis rates. In cultured mouse hepatocytes, MB prevented the mitochondrial permeability transition and loss of intracellular ATP without interfering with APAP bioactivation. In male C57BL/6J mice treated with APAP (450 mg/kg, ip), MB (10 mg/kg, ip, administered 90 min post-APAP) protected against hepatotoxicity, whereas mice treated with APAP alone developed massive centrilobular necrosis and increased serum ALT activity. APAP treatment inhibited complex II activity ex vivo but did not alter the protein expression levels of subunits SdhA or SdhC after 4 h. In conclusion, MB can effectively protect mice against APAP-induced liver injury by bypassing the NAPQI-altered mitochondrial complex II, thus alleviating the cellular energy crisis. Because MB is a clinically used drug, its potential application after APAP overdose in patients should be further explored. (Hepatology 2014;).</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 American Association for the Study of Liver Diseases.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Lee</LastName>
                    <ForeName>Kang Kwang</ForeName>
                    <Initials>KK</Initials>
                    <Affiliation>Department of Pharmaceutical Sciences, University of Connecticut, Storrs, CT.</Affiliation>
                </Author>
                <Author>
                    <LastName>Imaizumi</LastName>
                    <ForeName>Naoki</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author>
                    <LastName>Chamberland</LastName>
                    <ForeName>Sally R</ForeName>
                    <Initials>SR</Initials>
                </Author>
                <Author>
                    <LastName>Alder</LastName>
                    <ForeName>Nathan N</ForeName>
                    <Initials>NN</Initials>
                </Author>
                <Author>
                    <LastName>Boelsterli</LastName>
                    <ForeName>Urs A</ForeName>
                    <Initials>UA</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Hepatology</MedlineTA>
            <NlmUniqueID>8302946</NlmUniqueID>
            <ISSNLinking>0270-9139</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Complex II</Keyword>
            <Keyword MajorTopicYN="N">Hepatotoxicity</Keyword>
            <Keyword MajorTopicYN="N">Mitochondria</Keyword>
            <Keyword MajorTopicYN="N">NAPQI</Keyword>
            <Keyword MajorTopicYN="N">Succinate dehydrogenase</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>8</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.27385</ArticleId>
            <ArticleId IdType="pubmed">25142022</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25142021</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>25</Day>
        </DateCreated>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1471-2334</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>14</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>BMC infectious diseases</Title>
                <ISOAbbreviation>BMC Infect. Dis.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Leishmania amazonensis infection impairs dendritic cell migration from the inflammatory site to the draining lymph node.</ArticleTitle>
            <Pagination>
                <MedlinePgn>450</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1186/1471-2334-14-450</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In vitro studies show that Leishmania infection decreases the adhesion of inflammatory phagocytes to connective tissue by a mechanism dependent on the modulation of integrin function. However, we know little about the influence of this reduction in leukocyte adhesion on parasite dissemination from the infection site.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">In this work, we used a model of chronic peritonitis induced by thioglycollate to study the effect of L. amazonensis infection on the ability of inflammatory phagocyte populations to migrate from an inflammatory site to the draining lymph node. Uninfected or Leishmania-infected thioglycollate-elicited peritoneal exudate cells were transferred from C57BL/6 to BALB/c mice or from Ly5.1+ to Ly5.1- mice. The transferred cells were injected into the peritoneal cavity and tracked to the draining lymph node.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Migrating cells corresponded to approximately 1% of the injected leukocytes. The proportion of migrating CD11b+CD11c+ (myeloid dendritic cell) was lower after incubation with Leishmania (1.3 to 2.6 times lower in the experiments using C57BL/6 to BALB/c animals and 2.7 to 3.4 times lower in the experiments using Ly5.1+ to Ly5.1- animals) than after leukocyte incubation with medium alone (P???&lt;???0.01). There was no consistent decrease in the migration of CD11b+F4/80+ (macrophage) or SSChi GR-1+ (neutrophil) populations.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Coincubation with Leishmania changes the migratory pattern of dendritic cells in vivo. Such changes in dendritic cell migration may be associated with immunological events that maintain inflammation at the sites of infection.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Hermida</LastName>
                    <ForeName>Micely Dr</ForeName>
                    <Initials>MD</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Doria</LastName>
                    <ForeName>Priscila G</ForeName>
                    <Initials>PG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Taguchi</LastName>
                    <ForeName>Angela Mp</ForeName>
                    <Initials>AM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mengel</LastName>
                    <ForeName>Jos?? O</ForeName>
                    <Initials>JO</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dos-Santos</LastName>
                    <ForeName>Washington Lc</ForeName>
                    <Initials>WL</Initials>
                    <Affiliation>Centro de Pesquisas Gon??alo Moniz, Oswaldo Cruz Foundation, Fiocruz, LPBI, Salvador, Brazil. wluis@bahia.fiocruz.br.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>BMC Infect Dis</MedlineTA>
            <NlmUniqueID>100968551</NlmUniqueID>
            <ISSNLinking>1471-2334</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">1471-2334-14-450</ArticleId>
            <ArticleId IdType="doi">10.1186/1471-2334-14-450</ArticleId>
            <ArticleId IdType="pubmed">25142021</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25142017</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1521-4141</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>European journal of immunology</Title>
                <ISOAbbreviation>Eur. J. Immunol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Myeloid-derived suppressor cell functionality and interaction with Leishmania major parasites differ in C57BL/6 and BALB/c mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1002/eji.201344335</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Myeloid-derived suppressor cells (MDSCs) represent a heterogeneous population of CD11b(+) cells. According to the surface molecules Ly6G and Ly6C, MDSCs are further dissected into monocytic (Mo-MDSCs, CD11b(+) /Ly6C(high) /Ly6G(-) ) and polymorphonucleated suppressor cells (PMN-MDSCs, CD11b(+) /Ly6C(int) /Ly6G(+) ). Most published manuscripts focus on the suppressive role of MDSCs in cancer, whereas their impact in adaptive immunity against obligatory intracellular parasites is not well understood. Furthermore, it is not clear how the genetic background of mice influences MDSC functionality. Therefore, we implemented an experimental model of leishmaniasis and analyzed MDSC maturation and the impact of MDSCs on the parasite-specific T-cell responses in resistant C57BL/6 and susceptible BALB/c mice. This experimental setup demonstrated the impaired ability of BALB/c mice to originate Mo-MDSCs when compared with C57BL/6 mice. This phenotype is detectable after subcutaneous infection with parasites and is specifically represented by a reduced accumulation of Mo-MDSCs at the site of infection in BALB/c mice. Moreover, infected C57BL/6-derived MDSCs were able to suppress Leishmania-specific CD4(+) T cell- proliferation, whereas BALB/c-derived MDSCs harboring parasites lost this suppressive function. In conclusion, we demonstrate that: i) genetic background defines MDSC differentiation; and ii) Leishmania major parasites are able to modulate the suppressive effect of MDSCs in a strain-dependent manner. This article is protected by copyright. All rights reserved.</AbstractText>
                <CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Schmid</LastName>
                    <ForeName>Maximilian</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Inst. of Immunology, University of Regensburg, Regensburg, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zimara</LastName>
                    <ForeName>Nicole</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author>
                    <LastName>Wege</LastName>
                    <ForeName>Anja Kathrin</ForeName>
                    <Initials>AK</Initials>
                </Author>
                <Author>
                    <LastName>Ritter</LastName>
                    <ForeName>Uwe</ForeName>
                    <Initials>U</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Eur J Immunol</MedlineTA>
            <NlmUniqueID>1273201</NlmUniqueID>
            <ISSNLinking>0014-2980</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Leishmania major</Keyword>
            <Keyword MajorTopicYN="N">arginase-1</Keyword>
            <Keyword MajorTopicYN="N">bone marrow</Keyword>
            <Keyword MajorTopicYN="N">iNOS</Keyword>
            <Keyword MajorTopicYN="N">myeloid-derived suppressor cells</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>11</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1002/eji.201344335</ArticleId>
            <ArticleId IdType="pubmed">25142017</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25142016</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1098-1136</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Glia</Title>
                <ISOAbbreviation>Glia</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Altered microglial phagocytosis in GPR34-deficient mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1002/glia.22744</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">GPR34 is a Gi/o protein-coupled receptor (GPCR) of the nucleotide receptor P2Y12 -like group. This receptor is highly expressed in microglia, however, the functional relevance of GPR34 in these glial cells is unknown. Previous results suggested an impaired immune response in GPR34-deficient mice infected with Cryptococcus neoformans. Here we show that GPR34 deficiency results in morphological changes in retinal and cortical microglia. RNA sequencing analysis of microglia revealed a number of differentially expressed transcripts involved in cell motility and phagocytosis. We found no differences in microglial motility after entorhinal cortex lesion and in response to laser lesion. However, GPR34-deficient microglia showed reduced phagocytosis activity in both retina and acutely isolated cortical slices. Our study identifies GPR34 as an important signaling component controlling microglial function, morphology and phagocytosis. GLIA 2014.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Wiley Periodicals, Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Preissler</LastName>
                    <ForeName>Julia</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Institute of Biochemistry, Medical Faculty, University Leipzig, Leipzig, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Grosche</LastName>
                    <ForeName>Antje</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author>
                    <LastName>Lede</LastName>
                    <ForeName>Vera</ForeName>
                    <Initials>V</Initials>
                </Author>
                <Author>
                    <LastName>Le Duc</LastName>
                    <ForeName>Diana</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author>
                    <LastName>Kr??gel</LastName>
                    <ForeName>Katja</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author>
                    <LastName>Matyash</LastName>
                    <ForeName>Vitali</ForeName>
                    <Initials>V</Initials>
                </Author>
                <Author>
                    <LastName>Szulzewsky</LastName>
                    <ForeName>Frank</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author>
                    <LastName>Kallendrusch</LastName>
                    <ForeName>Sonja</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author>
                    <LastName>Immig</LastName>
                    <ForeName>Kerstin</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author>
                    <LastName>Kettenmann</LastName>
                    <ForeName>Helmut</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author>
                    <LastName>Bechmann</LastName>
                    <ForeName>Ingo</ForeName>
                    <Initials>I</Initials>
                </Author>
                <Author>
                    <LastName>Sch??neberg</LastName>
                    <ForeName>Torsten</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author>
                    <LastName>Schulz</LastName>
                    <ForeName>Angela</ForeName>
                    <Initials>A</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Glia</MedlineTA>
            <NlmUniqueID>8806785</NlmUniqueID>
            <ISSNLinking>0894-1491</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">GPCR</Keyword>
            <Keyword MajorTopicYN="N">GPR34</Keyword>
            <Keyword MajorTopicYN="N">OHSC</Keyword>
            <Keyword MajorTopicYN="N">RNA sequencing</Keyword>
            <Keyword MajorTopicYN="N">microglia</Keyword>
            <Keyword MajorTopicYN="N">neurodegenerative disease</Keyword>
            <Keyword MajorTopicYN="N">phagocytosis</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1002/glia.22744</ArticleId>
            <ArticleId IdType="pubmed">25142016</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25141992</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1432-0711</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Archives of gynecology and obstetrics</Title>
                <ISOAbbreviation>Arch. Gynecol. Obstet.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effect of CO2 pneumoperitoneum on the proliferation of human ovarian cancer cell line SKOV-3 and the expression of NM23-H1 and MMP-2.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study aims to investigate the impacts of CO2 pneumoperitoneum on the growth of ovarian cancer in nude mice and the expression of tumor metastasis suppressor gene (NM23-H1) and matrix metalloproteinase -2 (MMP-2) in SKOV-3 ovarian cancer cell line cancer tissue.</AbstractText>
                <AbstractText Label="METHOD" NlmCategory="METHODS">Forty five?? nude mice were used to establish ovarian cancer xenograft models by intraperitoneal injection of human ovarian cancer cell line SKOV-3. Murine xenograft models were divided into four groups: control group (only anesthetized for 0.5??h), laparotomy group (laparotomy for 0.5??h), CO2 pneumoperitoneum of 0.5??h, and CO2 pneumoperitoneum of 1??h group. Mice were killed after 12??weeks to observe intraperitoneal tumor growth and detected mRNA expression of NM23-H1 and MMP-2 in tumor tissues by RT-PCR.</AbstractText>
                <AbstractText Label="RESULT" NlmCategory="RESULTS">Our data show that xenograft tumors grew faster in the CO2 pneumoperitoneum groups than that in control and laparotomy groups and even faster in??the CO2 pneumoperitoneum of 1??h group. The mRNA expression of NM23-H1 in CO2 pneumoperitoneum groups was significantly lower than that in control group and laparotomy group (P??&lt;??0.01). Moreover, the longer duration of CO2 pneumoperitoneum negatively correlated with lower expression of NM23-H1 (P??&lt;??0.01). In contrast to NM23-H1, MMP-2 expression was significantly higher in CO2 pneumoperitoneum groups than that in the control group and laparotomy group (P??&lt;??0.01) and positively correlated with the duration of CO2 pneumoperitoneum (P??&lt;??0.01). In addition, there was a negative correlation between the expression of NM23-H1 and MMP-2 (r??=??-0.984, P??&lt;??0.05).</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The CO2 pneumoperitoneum could promote the proliferation and metastasis of human ovarian cancer in nude mice. This effect was positively correlated with the duration of CO2 pneumoperitoneum.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Ying</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Obstetrics and Gynecology, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Luo</LastName>
                    <ForeName>Xin</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author>
                    <LastName>Fan</LastName>
                    <ForeName>Bingjuan</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Huijuan</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author>
                    <LastName>Fu</LastName>
                    <ForeName>Aizhen</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author>
                    <LastName>Huang</LastName>
                    <ForeName>Jinzhi</ForeName>
                    <Initials>J</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Arch Gynecol Obstet</MedlineTA>
            <NlmUniqueID>8710213</NlmUniqueID>
            <ISSNLinking>0932-0067</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>1</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00404-014-3414-2</ArticleId>
            <ArticleId IdType="pubmed">25141992</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25141982</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1573-4994</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>22</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of fluorescence</Title>
                <ISOAbbreviation>J Fluoresc</ISOAbbreviation>
            </Journal>
            <ArticleTitle>In Vitro Culture and Characterization of Human Lung Cancer Circulating Tumor Cells Isolated by Size Exclusion from an Orthotopic Nude-Mouse Model Expressing Fluorescent Protein.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">In the present study, we demonstrate an animal model and recently introduced size-based exclusion method for circulating tumor cells (CTCs) isolation. The methodology enables subsequent in vitro CTC-culture and characterization. Human lung cancer cell line H460, expressing red fluorescent protein (H460-RFP), was orthotopically implanted in nude mice. CTCs were isolated by a size-based filtration method and successfully cultured in vitro on the separating membrane (MetaCell??), analyzed by means of time-lapse imaging. The cultured CTCs were heterogeneous in size and morphology even though they originated from a single tumor. The outer CTC-membranes were blebbing in general. Abnormal mitosis resulting in three daughter cells was frequently observed. The expression of RFP ensured that the CTCs originated from lung tumor. These readily isolatable, identifiable and cultivable CTCs can be used to characterize individual patient cancers and for screening of more effective treatment.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Kolostova</LastName>
                    <ForeName>Katarina</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Department of Laboratory Genetics, University Hospital Kralovske Vinohrady, Srobarova 50, 100 34, Prague, Czech Republic.</Affiliation>
                </Author>
                <Author>
                    <LastName>Zhang</LastName>
                    <ForeName>Yong</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author>
                    <LastName>Hoffman</LastName>
                    <ForeName>Robert M</ForeName>
                    <Initials>RM</Initials>
                </Author>
                <Author>
                    <LastName>Bobek</LastName>
                    <ForeName>Vladimir</ForeName>
                    <Initials>V</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Fluoresc</MedlineTA>
            <NlmUniqueID>9201341</NlmUniqueID>
            <ISSNLinking>1053-0509</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10895-014-1439-3</ArticleId>
            <ArticleId IdType="pubmed">25141982</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25141966</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1573-9368</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Transgenic research</Title>
                <ISOAbbreviation>Transgenic Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Impaired erythrocyte deformability in transgenic HO-1G143H mutant mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">To investigate the potential effects of variation of HO-1 activity on hemorheology, this study compared the hemorheological properties between transgenic HO-1G143H mutant mice and wild-type (WT) control mice. Fresh blood samples were obtained from mice via the ocular venous sinus. The whole blood viscosity was measured using a cone-plate viscometer. Erythrocyte deformability and aggregation was measured using ektacytometry. The elongation index was significantly reduced in the HO-1G143H mutant mice compared to the WT mice at the shear rates of 600, 800, and 1,000??s(-1). The integrated elongation index was decreased in the HO-1G143H mutant mice compared to the WT mice. There was no statistically significant difference between the HO-1G143H mutant mice and the WT mice in terms of whole blood viscosity, aggregation index, amplitude of aggregation, and aggregation half time. The present study demonstrated that a reduction in HO-1 activity results in an impaired erythrocyte deformability. Although the mechanism underlying this effect remains unclear, our study brings to light the participation of HO-1 in the variations of hemorheology.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Gan</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Institute of Transfusion Medicine, Academy of Military Medical Sciences, No. 27th Taiping Road, HaiDian, Beijing, China, chenlzu2005@163.com.</Affiliation>
                </Author>
                <Author>
                    <LastName>Yin</LastName>
                    <ForeName>Yujing</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author>
                    <LastName>Wang</LastName>
                    <ForeName>Bo</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>Penglong</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Qingjun</ForeName>
                    <Initials>Q</Initials>
                </Author>
                <Author>
                    <LastName>You</LastName>
                    <ForeName>Guoxing</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author>
                    <LastName>Zhao</LastName>
                    <ForeName>Jingxiang</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author>
                    <LastName>Xia</LastName>
                    <ForeName>Sha</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author>
                    <LastName>Zhao</LastName>
                    <ForeName>Lian</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author>
                    <LastName>Zhou</LastName>
                    <ForeName>Hong</ForeName>
                    <Initials>H</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Transgenic Res</MedlineTA>
            <NlmUniqueID>9209120</NlmUniqueID>
            <ISSNLinking>0962-8819</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>11</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11248-014-9829-5</ArticleId>
            <ArticleId IdType="pubmed">25141966</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25141924</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1347-8648</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>125</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of pharmacological sciences</Title>
                <ISOAbbreviation>J. Pharmacol. Sci.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>In vitro and in vivo effects of xanthorrhizol on human breast cancer mcf-7 cells treated with tamoxifen.</ArticleTitle>
            <Pagination>
                <MedlinePgn>375-85</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>This study investigated the herb-drug interaction of xanthorrhizol and tamoxifen in human breast cancer cells. Using MCF-7 cell line as an in vitro model, the herb-drug interaction between xanthorrhizol and tamoxifen was measured by MTT assay, luciferase reporter assay, and cell cycle analysis. The effects of xanthorrhizol on growth/autophagy related signaling were determined by immunostaining, western blotting, and real time RT-PCR. Additionally, the in vivo effect of xanthorrhizol and tamoxifen on athymic nude mice implanted with MCF-7 cells was evaluated. When MCF-7 cells were co-treated with tamoxifen and xanthorrhizol, there were no significant changes in terms of cell number, luciferase activity, percentage S-phase cells and LC3-II expression. However, using the MCF-7 implanted nude mice model, it was possible to detect significantly increased tumor volumes, a larger tumor size, and increased protein expression of P38 and P27(Kip1) in the xanthorrhizol + tamoxifen group compared to the tamoxifen-alone group. It can be concluded that while there is no significant herb-drug interaction between xanthorrhizol and tamoxifen in vitro, there is such an interaction in tumor-bearing mice, which provides important information that affects breast cancer treatment translational research.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Noomhorm</LastName>
                    <ForeName>Nattanant</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Institute of Traditional Medicine, School of Medicine, National Yang-Ming University, Taiwan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chang</LastName>
                    <ForeName>Chun-Ju</ForeName>
                    <Initials>CJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wen</LastName>
                    <ForeName>Che-Sheng</ForeName>
                    <Initials>CS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Jir-You</ForeName>
                    <Initials>JY</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Jiun-Liang</ForeName>
                    <Initials>JL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tseng</LastName>
                    <ForeName>Ling-Ming</ForeName>
                    <Initials>LM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Wei-Shone</ForeName>
                    <Initials>WS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chiu</LastName>
                    <ForeName>Jen-Hwey</ForeName>
                    <Initials>JH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shyr</LastName>
                    <ForeName>Yi-Ming</ForeName>
                    <Initials>YM</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Japan</Country>
            <MedlineTA>J Pharmacol Sci</MedlineTA>
            <NlmUniqueID>101167001</NlmUniqueID>
            <ISSNLinking>1347-8613</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">DN/JST.JSTAGE/jphs/14024FP</ArticleId>
            <ArticleId IdType="pubmed">25141924</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25141864</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1743-422X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>11</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Virology journal</Title>
                <ISOAbbreviation>Virol. J.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Chitosan microparticles loaded with yeast-derived PCV2 virus-like particles elicit antigen-specific cellular immune response in mice after oral administration.</ArticleTitle>
            <Pagination>
                <MedlinePgn>149</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Porcine circovirus type 2 (PCV2)-associated diseases are a major problem for the swine industry worldwide. In addition to improved management and husbandry practices, the availability of several anti-PCV2 vaccines provides an efficient immunological option for reducing the impact of these diseases. Most anti-PCV2 vaccines are marketed as injectable formulations. Although these are effective, there are problems associated with the use of injectable products, including laborious and time-consuming procedures, the induction of inflammatory responses at the injection site, and treatment-associated stress to the animals. Oral vaccines represent an improvement in antigen delivery technology; they overcome the problems associated with injection management and facilitate antigen boosting when an animals' immunity falls outside the protective window.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Chitosan microparticles were used as both a vehicle and mucosal adjuvant to deliver yeast-derived PCV2 virus-like particles (VLPs) in an attempt to develop an oral vaccine. The physical characteristics of the microparticles, including size, Zeta potential, and polydispersity, were examined along with the potential to induce PCV2-specific cellular immune responses in mice after oral delivery.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Feeding mice with PCV2 VLP-loaded, positively-charged chitosan microparticles with an average size of 2.5 mum induced the proliferation of PCV2-specific splenic CD4+/CD8+ lymphocytes and the subsequent production of IFN-gamma to levels comparable with those induced by an injectable commercial formulation.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Chitosan microparticles appear to be a safe, simple system on which to base PCV2 oral vaccines. Oral chitosan-mediated antigen delivery is a novel strategy that efficiently induces anti-PCV2 cellular responses in a mouse model. Further studies in swine are warranted.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Bucarey</LastName>
                    <ForeName>Sergio A</ForeName>
                    <Initials>SA</Initials>
                </Author>
                <Author>
                    <LastName>Pujol</LastName>
                    <ForeName>Myriam</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author>
                    <LastName>Poblete</LastName>
                    <ForeName>Joaqu??n</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author>
                    <LastName>Nu??ez</LastName>
                    <ForeName>Ignacio</ForeName>
                    <Initials>I</Initials>
                </Author>
                <Author>
                    <LastName>Tapia</LastName>
                    <ForeName>Cecilia V</ForeName>
                    <Initials>CV</Initials>
                </Author>
                <Author>
                    <LastName>Neira-Carrillo</LastName>
                    <ForeName>Andr??nico</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author>
                    <LastName>Martinez</LastName>
                    <ForeName>Jonat??n</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author>
                    <LastName>Bassa</LastName>
                    <ForeName>Oliver</ForeName>
                    <Initials>O</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Virol J</MedlineTA>
            <NlmUniqueID>101231645</NlmUniqueID>
            <ISSNLinking>1743-422X</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">1743-422X-11-149</ArticleId>
            <ArticleId IdType="doi">10.1186/1743-422X-11-149</ArticleId>
            <ArticleId IdType="pubmed">25141864</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25141847</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1528-1132</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical orthopaedics and related research</Title>
                <ISOAbbreviation>Clin. Orthop. Relat. Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>CORR Insights(??): Fractures in Geriatric Mice Show Decreased Callus Expansion and Bone Volume.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <AuthorList>
                <Author>
                    <LastName>Boskey</LastName>
                    <ForeName>Adele L</ForeName>
                    <Initials>AL</Initials>
                    <Affiliation>Research Division, Hospital for Special Surgery (affiliated with Weill Medical College of Cornell University), 535 E 70th Street, New York, NY, 10021, USA, Boskeya@HSS.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Clin Orthop Relat Res</MedlineTA>
            <NlmUniqueID>0075674</NlmUniqueID>
            <ISSNLinking>0009-921X</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11999-014-3892-3</ArticleId>
            <ArticleId IdType="pubmed">25141847</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25141839</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1573-7330</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of assisted reproduction and genetics</Title>
                <ISOAbbreviation>J. Assist. Reprod. Genet.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>TBHP-induced oxidative stress alters microRNAs expression in mouse testis.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Reactive oxygen species (ROS) and oxidative stress is one of the main reasons of male infertility. MicroRNAs (miRNAs) regulate multiple intracellular processes. Alterations in miRNAs expression may occur in different conditions and diseases. In this study, the effect of oxidative stress induced by tertiary-butyl hydroperoxide (TBHP) on the expression of candidate miRNAs in mouse testis was investigated.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">After determining median lethal dose (LD50), TBHP was intraperitoneally (ip) injected at the dilution of 1:10 LD50 into the adult male mice for 2weeks, and then testis tissues were removed in order to assay the ROS level. Total RNA was extracted and the expression of five miRNAs was quantified by reverse transcription-real time polymerase chain reaction (RT-qPCR).</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The flow cytometry analysis showed a significant increase in ROS level in testis. The expression of three out of five selected miRNAs, including miR-34a, miR-181b and miR-122a, showed some degrees of changes following exposure to oxidative stress. These miRNAs are involved in antioxidant responses, inflammation pathway and spermatogenesis arrest.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In conclusion, TBHP alters the miRNA expression profile of testis which might play a potential role in oxidative and antioxidative responses and spermatogenesis.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Fatemi</LastName>
                    <ForeName>Nayeralsadat</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Department of Genetics at Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, P.O. Box: 19395-4644, Tehran, Iran.</Affiliation>
                </Author>
                <Author>
                    <LastName>Sanati</LastName>
                    <ForeName>Mohammad Hossein</ForeName>
                    <Initials>MH</Initials>
                </Author>
                <Author>
                    <LastName>Shamsara</LastName>
                    <ForeName>Mehdi</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author>
                    <LastName>Moayer</LastName>
                    <ForeName>Fariborz</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author>
                    <LastName>Zavarehei</LastName>
                    <ForeName>Mansour Jamali</ForeName>
                    <Initials>MJ</Initials>
                </Author>
                <Author>
                    <LastName>Pouya</LastName>
                    <ForeName>Alireza</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author>
                    <LastName>Sayyahpour</LastName>
                    <ForeName>ForoughAzam</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author>
                    <LastName>Ayat</LastName>
                    <ForeName>Hoda</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author>
                    <LastName>Gourabi</LastName>
                    <ForeName>Hamid</ForeName>
                    <Initials>H</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Assist Reprod Genet</MedlineTA>
            <NlmUniqueID>9206495</NlmUniqueID>
            <ISSNLinking>1058-0468</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>4</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10815-014-0302-4</ArticleId>
            <ArticleId IdType="pubmed">25141839</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25141837</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1930-739X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Obesity (Silver Spring, Md.)</Title>
                <ISOAbbreviation>Obesity (Silver Spring)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Long-term inhibition of miR-21 leads to reduction of obesity in db/db mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1002/oby.20852</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess the effect of long-term pharmacological inhibition of miR-21 in a model of metabolic syndrome and obesity.</AbstractText>
                <AbstractText Label="DESIGN AND METHODS" NlmCategory="METHODS">Aged db/db mice were treated with locked nucleic acid-modified anti-miRs directed against miR-21 (LNA-21), control LNAs or PBS for 18 weeks. Cardiac function was assessed by echocardiography and the effect on body weight and white adipose tissue (WAT) was evaluated.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">MiR-21 expression was efficiently inhibited in the heart and WAT with no apparent liver toxicity or deterioration of kidney function. MiR-21 inhibition had no effect on cardiac hypertrophy as well as systolic and diastolic cardiac functions. However, levels of cardiac collagen 1 were modestly reduced in LNA-21 treated mice. MiR-21 inhibition reduced body weight, as well as adipocyte size and serum triglycerides were significantly decreased. The miR-21 targets TGF??-receptor 2 (TGFBR2) and phosphatase and tensin homolog (PTEN) were derepressed in WAT of LNA-21 treated mice and Sprouty1 and 2 were increased after miR-21 inhibition.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Long-term treatment with LNA-21 is safe and efficiently suppresses miR-21 expression. Cardiac function was not affected. LNA-21 treatment led to a significant weight loss and reduces adipocyte size as well as derepression of the targets TGFRB2, PTEN, and Sprouty1 and 2.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 The Obesity Society.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Seeger</LastName>
                    <ForeName>Timon</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>From the Institute for Cardiovascular Regeneration, Center of Molecular Medicine, University of Frankfurt, Frankfurt, Germany; Department of Cardiology, Internal Medicine III, University of Frankfurt, Frankfurt, Germany.</Affiliation>
                </Author>
                <Author>
                    <LastName>Fischer</LastName>
                    <ForeName>Ariane</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author>
                    <LastName>Muhly-Reinholz</LastName>
                    <ForeName>Marion</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author>
                    <LastName>Zeiher</LastName>
                    <ForeName>Andreas M</ForeName>
                    <Initials>AM</Initials>
                </Author>
                <Author>
                    <LastName>Dimmeler</LastName>
                    <ForeName>Stefanie</ForeName>
                    <Initials>S</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Obesity (Silver Spring)</MedlineTA>
            <NlmUniqueID>101264860</NlmUniqueID>
            <ISSNLinking>1930-7381</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1002/oby.20852</ArticleId>
            <ArticleId IdType="pubmed">25141837</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25141836</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1097-0177</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>243</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Developmental dynamics : an official publication of the American Association of Anatomists</Title>
                <ISOAbbreviation>Dev. Dyn.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A piggyBac transposon- and gateway-enhanced system for efficient BAC transgenesis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>C1</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1002/dvdy.24051</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Bacterial artificial chromosomes (BACs) have become increasingly popular vectors for making transgenic mice, as they are able to carry large genomic DNA fragments that in many cases are needed to reproduce the endogenous gene expression pattern. However, the efficiency of BAC transgenesis is generally low, and gene transfer to BAC vectors by recombination-mediated engineering (recombineering) is time-consuming and technically demanding.</AbstractText>
                <AbstractText Label="RESULTS AND CONCLUSIONS" NlmCategory="CONCLUSIONS">We present an enhanced system, comprising a BAC vector retrofitted with piggyBac DNA transposon elements and attL (Gateway) docking sites, that obviates these problems. Using this system, a gene-of-interest (such as a reporter gene) is transferred to the vector in a one-step in vitro reaction, and piggyBac transposition mediates transgene integration at high efficiency when microinjected into mouse zygotes with piggyBac transposase mRNA. We establish proof-of-principle for this system using a Wilms tumour-1 (Wt1) BAC to drive expression of an mCherry-2A-EGFP (RG) reporter gene, which yielded transgenic mice at a frequency of 33%, and recapitulated endogenous WT1 expression in developing gonads, kidneys and heart. The system we describe is applicable to any BAC transgenesis strategy. Developmental Dynamics 243:1086-1094, 2014. ?? 2014 Wiley Periodicals, Inc.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014 Wiley Periodicals, Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zhao</LastName>
                    <ForeName>Liang</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, 4072, Australia.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ng</LastName>
                    <ForeName>Ee Ting</ForeName>
                    <Initials>ET</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Koopman</LastName>
                    <ForeName>Peter</ForeName>
                    <Initials>P</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Dev Dyn</MedlineTA>
            <NlmUniqueID>9201927</NlmUniqueID>
            <ISSNLinking>1058-8388</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Wt1</Keyword>
            <Keyword MajorTopicYN="N">heart development</Keyword>
            <Keyword MajorTopicYN="N">kidney development</Keyword>
            <Keyword MajorTopicYN="N">sex determination</Keyword>
            <Keyword MajorTopicYN="N">testis development</Keyword>
            <Keyword MajorTopicYN="N">transgenic mice</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>5</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>5</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1002/dvdy.24051</ArticleId>
            <ArticleId IdType="pubmed">25141836</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25141818</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1672-0415</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Chinese journal of integrative medicine</Title>
                <ISOAbbreviation>Chin J Integr Med</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effect of p27 gene combined with Pientzehuang () on tumor growth in osteosarcoma-bearing nude mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To observe the effect of p27 gene recombinant adenovirus combined with Chinese medicine Pientzehuang () on the growth of xenografted human osteosarcoma in nude mice.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Tissue transplantation was used to construct the orthotopic model of human osteosarcoma Saos-2 cell in nude mice. Thirty tumor-bearing nude mice were randomly divided into 5 groups with 6 mice in each group: blank control group (model of osteosarcoma), empty vector group (recombinant adeno-associated virus-multiple cloning site), Pientzehuang group, p27 gene group and combined treatment group (p27 gene combined with Pientzehuang). The effect of combined treatment on human osteosarcoma was analyzed through the tumor formation, tumor volume and inhibition rate of tumor growth. The expression of p27 was measured by immunohistochemical staining and Western blot.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The orthotopic model of osteosarcoma in nude mice was successfully constructed. The general appearance of tumor-bearing nude mice in Pientzehuang and p27 gene groups was markedly improved compared with the blank control group; and in the combined treatment group it was significantly improved compared with the Pientzehuang and p27 gene groups. The tumor growth in the Pientzehuang and p27 gene groups was significantly inhibited compared with the blank control group (P&lt;0.05); while in the combined treatment group it was markedly inhibited compared with the Pientzehuang and p27 gene groups (P&lt;0.05). The rates of tumor growth inhibition were 34.1%, 56.5% and 63.8% in the Pientzehuang, p27 gene and combined treatment groups, respectively. Meanwhile, the protein expression of p27 gene in the p27 gene group was significantly increased compared with the blank control group (P&lt;0.05); and it was significantly increased in the combined treatment group compared with the p27 gene and Pientzehuang groups (P&lt;0.05).</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">p27 gene introduced by adenovirus combined with Pientzehuang can inhibit the growth of human osteosarcoma cell Saos-2 in nude mice.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Ren</LastName>
                    <ForeName>Shou-Song</ForeName>
                    <Initials>SS</Initials>
                    <Affiliation>Cheeloo Health Science Center of Shandong University, Jinan, 250012, China.</Affiliation>
                </Author>
                <Author>
                    <LastName>Yuan</LastName>
                    <ForeName>Fang</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Ying-Hong</ForeName>
                    <Initials>YH</Initials>
                </Author>
                <Author>
                    <LastName>Zhou</LastName>
                    <ForeName>Le-Tian</ForeName>
                    <Initials>LT</Initials>
                </Author>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>Jun</ForeName>
                    <Initials>J</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Chin J Integr Med</MedlineTA>
            <NlmUniqueID>101181180</NlmUniqueID>
            <ISSNLinking>1672-0415</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2011</Year>
                <Month>11</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11655-014-1766-x</ArticleId>
            <ArticleId IdType="pubmed">25141818</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25141794</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1478-6427</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>21</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Natural product research</Title>
                <ISOAbbreviation>Nat. Prod. Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Structure and hypolipidaemic activity of fucoidan extracted from brown seaweed Sargassum henslowianum.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1-5</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The aim of this study is to elucidate the structure and investigate the hypolipidaemic activity of a fucoidan extracted from brown seaweed Sargassum henslowianum collected at Hai Van-Son Cha peninsula, Hue province, Vietnam by using tandem electrospray ionisation mass spectrometry. The results demonstrated that the fucoidan has ??(1???????3)-linked l-fucopyranose backbone and sulphate groups occupied mostly at C-2, C-4 and sometimes at C-3 position of fucose residues. The results of in vivo bioactivity examination revealed that the fucoidan in the dose of 100??mg/kgP/day by oral administration helped decrease cholesterol, triglyceride and LDL-cholesterol levels on obese mice.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Cuong</LastName>
                    <ForeName>Ho Duc</ForeName>
                    <Initials>HD</Initials>
                    <Affiliation>a School of Chemical Engineering, Hanoi University of Science and Technology , Ha Noi , Viet Nam.</Affiliation>
                </Author>
                <Author>
                    <LastName>Thuy</LastName>
                    <ForeName>Thanh Thi Thu</ForeName>
                    <Initials>TT</Initials>
                </Author>
                <Author>
                    <LastName>Huong</LastName>
                    <ForeName>Tran Thu</ForeName>
                    <Initials>TT</Initials>
                </Author>
                <Author>
                    <LastName>Ly</LastName>
                    <ForeName>Bui Minh</ForeName>
                    <Initials>BM</Initials>
                </Author>
                <Author>
                    <LastName>Van</LastName>
                    <ForeName>Tran Thi Thanh</ForeName>
                    <Initials>TT</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Nat Prod Res</MedlineTA>
            <NlmUniqueID>101167924</NlmUniqueID>
            <ISSNLinking>1478-6419</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Fucoidan</Keyword>
            <Keyword MajorTopicYN="N">brown seaweed Sargassum henslowianum</Keyword>
            <Keyword MajorTopicYN="N">hypolipidaemic activity</Keyword>
            <Keyword MajorTopicYN="N">structure</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14786419.2014.948436</ArticleId>
            <ArticleId IdType="pubmed">25141794</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
        <PMID Version="1">25141543</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0019-5189</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>52</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Indian journal of experimental biology</Title>
                <ISOAbbreviation>Indian J. Exp. Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Punarnavine, an alkaloid isolated from ethanolic extract of Boerhaavia diffusa Linn. reverses depression-like behaviour in mice subjected to chronic unpredictable mild stress.</ArticleTitle>
            <Pagination>
                <MedlinePgn>799-807</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Punarnavine (20 and 40 mg/kg) and fluoxetine (20 mg/kg) per se administered orally for 14 successive days significantly decreased immobility periods of both unstressed and stressed mice in forced swim test. These drugs also significantly decreased sucrose preference in both stressed and unstressed mice as compared to their respective controls, indicating significant antidepressant-like activity. The drugs did not show any significant effect on locomotor activity of mice. The alkaloid also significantly decreased monoamine oxidase (MAO-A) activity, malondialdehyde levels in both unstressed and stressed mice; and significantly reversed the stress-induced decrease in reduced glutathione and catalase activity. It also significantly attenuated the stress-induced increase in plasma nitrite and corticosterone levels. Thus, punarnavine showed antidepressant-like activity in unstressed and stressed mice probably through inhibition of brain MAO-A activity, decrease in plasma nitrite levels and due to its antioxidant activity. In addition, punarnavine also showed antidepressant-like activity in stressed mice possibly through decrease in plasma corticosterone levels.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Dhingra</LastName>
                    <ForeName>Dinesh</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Valecha</LastName>
                    <ForeName>Rekha</ForeName>
                    <Initials>R</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>India</Country>
            <MedlineTA>Indian J Exp Biol</MedlineTA>
            <NlmUniqueID>0233411</NlmUniqueID>
            <ISSNLinking>0019-5189</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25141543</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
        <PMID Version="1">25141540</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0019-5189</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>52</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Indian journal of experimental biology</Title>
                <ISOAbbreviation>Indian J. Exp. Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>43 kDa and 66 kDa, two blood stage antigens induce immune response in Plasmodium berghei malaria.</ArticleTitle>
            <Pagination>
                <MedlinePgn>781-6</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The hunt for an effective vaccine against malaria still continues. Several new target antigens as candidates for vaccine design are being explored and tested for their efficacy. In the present study the sera from mice immunized with 24,000 x g fraction of Plasmodium berghei has been used to identify highly immunogenic blood stage antigens. The protective antibodies present in immune sera were covalently immobilized on CNBr activated sepharose 4B and used for affinity chromatography purification of antigens present in blood stages of P. berghei. Two polypeptides of 66 and 43 kDa molecular weights proved to be highly immunogenic. They exhibited a strong humoral immune response in mice as evident by high titres in ELISA and IFA. Protective immunity by these two antigens was apparent by in vivo and in vitro studies. These two proteins could further be analysed and used as antigens in malaria vaccine design.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Pirta</LastName>
                    <ForeName>Chhaya</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Banyal</LastName>
                    <ForeName>H S</ForeName>
                    <Initials>HS</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>India</Country>
            <MedlineTA>Indian J Exp Biol</MedlineTA>
            <NlmUniqueID>0233411</NlmUniqueID>
            <ISSNLinking>0019-5189</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25141540</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
        <PMID Version="1">25141538</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0019-5189</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>52</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Indian journal of experimental biology</Title>
                <ISOAbbreviation>Indian J. Exp. Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Nano gold conjugation, anti-arthritic potential and toxicity studies of snake Naja kaouthia (Lesson, 1831) venom protein toxin NKCT1 in male albino rats and mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>763-72</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Nanoscience and Nanotechnology have found their way in the fields of pharmacology and medicine. The conjugation of drug to nanoparticles combines the properties of both. In this study, gold nanoparticle (GNP) was conjugated with NKCT1, a cytotoxic protein toxin from Indian cobra venom for evaluation of anti-arthritic activity and toxicity in experimental animal models. GNP conjugated NKCT1 (GNP-NKCT1) synthesized by NaBH4 reduction method was stable at room temperature (25 +/- 2 degrees C), pH 7.2. Hydrodynamic size of GNP-NKCT1 was 68-122 nm. Arthritis was developed by Freund's complete adjuvant induction in male albino rats and treatment was done with NKCT1/GNP-NKCT1/standard drug. The paw/ankle swelling, urinary markers, serum markers and cytokines were changed significantly in arthritic control rats which were restored after GNP-NKCT1 treatment. Acute toxicity study revealed that GNP conjugation increased the minimum lethal dose value of NKCT1 and partially reduced the NKCT1 induced increase of the serum biochemical tissue injury markers. Histopathological study showed partial restoration of toxic effect in kidney tissue after GNP conjugation. Normal lymphocyte count in culture was in the order of GNP-NKCT1 &gt; NKCT1 &gt; Indomethacine treatment. The present study confirmed that GNP conjugation increased the antiarthritic activity and decreased toxicity profile of NKCT1.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Saha</LastName>
                    <ForeName>Partha Pratim</ForeName>
                    <Initials>PP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bhowmik</LastName>
                    <ForeName>Tanmoy</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dasgupta</LastName>
                    <ForeName>Anjan Kumar</ForeName>
                    <Initials>AK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gomes</LastName>
                    <ForeName>Antony</ForeName>
                    <Initials>A</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>India</Country>
            <MedlineTA>Indian J Exp Biol</MedlineTA>
            <NlmUniqueID>0233411</NlmUniqueID>
            <ISSNLinking>0019-5189</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25141538</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
        <PMID Version="1">25141459</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0024-7766</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>46</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <Year>2013</Year>
                        <Month>Dec</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Lymphology</Title>
                <ISOAbbreviation>Lymphology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Hyaluronidase treatment of acute lymphedema in a mouse tail model.</ArticleTitle>
            <Pagination>
                <MedlinePgn>160-72</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The purpose of this study was to investigate the impact of hyaluronidase (HAase) on lymphedema using an acute mouse tail lymphedema model. Six-week-old mice served to produce acute lymphedema and were then either treated with HAase injection or used as operative controls. An additional group of unmanipulated normal mice was used for comparison. Tail volumes were measured for 23 days and histological changes examined. Western blot analysis was conducted to quantify lymphatic vessel endothelial hyaluronan receptor (LYVE)-1, tumor necrosis factor (TNF)-alpha, transforming growth factor (TGF)-beta1, podoplanin, CD 44, and vascular endothelial growth factor receptor3 (VEGFR3) expression levels. The operative control group showed an increase in thickness of the dermis and subdermis, microlymphatic dilatation, and an increase in neutrophils. In contrast, the HAase treated group exhibited alleviation of inflammation evidenced by a decline in microlymphatic dilatation and neutrophils and an overall increase in microlymphatic vessels. Western blot analysis demonstrated that TNF-alpha and TGF-beta1 expression declined but CD44 expression increased in the HAase treated group. Levels of LYVE1, podoplanin, and VEGFR3 also increased significantly in the HAase group. Our results indicate that HAase treatment in the acute mouse tail model reduced lymphedema volume possibly through degradation of HA trafficking, which reduced inflammation and fibrosis in tissues and stimulated lymphangiogenesis.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Jeong</LastName>
                    <ForeName>H J</ForeName>
                    <Initials>HJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Roh</LastName>
                    <ForeName>K H</ForeName>
                    <Initials>KH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>G C</ForeName>
                    <Initials>GC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Y O</ForeName>
                    <Initials>YO</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>J H</ForeName>
                    <Initials>JH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>M J</ForeName>
                    <Initials>MJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sim</LastName>
                    <ForeName>Y J</ForeName>
                    <Initials>YJ</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Lymphology</MedlineTA>
            <NlmUniqueID>0155112</NlmUniqueID>
            <ISSNLinking>0024-7766</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25141459</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Process">
        <PMID Version="1">25141393</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1340-2544</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>34</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology</Title>
                <ISOAbbreviation>Nihon Shinkei Seishin Yakurigaku Zasshi</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[Participation of mTOR signal system in autistic behavior of mice modeling tuberous sclerosis].</ArticleTitle>
            <Pagination>
                <MedlinePgn>51-2</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Sato</LastName>
                    <ForeName>Atsushi</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kasai</LastName>
                    <ForeName>Shinya</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kobayashi</LastName>
                    <ForeName>Toshiyuki</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Takamatsu</LastName>
                    <ForeName>Yukio</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hino</LastName>
                    <ForeName>Okio</ForeName>
                    <Initials>O</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ikeda</LastName>
                    <ForeName>Kazutaka</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mizuguchi</LastName>
                    <ForeName>Masashi</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>jpn</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Japan</Country>
            <MedlineTA>Nihon Shinkei Seishin Yakurigaku Zasshi</MedlineTA>
            <NlmUniqueID>9509023</NlmUniqueID>
            <ISSNLinking>1340-2544</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>22</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25141393</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25141265</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">2040-1744</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>2</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2011</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of developmental origins of health and disease</Title>
                <ISOAbbreviation>J Dev Orig Health Dis</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Novel thromboxane A2 analog-induced IUGR mouse model.</ArticleTitle>
            <Pagination>
                <MedlinePgn>291-301</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1017/S2040174411000535</ELocationID>
            <Abstract>
                <AbstractText>Rodents, particularly rats, are used in the majority of intrauterine growth restriction (IUGR) research. An important tool that is lacking in this field is the ability to impose IUGR on transgenic mice. We therefore developed a novel mouse model of chronic IUGR using U-46619, a thromboxane A2 (TXA2) analog, infusion. TXA2 overproduction is prevalent in human pregnancies complicated by cigarette smoking, diabetes mellitus and preeclampsia. In this model, U-46619 micro-osmotic pump infusion in the last week of C57BL/6J mouse gestation caused maternal hypertension. IUGR pups weighed 15% less, had lighter brain, lung, liver and kidney weights, but had similar nose-to-anus lengths compared with sham pups at birth. Metabolically, IUGR pups showed increased essential branched-chain amino acids. They were normoglycemic yet hypoinsulinemic. They showed decreased hepatic mRNA levels of total insulin-like growth factor-1 and its variants, but increased level of peroxisome proliferator-activated receptor-gamma coactivator-1 alpha. IUGR offspring were growth restricted from birth (P1) through postnatal day 21 (P21). IUGR males caught up with sham males in weight by P28, whereas IUGR females caught up with sham females by P77. IUGR males surpassed sham males in weight by P238. In summary, we have a non-brain sparing IUGR mouse model that has a relative ease of surgical IUGR induction and exhibits features similar to the chronic IUGR offspring of humans and other animal models. As transgenic technology predominates in mice, this model now permits the imposition of IUGR on transgenic mice to interrogate mechanisms of fetal origins of adult disease.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Fung</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Pediatrics/Neonatology, University of Utah, Salt Lake City, UT, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brown</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Pediatrics/Neonatology, University of Utah, Salt Lake City, UT, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cox</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Pediatrics/Neonatology, University of Utah, Salt Lake City, UT, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Callaway</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Pediatrics/Neonatology, University of Utah, Salt Lake City, UT, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>McKnight</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Pediatrics/Neonatology, University of Utah, Salt Lake City, UT, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lane</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Pediatrics/Neonatology, University of Utah, Salt Lake City, UT, USA.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>J Dev Orig Health Dis</MedlineTA>
            <NlmUniqueID>101517692</NlmUniqueID>
            <ISSNLinking>2040-1744</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2011</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2011</Year>
                <Month>10</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S2040174411000535</ArticleId>
            <ArticleId IdType="doi">10.1017/S2040174411000535</ArticleId>
            <ArticleId IdType="pubmed">25141265</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25140925</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">2040-1744</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>2</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2011</Year>
                        <Month>Apr</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of developmental origins of health and disease</Title>
                <ISOAbbreviation>J Dev Orig Health Dis</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Perinatal programming of murine immune responses by polyunsaturated fatty acids.</ArticleTitle>
            <Pagination>
                <MedlinePgn>112-23</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1017/S204017441000067X</ELocationID>
            <Abstract>
                <AbstractText>Linoleic acid and ??-linolenic acid are essential fatty acids (eFAs) and have to be acquired from the diet. eFAs are the precursors for long-chain polyunsaturated fatty acids (lcPUFAs), which are important immune-modulating compounds. lcPUFAs can be converted into eicosanoids and other mediators. They affect membrane structure and fluidity and can alter gene expression. There has been a marked change in dietary fatty acid intake over the last several decades. Since eFAs are acquired from the diet and immune development occurs mainly perinatally, the maternal diet may influence fetal and neonatal eFA levels, and thereby lcPUFA status, and thus immune development and function. To study whether early exposure to eFAs can program immune function, mice were fed diets varying in the ratio of ??-3 to ??-6-eFAs during pregnancy and/or lactation. After weaning, pups received a Western-style diet. At 11 weeks of age, the effects of maternal diet on the offspring's allergic and vaccination responses were examined using the T-helper 2 driven ovalbumin-induced allergy model and the T-helper 1 driven influenza-vaccination model, respectively. Offspring of dams fed a high ??-linolenic acid diet during lactation showed an enhanced vaccination response. As diets with either low or high ??-3/??-6-eFA ratio attenuated the T-helper 2 allergic response, the high ??-linolenic acid diet fed during lactation had the most pronounced effect. These results indicate that there is a programming effect of maternal diet on the offspring's immune response and that in mice the window of greatest susceptibility to maternal dietary intervention is the lactation/suckling period.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>van Vlies</LastName>
                    <ForeName>N</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>1Division of Pharmacology, Department of Pharmaceutical Sciences, Utrecht University, The Netherlands.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hogenkamp</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>1Division of Pharmacology, Department of Pharmaceutical Sciences, Utrecht University, The Netherlands.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fear</LastName>
                    <ForeName>A L</ForeName>
                    <Initials>AL</Initials>
                    <Affiliation>2Institute of Human Nutrition, Department of School of Medicine, University of Southampton, Southampton, United Kingdom.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>van Esch</LastName>
                    <ForeName>B C</ForeName>
                    <Initials>BC</Initials>
                    <Affiliation>1Division of Pharmacology, Department of Pharmaceutical Sciences, Utrecht University, The Netherlands.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Oosting</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>3Platform Immunology, Danone Research, Centre for Specialized Nutrition, Wageningen, The Netherlands.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>van de Heijning</LastName>
                    <ForeName>B</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>3Platform Immunology, Danone Research, Centre for Specialized Nutrition, Wageningen, The Netherlands.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>van der Beek</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>3Platform Immunology, Danone Research, Centre for Specialized Nutrition, Wageningen, The Netherlands.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Calder</LastName>
                    <ForeName>P C</ForeName>
                    <Initials>PC</Initials>
                    <Affiliation>2Institute of Human Nutrition, Department of School of Medicine, University of Southampton, Southampton, United Kingdom.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Garssen</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>1Division of Pharmacology, Department of Pharmaceutical Sciences, Utrecht University, The Netherlands.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>J Dev Orig Health Dis</MedlineTA>
            <NlmUniqueID>101517692</NlmUniqueID>
            <ISSNLinking>2040-1744</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2011</Year>
                <Month>4</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2011</Year>
                <Month>4</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S204017441000067X</ArticleId>
            <ArticleId IdType="doi">10.1017/S204017441000067X</ArticleId>
            <ArticleId IdType="pubmed">25140925</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25141261</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2324-8645</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Human gene therapy. Clinical development</Title>
                <ISOAbbreviation>Hum Gene Ther Clin Dev</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Adenovirus-mediated FKHRL1/TM sensitizes melanoma cells to apoptosis induced by temozolomide.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Melanoma exhibits variable resistance to the alkylating agent temozolomide (TMZ). We evaluated the potential of adenovirus expressing forkhead human transcription factor like 1 triple mutant (Ad-FKHRL1/TM) to sensitize melanoma cells to TMZ. Four melanoma cell lines were treated with Ad-FKHRL1/TM and TMZ, alone or in combination. Apoptosis was assessed by activation and inhibition of caspase pathway, nuclei fragmentation, and annexin V staining. The potential therapeutic efficacy of Ad-FKHRL1/TM with TMZ was also assessed in a mouse melanoma xenograft model. Combination therapy of Ad-FKHRL1/TM and TMZ resulted in greater cell killing (&lt;20% cell viability) compared to single therapy and controls (p&lt;0.05). Combination indices of Ad-FKHRL1/TM and TMZ therapy indicated significant (p&lt;0.05) synergistic killing effect. Greater apoptosis induction was found in cells treated with Ad-FKHRL1/TM and TMZ than Ad-FKHRL1/TM or TMZ-treated cells alone. Treatment with temozolomide enhanced adenovirus transgene expression in a cell type-dependent manner. In an in vivo model, combination therapy of Ad-FKHRL1/TM with TMZ results in greater tumor growth reduction in comparison with single treatments. We suggest that Ad-FKHRL1/TM is a promising vector to sensitize melanoma cells to TMZ, and that a combination of both approaches would be effective in the clinical setting.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Egger</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>University of Louisville, Surgery, Louisville, Kentucky, United States ; michael.egger@louisville.edu.</Affiliation>
                </Author>
                <Author>
                    <LastName>McNally</LastName>
                    <ForeName>Lacey</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author>
                    <LastName>Nitz</LastName>
                    <ForeName>Jonathan</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author>
                    <LastName>McMasters</LastName>
                    <ForeName>Kelly M</ForeName>
                    <Initials>KM</Initials>
                </Author>
                <Author>
                    <LastName>Gomez-Gutierrez</LastName>
                    <ForeName>Jorge G</ForeName>
                    <Initials>JG</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Hum Gene Ther Clin Dev</MedlineTA>
            <NlmUniqueID>101607433</NlmUniqueID>
            <ISSNLinking>2324-8637</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1089/hum.2014.022</ArticleId>
            <ArticleId IdType="pubmed">25141261</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25141257</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Pharmacokinetics-pharmacodynamics analysis of bicyclic 4-nitroimidazole analogs in a murine model of tuberculosis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e105222</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0105222</ELocationID>
            <Abstract>
                <AbstractText>PA-824 is a bicyclic 4-nitroimidazole, currently in phase II clinical trials for the treatment of tuberculosis. Dose fractionation pharmacokinetic-pharmacodynamic studies in mice indicated that the driver of PA-824 in vivo efficacy is the time during which the free drug concentrations in plasma are above the MIC (fT&gt;MIC). In this study, a panel of closely related potent bicyclic 4-nitroimidazoles was profiled in both in vivo PK and efficacy studies. In an established murine TB model, the efficacy of diverse nitroimidazole analogs ranged between 0.5 and 2.3 log CFU reduction compared to untreated controls. Further, a retrospective analysis was performed for a set of seven nitroimidazole analogs to identify the PK parameters that correlate with in vivo efficacy. Our findings show that the in vivo efficacy of bicyclic 4-nitroimidazoles correlated better with lung PK than with plasma PK. Further, nitroimidazole analogs with moderate-to-high volume of distribution and Lung to plasma ratios of &gt;2 showed good efficacy. Among all the PK-PD indices, total lung T&gt;MIC correlated the best with in vivo efficacy (rs???=???0.88) followed by lung Cmax/MIC and AUC/MIC. Thus, lung drug distribution studies could potentially be exploited to guide the selection of compounds for efficacy studies, thereby accelerating the drug discovery efforts in finding new nitroimidazole analogs.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Lakshminarayana</LastName>
                    <ForeName>Suresh B</ForeName>
                    <Initials>SB</Initials>
                    <Affiliation>Novartis Institute for Tropical Diseases, Singapore, Singapore.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Boshoff</LastName>
                    <ForeName>Helena I M</ForeName>
                    <Initials>HI</Initials>
                    <Affiliation>Tuberculosis Research Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cherian</LastName>
                    <ForeName>Joseph</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Novartis Institute for Tropical Diseases, Singapore, Singapore.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ravindran</LastName>
                    <ForeName>Sindhu</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Novartis Institute for Tropical Diseases, Singapore, Singapore.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Goh</LastName>
                    <ForeName>Anne</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Novartis Institute for Tropical Diseases, Singapore, Singapore.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jiricek</LastName>
                    <ForeName>Jan</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Novartis Institute for Tropical Diseases, Singapore, Singapore.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nanjundappa</LastName>
                    <ForeName>Mahesh</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Novartis Institute for Tropical Diseases, Singapore, Singapore.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nayyar</LastName>
                    <ForeName>Amit</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Tuberculosis Research Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gurumurthy</LastName>
                    <ForeName>Meera</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Novartis Institute for Tropical Diseases, Singapore, Singapore.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Singh</LastName>
                    <ForeName>Ramandeep</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Tuberculosis Research Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dick</LastName>
                    <ForeName>Thomas</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Novartis Institute for Tropical Diseases, Singapore, Singapore.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Blasco</LastName>
                    <ForeName>Francesca</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Novartis Institute for Tropical Diseases, Singapore, Singapore.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Barry</LastName>
                    <ForeName>Clifton E</ForeName>
                    <Initials>CE</Initials>
                    <Suffix>3rd</Suffix>
                    <Affiliation>Tuberculosis Research Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ho</LastName>
                    <ForeName>Paul C</ForeName>
                    <Initials>PC</Initials>
                    <Affiliation>Department of Pharmacy, National University of Singapore, Singapore, Singapore.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Manjunatha</LastName>
                    <ForeName>Ujjini H</ForeName>
                    <Initials>UH</Initials>
                    <Affiliation>Novartis Institute for Tropical Diseases, Singapore, Singapore.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>8</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0105222</ArticleId>
            <ArticleId IdType="pii">PONE-D-14-15690</ArticleId>
            <ArticleId IdType="pubmed">25141257</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25141224</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Nucleotide-Oligomerization-Domain-2 Affects Commensal Gut Microbiota Composition and Intracerebral Immunopathology in Acute Toxoplasma gondii Induced Murine Ileitis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e105120</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0105120</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Within one week following peroral high dose infection with Toxoplasma (T.) gondii, susceptible mice develop non-selflimiting acute ileitis due to an underlying Th1-type immunopathology. The role of the innate immune receptor nucleotide-oligomerization-domain-2 (NOD2) in mediating potential extra-intestinal inflammatory sequelae including the brain, however, has not been investigated so far.</AbstractText>
                <AbstractText Label="METHODOLOGY/PRINCIPAL FINDINGS" NlmCategory="RESULTS">Following peroral infection with 100 cysts of T. gondii strain ME49, NOD2-/- mice displayed more severe ileitis and higher small intestinal parasitic loads as compared to wildtype (WT) mice. However, systemic (i.e. splenic) levels of pro-inflammatory cytokines such as TNF-?? and IFN-?? were lower in NOD2-/- mice versus WT controls at day 7 p.i. Given that the immunopathological outcome might be influenced by the intestinal microbiota composition, which is shaped by NOD2, we performed a quantitative survey of main intestinal bacterial groups by 16S rRNA analysis. Interestingly, Bifidobacteria were virtually absent in NOD2-/- but not WT mice, whereas differences in remaining bacterial species were rather subtle. Interestingly, more distinct intestinal inflammation was accompanied by higher bacterial translocation rates to extra-intestinal tissue sites such as liver, spleen, and kidneys in T. gondii infected NOD2-/- mice. Strikingly, intracerebral inflammatory foci could be observed as early as seven days following T. gondii infection irrespective of the genotype of animals, whereas NOD2-/- mice exhibited higher intracerebral parasitic loads, higher F4/80 positive macrophage and microglia numbers as well as higher IFN-?? mRNA expression levels as compared to WT control animals.</AbstractText>
                <AbstractText Label="CONCLUSION/SIGNIFICANCE" NlmCategory="CONCLUSIONS">NOD2 signaling is involved in protection of mice from T. gondii induced acute ileitis. The parasite-induced Th1-type immunopathology at intestinal as well as extra-intestinal sites including the brain is modulated in a NOD2-dependent manner.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Heimesaat</LastName>
                    <ForeName>Markus M</ForeName>
                    <Initials>MM</Initials>
                    <Affiliation>Department of Microbiology and Hygiene, Charit?? - University Medicine Berlin, Berlin, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dunay</LastName>
                    <ForeName>Ildiko R</ForeName>
                    <Initials>IR</Initials>
                    <Affiliation>Department of Microbiology and Hygiene, University of Magdeburg, Magdeburg, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Alutis</LastName>
                    <ForeName>Marie</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Microbiology and Hygiene, Charit?? - University Medicine Berlin, Berlin, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fischer</LastName>
                    <ForeName>Andr??</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Microbiology and Hygiene, Charit?? - University Medicine Berlin, Berlin, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>M??hle</LastName>
                    <ForeName>Luisa</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Microbiology and Hygiene, University of Magdeburg, Magdeburg, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>G??bel</LastName>
                    <ForeName>Ulf B</ForeName>
                    <Initials>UB</Initials>
                    <Affiliation>Department of Microbiology and Hygiene, Charit?? - University Medicine Berlin, Berlin, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>K??hl</LastName>
                    <ForeName>Anja A</ForeName>
                    <Initials>AA</Initials>
                    <Affiliation>Department of Internal Medicine, Rheumatology and Clinical Immunology/Research Center ImmunoSciences (RCIS), Charit?? - University Medicine Berlin, Berlin, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bereswill</LastName>
                    <ForeName>Stefan</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Microbiology and Hygiene, Charit?? - University Medicine Berlin, Berlin, Germany.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>18</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0105120</ArticleId>
            <ArticleId IdType="pii">PONE-D-14-16521</ArticleId>
            <ArticleId IdType="pubmed">25141224</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25141178</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1476-4687</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Nature</Title>
                <ISOAbbreviation>Nature</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Diabetes recovery by age-dependent conversion of pancreatic ??-cells into insulin producers.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="doi">10.1038/nature13633</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Total or near-total loss of insulin-producing ??-cells occurs in type 1 diabetes. Restoration of insulin production in type 1 diabetes is thus a major medical challenge. We previously observed in mice in which ??-cells are completely ablated that the pancreas reconstitutes new insulin-producing cells in the absence of autoimmunity. The process involves the contribution of islet non-??-cells; specifically, glucagon-producing ??-cells begin producing insulin by a process of reprogramming (transdifferentiation) without proliferation. Here we show the influence of age on ??-cell reconstitution from heterologous islet cells after near-total ??-cell loss in mice. We found that senescence does not alter ??-cell plasticity: ??-cells can reprogram to produce insulin from puberty through to adulthood, and also in aged individuals, even a long time after ??-cell loss. In contrast, before puberty there is no detectable ??-cell conversion, although ??-cell reconstitution after injury is more efficient, always leading to diabetes recovery. This process occurs through a newly discovered mechanism: the spontaneous en masse reprogramming of somatostatin-producing ??-cells. The juveniles display 'somatostatin-to-insulin' ??-cell conversion, involving dedifferentiation, proliferation and re-expression of islet developmental regulators. This juvenile adaptability relies, at least in part, upon the combined action of FoxO1 and downstream effectors. Restoration of insulin producing-cells from non-??-cell origins is thus enabled throughout life via ??- or ??-cell spontaneous reprogramming. A landscape with multiple intra-islet cell interconversion events is emerging, offering new perspectives for therapy.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Chera</LastName>
                    <ForeName>Simona</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Genetic Medicine &amp;Development, Faculty of Medicine, University of Geneva, 1 rue Michel-Servet, 1211 Geneva-4, Switzerland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Baronnier</LastName>
                    <ForeName>Delphine</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Department of Genetic Medicine &amp;Development, Faculty of Medicine, University of Geneva, 1 rue Michel-Servet, 1211 Geneva-4, Switzerland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ghila</LastName>
                    <ForeName>Luiza</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Genetic Medicine &amp;Development, Faculty of Medicine, University of Geneva, 1 rue Michel-Servet, 1211 Geneva-4, Switzerland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Cigliola</LastName>
                    <ForeName>Valentina</ForeName>
                    <Initials>V</Initials>
                    <Affiliation>Department of Genetic Medicine &amp;Development, Faculty of Medicine, University of Geneva, 1 rue Michel-Servet, 1211 Geneva-4, Switzerland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Jensen</LastName>
                    <ForeName>Jan N</ForeName>
                    <Initials>JN</Initials>
                    <Affiliation>Novo Nordisk A/S, Niels Steensens Vej 6, DK-2820 Gentofte, Denmark.</Affiliation>
                </Author>
                <Author>
                    <LastName>Gu</LastName>
                    <ForeName>Guoqiang</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Cell and Developmental Biology, Vanderbilt University Medical Center, 465 21st Av. South, Nashville, Tennessee 37232, USA.</Affiliation>
                </Author>
                <Author>
                    <LastName>Furuyama</LastName>
                    <ForeName>Kenichiro</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Department of Genetic Medicine &amp;Development, Faculty of Medicine, University of Geneva, 1 rue Michel-Servet, 1211 Geneva-4, Switzerland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Thorel</LastName>
                    <ForeName>Fabrizio</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Department of Genetic Medicine &amp;Development, Faculty of Medicine, University of Geneva, 1 rue Michel-Servet, 1211 Geneva-4, Switzerland.</Affiliation>
                </Author>
                <Author>
                    <LastName>Gribble</LastName>
                    <ForeName>Fiona M</ForeName>
                    <Initials>FM</Initials>
                    <Affiliation>Cambridge Institute for Medical Research, Hills Road, Cambridge CB2 0XY, UK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Reimann</LastName>
                    <ForeName>Frank</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Cambridge Institute for Medical Research, Hills Road, Cambridge CB2 0XY, UK.</Affiliation>
                </Author>
                <Author>
                    <LastName>Herrera</LastName>
                    <ForeName>Pedro L</ForeName>
                    <Initials>PL</Initials>
                    <Affiliation>Department of Genetic Medicine &amp;Development, Faculty of Medicine, University of Geneva, 1 rue Michel-Servet, 1211 Geneva-4, Switzerland.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <GrantList>
                <Grant>
                    <GrantID>U01 DK072522</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>U01 DK089566</GrantID>
                    <Acronym>DK</Acronym>
                    <Agency>NIDDK NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Nature</MedlineTA>
            <NlmUniqueID>0410462</NlmUniqueID>
            <ISSNLinking>0028-0836</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>7</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">nature13633</ArticleId>
            <ArticleId IdType="doi">10.1038/nature13633</ArticleId>
            <ArticleId IdType="pubmed">25141178</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25141172</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>A direct projection from mouse primary visual cortex to dorsomedial striatum.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e104501</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0104501</ELocationID>
            <Abstract>
                <AbstractText>The mammalian striatum receives inputs from many cortical areas, but the existence of a direct axonal projection from the primary visual cortex (V1) is controversial. In this study we use anterograde and retrograde tracing techniques to demonstrate that V1 directly innervates a topographically defined longitudinal strip of dorsomedial striatum in mice. We find that this projection forms functional excitatory synapses with direct and indirect pathway striatal projection neurons (SPNs) and engages feed-forward inhibition onto these cells. Importantly, stimulation of V1 afferents is sufficient to evoke phasic firing in SPNs. These findings therefore identify a striatal region that is functionally innervated by V1 and suggest that early visual processing may play an important role in striatal-based behaviors.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Khibnik</LastName>
                    <ForeName>Lena A</ForeName>
                    <Initials>LA</Initials>
                    <Affiliation>Department of Neurobiology, Howard Hughes Medical Institute, Harvard Medical School, Boston, Massachusetts, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tritsch</LastName>
                    <ForeName>Nicolas X</ForeName>
                    <Initials>NX</Initials>
                    <Affiliation>Department of Neurobiology, Howard Hughes Medical Institute, Harvard Medical School, Boston, Massachusetts, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sabatini</LastName>
                    <ForeName>Bernardo L</ForeName>
                    <Initials>BL</Initials>
                    <Affiliation>Department of Neurobiology, Howard Hughes Medical Institute, Harvard Medical School, Boston, Massachusetts, United States of America.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>2</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0104501</ArticleId>
            <ArticleId IdType="pii">PONE-D-14-14783</ArticleId>
            <ArticleId IdType="pubmed">25141172</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25141170</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1948-7193</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>ACS chemical neuroscience</Title>
                <ISOAbbreviation>ACS Chem Neurosci</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Synthesis, Biophysical, and Pharmacological Evaluation of the Melanocortin Agonist AST3-88: Modifications of Peptide Backbone at Trp 7 Position lead to a Potent, Selective and Stable Ligand of the Melanocortin 4 receptor (MC4R).</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The melanocortin-3 (MC3R) and melanocortin-4 (MC4R) receptors are expressed in the brain and are implicated in the regulation of food intake and energy homeostasis. The endogenous agonist ligands for these receptors (??, ??, ??-MSH and ACTH) are linear peptides with limited receptor subtype selectivity and metabolic stability, thus minimizing their use as probes to characterize the overlapping pharmacological and physiological functions of the melanocortin receptor subtypes. In the present study an engineered template, in which the peptide backbone was modified by a heterocyclic reverse turn mimetic at the Trp7 residue was synthesized using solid phase peptide synthesis and characterized by a ??-galactosidase cAMP based reporter gene assay. The functional assay identified a ~5 nM mouse MC4R agonist (AST3-88) with more than 50-fold selectivity over the mMC3R. Biophysical studies (2D-1H NMR spectroscopy and molecular dynamics) of AST3-88 identified a type VIII ??-turn secondary structure spanning the pharmacophore domain stabilized by the intramolecular interactions between the side chains of the His and Trp residues. Enzymatic studies of AST3-88 revealed enhanced stability of AST3-88 over the ??-MSH endogenous peptide in rat serum. Upon central administration of AST3-88 into rats, a decreased food intake response was observed. This is the first study to probe the in vivo physiological activity of this engineered peptide-heterocycle template. These findings advance the present knowledge of pharmacophore design for potent, selective, and metabolically stable melanocortin ligands.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Singh</LastName>
                    <ForeName>Anamika</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author>
                    <LastName>Dirain</LastName>
                    <ForeName>Marvin Louie Servanez</ForeName>
                    <Initials>ML</Initials>
                </Author>
                <Author>
                    <LastName>Wilczynski</LastName>
                    <ForeName>Andrzej M</ForeName>
                    <Initials>AM</Initials>
                </Author>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Chi</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author>
                    <LastName>Gosnell</LastName>
                    <ForeName>Blake A</ForeName>
                    <Initials>BA</Initials>
                </Author>
                <Author>
                    <LastName>Levine</LastName>
                    <ForeName>Allen S</ForeName>
                    <Initials>AS</Initials>
                </Author>
                <Author>
                    <LastName>Edison</LastName>
                    <ForeName>Arthur S</ForeName>
                    <Initials>AS</Initials>
                </Author>
                <Author>
                    <LastName>Haskell-Luevano</LastName>
                    <ForeName>Carrie</ForeName>
                    <Initials>C</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>ACS Chem Neurosci</MedlineTA>
            <NlmUniqueID>101525337</NlmUniqueID>
            <ISSNLinking>1948-7193</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1021/cn5000953</ArticleId>
            <ArticleId IdType="pubmed">25141170</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25141153</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Sox17 regulates liver lipid metabolism and adaptation to fasting.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e104925</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0104925</ELocationID>
            <Abstract>
                <AbstractText>Liver is a major regulator of lipid metabolism and adaptation to fasting, a process involving PPARalpha activation. We recently showed that the Vnn1 gene is a PPARalpha target gene in liver and that release of the Vanin-1 pantetheinase in serum is a biomarker of PPARalpha activation. Here we set up a screen to identify new regulators of adaptation to fasting using the serum Vanin-1 as a marker of PPARalpha activation. Mutagenized mice were screened for low serum Vanin-1 expression. Functional interactions with PPARalpha were investigated by combining transcriptomic, biochemical and metabolic approaches. We characterized a new mutant mouse in which hepatic and serum expression of Vanin-1 is depressed. This mouse carries a mutation in the HMG domain of the Sox17 transcription factor. Mutant mice display a metabolic phenotype featuring lipid abnormalities and inefficient adaptation to fasting. Upon fasting, a fraction of the PPAR??-driven transcriptional program is no longer induced and associated with impaired fatty acid oxidation. The transcriptional phenotype is partially observed in heterozygous Sox17+/- mice. In mutant mice, the fasting phenotype but not all transcriptomic signature is rescued by the administration of the PPARalpha agonist fenofibrate. These results identify a novel role for Sox17 in adult liver as a modulator of the metabolic adaptation to fasting.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Rommelaere</LastName>
                    <ForeName>Samuel</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Centre d'Immunologie de Marseille-Luminy (CIML), Aix-Marseille University, UM2, Marseille, France; Institut National de la Sant?? et de la Recherche M??dicale (INSERM), U1104, Marseille, France; Centre National de la Recherche Scientifique (CNRS), UMR7280, Marseille, France.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Millet</LastName>
                    <ForeName>Virginie</ForeName>
                    <Initials>V</Initials>
                    <Affiliation>Centre d'Immunologie de Marseille-Luminy (CIML), Aix-Marseille University, UM2, Marseille, France; Institut National de la Sant?? et de la Recherche M??dicale (INSERM), U1104, Marseille, France; Centre National de la Recherche Scientifique (CNRS), UMR7280, Marseille, France.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vu Manh</LastName>
                    <ForeName>Thien-Phong</ForeName>
                    <Initials>TP</Initials>
                    <Affiliation>Centre d'Immunologie de Marseille-Luminy (CIML), Aix-Marseille University, UM2, Marseille, France; Institut National de la Sant?? et de la Recherche M??dicale (INSERM), U1104, Marseille, France; Centre National de la Recherche Scientifique (CNRS), UMR7280, Marseille, France.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gensollen</LastName>
                    <ForeName>Thomas</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Centre d'Immunologie de Marseille-Luminy (CIML), Aix-Marseille University, UM2, Marseille, France; Institut National de la Sant?? et de la Recherche M??dicale (INSERM), U1104, Marseille, France; Centre National de la Recherche Scientifique (CNRS), UMR7280, Marseille, France.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Andreoletti</LastName>
                    <ForeName>Pierre</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Universit?? de Bourgogne, Laboratoire BioPeroxIL, EA7270, Dijon, France.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cherkaoui-Malki</LastName>
                    <ForeName>Mustapha</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Universit?? de Bourgogne, Laboratoire BioPeroxIL, EA7270, Dijon, France.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bourges</LastName>
                    <ForeName>Christophe</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Centre d'Immunologie de Marseille-Luminy (CIML), Aix-Marseille University, UM2, Marseille, France; Institut National de la Sant?? et de la Recherche M??dicale (INSERM), U1104, Marseille, France; Centre National de la Recherche Scientifique (CNRS), UMR7280, Marseille, France.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Escali??re</LastName>
                    <ForeName>Bertrand</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Centre d'Immunologie de Marseille-Luminy (CIML), Aix-Marseille University, UM2, Marseille, France; Institut National de la Sant?? et de la Recherche M??dicale (INSERM), U1104, Marseille, France; Centre National de la Recherche Scientifique (CNRS), UMR7280, Marseille, France.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Du</LastName>
                    <ForeName>Xin</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>University of Texas Southwestern Medical Center, Center for Genetics of Host Defense, Dallas, Texas, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xia</LastName>
                    <ForeName>Yu</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>University of Texas Southwestern Medical Center, Center for Genetics of Host Defense, Dallas, Texas, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Imbert</LastName>
                    <ForeName>Jean</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Institut National de la Sant?? et de la Recherche M??dicale (INSERM), Aix-Marseille University, UMR_S 1090, TGML/TAGC, Marseille, France.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Beutler</LastName>
                    <ForeName>Bruce</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>University of Texas Southwestern Medical Center, Center for Genetics of Host Defense, Dallas, Texas, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kanai</LastName>
                    <ForeName>Yoshiakira</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Department of Veterinary Anatomy, University of Tokyo, Bunkyo-ku, Tokyo, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Malissen</LastName>
                    <ForeName>Bernard</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Centre d'Immunologie de Marseille-Luminy (CIML), Aix-Marseille University, UM2, Marseille, France; Institut National de la Sant?? et de la Recherche M??dicale (INSERM), U1104, Marseille, France; Centre National de la Recherche Scientifique (CNRS), UMR7280, Marseille, France.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Malissen</LastName>
                    <ForeName>Marie</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Centre d'Immunologie de Marseille-Luminy (CIML), Aix-Marseille University, UM2, Marseille, France; Institut National de la Sant?? et de la Recherche M??dicale (INSERM), U1104, Marseille, France; Centre National de la Recherche Scientifique (CNRS), UMR7280, Marseille, France.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tailleux</LastName>
                    <ForeName>Anne</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Institut Pasteur de Lille, INSERM U1011, Universit?? de Lille 2, EGID, Lille, France.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Staels</LastName>
                    <ForeName>Bart</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Institut Pasteur de Lille, INSERM U1011, Universit?? de Lille 2, EGID, Lille, France.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Galland</LastName>
                    <ForeName>Franck</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Centre d'Immunologie de Marseille-Luminy (CIML), Aix-Marseille University, UM2, Marseille, France; Institut National de la Sant?? et de la Recherche M??dicale (INSERM), U1104, Marseille, France; Centre National de la Recherche Scientifique (CNRS), UMR7280, Marseille, France.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Naquet</LastName>
                    <ForeName>Philippe</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Centre d'Immunologie de Marseille-Luminy (CIML), Aix-Marseille University, UM2, Marseille, France; Institut National de la Sant?? et de la Recherche M??dicale (INSERM), U1104, Marseille, France; Centre National de la Recherche Scientifique (CNRS), UMR7280, Marseille, France.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>1</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0104925</ArticleId>
            <ArticleId IdType="pii">PONE-D-14-01233</ArticleId>
            <ArticleId IdType="pubmed">25141153</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25141115</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1980-5322</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>69</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Clinics (S??o Paulo, Brazil)</Title>
                <ISOAbbreviation>Clinics (Sao Paulo)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effects of ovariectomy on the secretory apparatus in the right atrial cardiomyocytes of middle-aged mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>554-8</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S1807-59322014000800554</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The aim of the present study was to evaluate the effects of ovariectomy on the secretory apparatus of natriuretic peptides in right atrial cardiomyocytes.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Nine-month-old mice underwent bilateral ovariectomy or sham surgery. The blood exam of the ovariectomized mice showed results consistent with castrated females. Systolic blood pressure was measured after ovariectomy (9 mo of age) and at the moment of sacrifice (12 mo of age). Fragments of the right atrium were collected and prepared for electron microscopy examination. The following variables were quantified: the quantitative density and area of the natriuretic peptide granules, the relative volume of euchromatin in the nucleus, the number of pores per 10 ??m of the nuclear membrane and the relative volumes of the mitochondria and Golgi complex.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The cardiomyocytes obtained from ovariectomized mice indicated that the quantitative density and the area of secretory granules of natriuretic peptides were significantly lower compared with the sham-operated mice. Furthermore, there was a decrease in the relative volume of euchromatin, a lower density of nuclear pores, and lower relative volumes of the mitochondria and Golgi complex in the ovariectomized mice compared with the sham-operated mice. These findings suggest a pool with a low turnover rate, i.e., low synthesis and elimination of natriuretic peptides.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">A lack of estrogen caused hypotrophy of the secretory apparatus in right atrial cardiomyocytes that could explain the weak synthesis of natriuretic peptides in mice. Furthermore, one of the mechanisms of blood pressure control was lost, which may explain, in part, the elevated blood pressure in ovariectomized mice.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Souza</LastName>
                    <ForeName>Romeu R de</ForeName>
                    <Initials>RR</Initials>
                    <Affiliation>ICB-USP and Department of Biology, Department of Anatomy, S??o Judas Tadeu University, S??o Paulo, SP, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Oliveira</LastName>
                    <ForeName>Vanessa C de</ForeName>
                    <Initials>VC</Initials>
                    <Affiliation>Departament of Anatomy, S??o Judas Tadeu University, S??o Paulo, SP, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Curi</LastName>
                    <ForeName>Tania Cristina P</ForeName>
                    <Initials>TC</Initials>
                    <Affiliation>Institute of Physical Activity Sciences and Sports, Cruzeiro do Sul University.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Maldonado</LastName>
                    <ForeName>Diogo C</ForeName>
                    <Initials>DC</Initials>
                    <Affiliation>Department of Anatomy, Federal University of S??o Paulo, Department of Morphology and Genetics and Nove de Julho University, S??o Paulo, SP, Brazil.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Brazil</Country>
            <MedlineTA>Clinics (Sao Paulo)</MedlineTA>
            <NlmUniqueID>101244734</NlmUniqueID>
            <ISSNLinking>1807-5932</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hypertension. 2005 Oct;46(4):998-1003</RefSource>
                <PMID Version="1">16157791</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Physiol Regul Integr Comp Physiol. 2007 Jul;293(1):R267-75</RefSource>
                <PMID Version="1">17475680</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Nutr. 2007 Aug;46(5):245-50</RefSource>
                <PMID Version="1">17514378</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Anat. 2007;189(5):457-64</RefSource>
                <PMID Version="1">17910399</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Am Coll Cardiol. 2007 Dec 18;50(25):2357-68</RefSource>
                <PMID Version="1">18154959</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11765-70</RefSource>
                <PMID Version="1">11562484</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Sci (Lond). 2001 Nov;101(5):447-53</RefSource>
                <PMID Version="1">11672449</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cardiovasc Res. 2003 Jan;57(1):186-94</RefSource>
                <PMID Version="1">12504828</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Mol Cell Cardiol. 2003 Aug;35(8):915-22</RefSource>
                <PMID Version="1">12878478</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bull Exp Biol Med. 2004 Jul;138(1):1-4</RefSource>
                <PMID Version="1">15514738</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Anat Rec. 1979 Jan;193(1):55-69</RefSource>
                <PMID Version="1">760596</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Microsc. 1986 Jul;143(Pt 1):3-45</RefSource>
                <PMID Version="1">3761363</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Fertil Steril. 1988 Nov;50(5):743-6</RefSource>
                <PMID Version="1">2972566</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell Tissue Res. 1989 Mar;255(3):673-4</RefSource>
                <PMID Version="1">2523242</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biol Chem Hoppe Seyler. 1992 Apr;373(4):213-8</RefSource>
                <PMID Version="1">1534483</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Jikken Dobutsu. 1992 Jul;41(3):321-8</RefSource>
                <PMID Version="1">1387089</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Life Sci. 1993;53(9):689-96</RefSource>
                <PMID Version="1">8355570</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Aging (Milano). 1994 Jun;6(3):167-74</RefSource>
                <PMID Version="1">7993924</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hypertension. 1997 Sep;30(3 Pt 2):549-56</RefSource>
                <PMID Version="1">9322980</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hypertension. 1997 Sep;30(3 Pt 2):767-71</RefSource>
                <PMID Version="1">9323020</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Recent Prog Horm Res. 2000;55:163-93; discussion 194-5</RefSource>
                <PMID Version="1">11036937</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Physiol Regul Integr Comp Physiol. 2000 Nov;279(5):R1599-605</RefSource>
                <PMID Version="1">11049841</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am Heart J. 2001 May;141(5):751-8</RefSource>
                <PMID Version="1">11320362</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Circulation. 2001 Sep 18;104(12):1419-23</RefSource>
                <PMID Version="1">11560859</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Endocrinol. 1997 Dec;137(6):664-9</RefSource>
                <PMID Version="1">9437234</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Invest. 1998 Jul 1;102(1):176-83</RefSource>
                <PMID Version="1">9649571</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cardiovasc Res. 1999 Mar;41(3):524-31</RefSource>
                <PMID Version="1">10435024</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Endocrinol. 2005 Jan;184(1):209-17</RefSource>
                <PMID Version="1">15642797</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Obstet Gynecol Reprod Biol. 2005 Apr 1;119(2):215-8</RefSource>
                <PMID Version="1">15808383</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Endocrinology. 2008 Mar;149(3):1399-406</RefSource>
                <PMID Version="1">18063689</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Scand J Med Sci Sports. 2008 Jun;18(3):346-53</RefSource>
                <PMID Version="1">17555537</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Histochem Cell Biol. 2008 Aug;130(2):299-313</RefSource>
                <PMID Version="1">18553098</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Cardiol. 2008 Nov 12;130(2):196-204</RefSource>
                <PMID Version="1">18083251</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Maturitas. 2010 Mar;65(3):267-71</RefSource>
                <PMID Version="1">20004069</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cardiovasc Res. 2012 Dec 1;96(3):411-21</RefSource>
                <PMID Version="1">22962310</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Menopause. 2013 May;20(5):554-60</RefSource>
                <PMID Version="1">23615647</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <OtherID Source="NLM">PMC4129560</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>1</Month>
                <Day>07</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S1807-59322014000800554</ArticleId>
            <ArticleId IdType="pubmed">25141115</ArticleId>
            <ArticleId IdType="pmc">PMC4129560</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25141063</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1548-4475</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>43</Volume>
                    <Issue>9</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Lab animal</Title>
                <ISOAbbreviation>Lab Anim (NY)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>An animal tracking system for behavior analysis using radio frequency identification.</ArticleTitle>
            <Pagination>
                <MedlinePgn>321-7</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/laban.547</ELocationID>
            <Abstract>
                <AbstractText>Evaluating the behavior of mice and rats has substantially contributed to the progress of research in many scientific fields. Researchers commonly observe recorded video of animal behavior and manually record their observations for later analysis, but this approach has several limitations. The authors developed an automated system for tracking and analyzing the behavior of rodents that is based on radio frequency identification (RFID) in an ultra-high-frequency bandwidth. They provide an overview of the system's hardware and software components as well as describe their technique for surgically implanting passive RFID tags in mice. Finally, the authors present the findings of two validation studies to compare the accuracy of the RFID system versus commonly used approaches for evaluating the locomotor activity and object exploration of mice.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Catarinucci</LastName>
                    <ForeName>Luca</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Innovation Engineering, University of Salento, Lecce, Italy.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Colella</LastName>
                    <ForeName>Riccardo</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Department of Innovation Engineering, University of Salento, Lecce, Italy.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mainetti</LastName>
                    <ForeName>Luca</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Innovation Engineering, University of Salento, Lecce, Italy.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Patrono</LastName>
                    <ForeName>Luigi</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Innovation Engineering, University of Salento, Lecce, Italy.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pieretti</LastName>
                    <ForeName>Stefano</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Therapeutic Research and Medicine Evaluation, Italian National Institute of Health, Rome, Italy.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Secco</LastName>
                    <ForeName>Andrea</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Innovation Engineering, University of Salento, Lecce, Italy.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sergi</LastName>
                    <ForeName>Ilaria</ForeName>
                    <Initials>I</Initials>
                    <Affiliation>Department of Innovation Engineering, University of Salento, Lecce, Italy.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Lab Anim (NY)</MedlineTA>
            <NlmUniqueID>0417737</NlmUniqueID>
            <ISSNLinking>0093-7355</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>10</Month>
                <Day>09</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">laban.547</ArticleId>
            <ArticleId IdType="doi">10.1038/laban.547</ArticleId>
            <ArticleId IdType="pubmed">25141063</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25141025</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1557-8534</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Stem cells and development</Title>
                <ISOAbbreviation>Stem Cells Dev.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Isolation and Propagation of Neural Crest Stem Cells from Mouse Embryonic Stem Cells via Cranial Neurospheres.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The developmental fate of the multipotent neural crest (NC) is determined along with the neural axis in which NC cells are generated. Only the cranial NC can differentiate to mesectodermal derivatives such as osteoblasts, chondrocytes, and adipocytes in vivo. Here, we attempted to selectively differentiate mouse embryonic stem (ES) cells into cranial NC stem cells and propagate them to explore their developmental potential to differentiate into mesectodermal derivatives. Using aggregation cultures in feeder- and serum-free neural induction medium (NIM) without serum replacement and L-glutamine, we obtained NIM neurospheres composed of neuroepithelium. The NIM neurospheres expressed the rostral markers Otx1 and Otx2, but not non-rostral markers Hoxb4, Hoxb9, Lbx1, and TH, which characterize cranial neurospheres. Subsequently, AP2??, Sox9, p75, Snail, Slug, and Twist-positive NC cells were differentiated in 4-day adhesion cultures of cranial neurospheres. Additionally, sphere clusters in adhesion cultures were differentiated into osteoblast while migrating cells were not. By taking advantage of the sphere-formation capability, we isolated and propagated NC stem cells from the sphere clusters and confirmed their multipotency. NC stem cells expressed NC and stem cell markers, and maintained differentiation potency in the NC derivatives. These results show that cranial NC stem cells were obtained reproducibly and efficiently without special inducing factors, gene transfection or fluorescence-activated cell sorting (FACS) selection.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Minamino</LastName>
                    <ForeName>Yuki</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Research Institute for Microbial Diseases, Osaka University, Department of Cell Biology, Suita, Osaka, Japan ; yuki0220@mopera.net.</Affiliation>
                </Author>
                <Author>
                    <LastName>Ohnishi</LastName>
                    <ForeName>Yuichi</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author>
                    <LastName>Kakudo</LastName>
                    <ForeName>Kenji</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author>
                    <LastName>Nozaki</LastName>
                    <ForeName>Masami</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Stem Cells Dev</MedlineTA>
            <NlmUniqueID>101197107</NlmUniqueID>
            <ISSNLinking>1547-3287</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1089/scd.2014.0152</ArticleId>
            <ArticleId IdType="pubmed">25141025</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25140929</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1873-2518</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>17</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Vaccine</Title>
                <ISOAbbreviation>Vaccine</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Novel G3/DT adjuvant promotes the induction of protective T cells responses after vaccination with a seasonal trivalent inactivated split-virion influenza vaccine.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <ELocationID EIdType="pii">S0264-410X(14)01116-5</ELocationID>
            <ELocationID EIdType="doi">10.1016/j.vaccine.2014.08.003</ELocationID>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Vaccines used against seasonal influenza are poorly effective against influenza A viruses of novel subtypes that may have pandemic potential. Furthermore, pre(pandemic) influenza vaccines are poorly immunogenic, which can be overcome by the use of adjuvants. A limited number of adjuvants has been approved for use in humans, however there is a need for alternative safe and effective adjuvants that can enhance the immunogenicity of influenza vaccines and that promote the induction of broad-protective T cell responses. Here we evaluated a novel nanoparticle, G3, as an adjuvant for a seasonal trivalent inactivated influenza vaccine in a mouse model. The G3 adjuvant was formulated with or without steviol glycosides (DT, for diterpenoid). The use of both formulations enhanced the virus-specific antibody response to all three vaccine strains considerably. The adjuvants were well tolerated without any signs of discomfort. To assess the protective potential of the vaccine-induced immune responses, an antigenically distinct influenza virus strain, A/Puerto Rico/8/34 (A/PR/8/34), was used for challenge infection. The vaccine-induced antibodies did not cross-react with strain A/PR/8/34 in HI and VN assays. However, mice immunized with the G3/DT-adjuvanted vaccine were partially protected against A/PR/8/34 infection, which correlated with the induction of anamnestic virus-specific CD8(+) T cell responses, which were not observed with the use of G3 without DT. Both formulations induced maturation of human dendritic cells and promoted antigen presentation to a similar extent. In conclusion, G3/DT is a promising adjuvant formulation that not only potentiates the antibody response induced by influenza vaccines, but also induces T cell immunity which could afford broader protection against antigenically distinct influenza viruses.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014. Published by Elsevier Ltd.</CopyrightInformation>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>van de Sandt</LastName>
                    <ForeName>Carolien E</ForeName>
                    <Initials>CE</Initials>
                    <Affiliation>Department of Viroscience, Erasmus MC, PO Box 2040, 3000 CA Rotterdam, The Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Kreijtz</LastName>
                    <ForeName>Joost H C M</ForeName>
                    <Initials>JH</Initials>
                    <Affiliation>Department of Viroscience, Erasmus MC, PO Box 2040, 3000 CA Rotterdam, The Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Geelhoed-Mieras</LastName>
                    <ForeName>Martina M</ForeName>
                    <Initials>MM</Initials>
                    <Affiliation>Department of Viroscience, Erasmus MC, PO Box 2040, 3000 CA Rotterdam, The Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Trierum</LastName>
                    <ForeName>Stella E Vogelzang-van</ForeName>
                    <Initials>SE</Initials>
                    <Affiliation>Department of Viroscience, Erasmus MC, PO Box 2040, 3000 CA Rotterdam, The Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Nieuwkoop</LastName>
                    <ForeName>Nella J</ForeName>
                    <Initials>NJ</Initials>
                    <Affiliation>Department of Viroscience, Erasmus MC, PO Box 2040, 3000 CA Rotterdam, The Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>van de Vijver</LastName>
                    <ForeName>David A M C</ForeName>
                    <Initials>DA</Initials>
                    <Affiliation>Department of Viroscience, Erasmus MC, PO Box 2040, 3000 CA Rotterdam, The Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Fouchier</LastName>
                    <ForeName>Ron A M</ForeName>
                    <Initials>RA</Initials>
                    <Affiliation>Department of Viroscience, Erasmus MC, PO Box 2040, 3000 CA Rotterdam, The Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Osterhaus</LastName>
                    <ForeName>Albert D M E</ForeName>
                    <Initials>AD</Initials>
                    <Affiliation>Department of Viroscience, Erasmus MC, PO Box 2040, 3000 CA Rotterdam, The Netherlands; ViroClinics Biosciences BV, Marconistraat 16, 3029 AK Rotterdam, The Netherlands.</Affiliation>
                </Author>
                <Author>
                    <LastName>Morein</LastName>
                    <ForeName>Bror</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Infectious Diseases Department of Medical Sciences, Uppsala University, MoreinX, Dag Hammarskj??ldsv??g 34 A, 751 83 Uppsala, Sweden.</Affiliation>
                </Author>
                <Author>
                    <LastName>Rimmelzwaan</LastName>
                    <ForeName>Guus F</ForeName>
                    <Initials>GF</Initials>
                    <Affiliation>Department of Viroscience, Erasmus MC, PO Box 2040, 3000 CA Rotterdam, The Netherlands; ViroClinics Biosciences BV, Marconistraat 16, 3029 AK Rotterdam, The Netherlands. Electronic address: g.rimmelzwaan@erasmusmc.nl.</Affiliation>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>17</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Vaccine</MedlineTA>
            <NlmUniqueID>8406899</NlmUniqueID>
            <ISSNLinking>0264-410X</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Adjuvant</Keyword>
            <Keyword MajorTopicYN="N">Heterosubtypic immunity</Keyword>
            <Keyword MajorTopicYN="N">Split virion vaccine</Keyword>
            <Keyword MajorTopicYN="N">T cells</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>4</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0264-410X(14)01116-5</ArticleId>
            <ArticleId IdType="doi">10.1016/j.vaccine.2014.08.003</ArticleId>
            <ArticleId IdType="pubmed">25140929</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25140889</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>4-1BBL Enhances CD8+ T Cell Responses Induced by Vectored Vaccines in Mice but Fails to Improve Immunogenicity in Rhesus Macaques.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e105520</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0105520</ELocationID>
            <Abstract>
                <AbstractText>T cells play a central role in the immune response to many of the world's major infectious diseases. In this study we investigated the tumour necrosis factor receptor superfamily costimulatory molecule, 4-1BBL (CD137L, TNFSF9), for its ability to increase T cell immunogenicity induced by a variety of recombinant vectored vaccines. To efficiently test this hypothesis, we assessed a number of promoters and developed a stable bi-cistronic vector expressing both the antigen and adjuvant. Co-expression of 4-1BBL, together with our model antigen TIP, was shown to increase the frequency of murine antigen-specific IFN-?? secreting CD8+ T cells in three vector platforms examined. Enhancement of the response was not limited by co-expression with the antigen, as an increase in CD8+ immunogenicity was also observed by co-administration of two vectors each expressing only the antigen or adjuvant. However, when this regimen was tested in non-human primates using a clinical malaria vaccine candidate, no adjuvant effect of 4-1BBL was observed limiting its potential use as a single adjuvant for translation into a clinical vaccine.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Spencer</LastName>
                    <ForeName>Alexandra J</ForeName>
                    <Initials>AJ</Initials>
                    <Affiliation>The Jenner Institute, University of Oxford, Oxford, United Kingdom.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Furze</LastName>
                    <ForeName>Julie</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>The Jenner Institute, University of Oxford, Oxford, United Kingdom.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Honeycutt</LastName>
                    <ForeName>Jared D</ForeName>
                    <Initials>JD</Initials>
                    <Affiliation>The Jenner Institute, University of Oxford, Oxford, United Kingdom.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Calvert</LastName>
                    <ForeName>Alice</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>The Jenner Institute, University of Oxford, Oxford, United Kingdom.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Saurya</LastName>
                    <ForeName>Saroj</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>The Jenner Institute, University of Oxford, Oxford, United Kingdom.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Colloca</LastName>
                    <ForeName>Stefano</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Okair??s, Rome, Italy.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wyllie</LastName>
                    <ForeName>David H</ForeName>
                    <Initials>DH</Initials>
                    <Affiliation>The Jenner Institute, University of Oxford, Oxford, United Kingdom.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gilbert</LastName>
                    <ForeName>Sarah C</ForeName>
                    <Initials>SC</Initials>
                    <Affiliation>The Jenner Institute, University of Oxford, Oxford, United Kingdom.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bregu</LastName>
                    <ForeName>Migena</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>The Jenner Institute, University of Oxford, Oxford, United Kingdom.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cottingham</LastName>
                    <ForeName>Matthew G</ForeName>
                    <Initials>MG</Initials>
                    <Affiliation>The Jenner Institute, University of Oxford, Oxford, United Kingdom.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hill</LastName>
                    <ForeName>Adrian V S</ForeName>
                    <Initials>AV</Initials>
                    <Affiliation>The Jenner Institute, University of Oxford, Oxford, United Kingdom.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0105520</ArticleId>
            <ArticleId IdType="pii">PONE-D-14-20059</ArticleId>
            <ArticleId IdType="pubmed">25140889</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25140871</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1554-8937</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>ACS chemical biology</Title>
                <ISOAbbreviation>ACS Chem. Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Synthetic Antibodies with a Human Framework that Protect Mice from Lethal Sudan Ebolavirus Challenge.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The ebolaviruses cause severe and rapidly progressing hemorrhagic fever. There are five ebolavirus species; although much is known about Zaire ebolavirus (EBOV) and its neutralization by antibodies, little is known about Sudan ebolavirus (SUDV), which is emerging with increasing frequency. Here we describe monoclonal antibodies containing a human framework that potently inhibit infection by SUDV and protect mice from lethal challenge. The murine antibody 16F6, which binds the SUDV envelope glycoprotein (GP), served as the starting point for design. Sequence and structural alignment revealed similarities between 16F6 and YADS1, a synthetic antibody with a humanized scaffold. A focused phage library was constructed and screened to impart 16F6-like recognition properties onto the YADS1 scaffold. A panel of 17 antibodies were characterized and found to have a range of neutralization potentials against a pseudotype virus infection model. Neutralization correlated with GP binding as determined by ELISA. Two of these clones, E10 and F4, potently inhibited authentic SUDV and conferred protection and memory immunity in mice from lethal SUDV challenge. E10 and F4 were further shown to bind to the same epitope on GP as 16F6 with comparable affinities. These antibodies represent strong immunotherapeutic candidates for treatment of SUDV infection.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Gang</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author>
                    <LastName>Koellhoffer</LastName>
                    <ForeName>Jayne F</ForeName>
                    <Initials>JF</Initials>
                </Author>
                <Author>
                    <LastName>Zak</LastName>
                    <ForeName>Samantha E</ForeName>
                    <Initials>SE</Initials>
                </Author>
                <Author>
                    <LastName>Frei</LastName>
                    <ForeName>Julia C</ForeName>
                    <Initials>JC</Initials>
                </Author>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Nina</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author>
                    <LastName>Long</LastName>
                    <ForeName>Hua</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author>
                    <LastName>Yi</LastName>
                    <ForeName>Wei</ForeName>
                    <Initials>W</Initials>
                </Author>
                <Author>
                    <LastName>Nagar</LastName>
                    <ForeName>Kaajal</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author>
                    <LastName>Pan</LastName>
                    <ForeName>Guohua</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author>
                    <LastName>Chandran</LastName>
                    <ForeName>Kartik</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author>
                    <LastName>Dye</LastName>
                    <ForeName>John M</ForeName>
                    <Initials>JM</Initials>
                </Author>
                <Author>
                    <LastName>Sidhu</LastName>
                    <ForeName>Sachdev S</ForeName>
                    <Initials>SS</Initials>
                </Author>
                <Author>
                    <LastName>Lai</LastName>
                    <ForeName>Jonathan R</ForeName>
                    <Initials>JR</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>ACS Chem Biol</MedlineTA>
            <NlmUniqueID>101282906</NlmUniqueID>
            <ISSNLinking>1554-8929</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1021/cb5006454</ArticleId>
            <ArticleId IdType="pubmed">25140871</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25140804</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>In vivo efficacy of a synthetic coumarin derivative in a murine model of aspergillosis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e103039</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0103039</ELocationID>
            <Abstract>
                <AbstractText>Despite advances in therapeutic modalities, aspergillosis remains a leading cause of mortality. This has necessitated the identification of effective and safe antifungal molecules. In the present study, in vivo safety and antifungal efficacy of a coumarin derivative, N, N, N-Triethyl-11-(4-methyl-2-oxo-2H-benzopyran-7-yloxy)-11-oxoundecan-1-aminium bromide (SCD-1), was investigated. The maximum tolerable dose of compound was determined according to OECD 423 guidelines. The compound could be assigned to category IV of the Globally Harmonized System and its LD50 cut-off was found to be 2000 mg/kg body weight. The survival increased in Aspergillus fumigatus-infected mice treated with a dose of 200 mg/kg, orally or 100 mg/kg body weight, intraperitoneally, of SCD-1 in comparison to infected-untreated animals. The SCD-1 treatment resulted in significant reduction in colony counts in vital organs of the animals. Its protective effect was also observed on day 14 as there was marked reduction in fungal colonies. The treatment with SCD-1 also reduced the levels of serum biochemical parameters with respect to infected-untreated animals. It could be concluded that SCD-1 is a quite safe antifungal compound, which conferred dose dependent protection against experimental aspergillosis. Therefore, SCD-1 holds potential for developing new formulations for aspergillosis.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Singh</LastName>
                    <ForeName>Seema</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Diagnostic Biochemistry, CSIR-Institute of Genomics and Integrative Biology, Delhi, India; Department of Biotechnology, University of Pune, Pune, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dabur</LastName>
                    <ForeName>Rajesh</ForeName>
                    <Initials>R</Initials>
                    <Affiliation>Department of Biochemistry, Maharishi Dayanand University, Rohtak, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gatne</LastName>
                    <ForeName>Madhumanjiri M</ForeName>
                    <Initials>MM</Initials>
                    <Affiliation>Department of Pharmacology and Toxicology, Bombay Veterinary College, Parel, Mumbai, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Singh</LastName>
                    <ForeName>Bharat</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Diagnostic Biochemistry, CSIR-Institute of Genomics and Integrative Biology, Delhi, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gupta</LastName>
                    <ForeName>Shilpi</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Chemistry, University of Delhi, New Delhi, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pawar</LastName>
                    <ForeName>Sharad</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Pharmacology, National Research Institute of Basic Ayurvedic Sciences, Kothrud, Pune, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sharma</LastName>
                    <ForeName>Sunil K</ForeName>
                    <Initials>SK</Initials>
                    <Affiliation>Department of Chemistry, University of Delhi, New Delhi, India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sharma</LastName>
                    <ForeName>Gainda L</ForeName>
                    <Initials>GL</Initials>
                    <Affiliation>Diagnostic Biochemistry, CSIR-Institute of Genomics and Integrative Biology, Delhi, India.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0103039</ArticleId>
            <ArticleId IdType="pii">PONE-D-13-51033</ArticleId>
            <ArticleId IdType="pubmed">25140804</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25140802</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Reducing Igf-1r Levels Leads To Paradoxical and Sexually Dimorphic Effects in HD Mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e105595</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0105595</ELocationID>
            <Abstract>
                <AbstractText>Many of the neurodegenerative diseases that afflict people in later life are associated with the formation of protein aggregates. These so-called &quot;proteinopathies&quot; include Alzheimer's disease (AD) and Huntington's disease (HD). The insulin/insulin-like growth factor signalling (IIS) pathway has been proposed to modulate such diseases in model organisms, as well as the general ageing process. In this pathway, insulin-like growth factor binds to insulin-like growth factor receptors, such as the insulin-like growth factor 1 receptor (IGF-1R). Heterozygous deletion of Igf-1r has been shown to lead to increased lifespan in mice. Reducing the activity of this pathway had benefits in a HD C. elegans model, and some of these may be attributed to the expected inhibition of mTOR activity resulting in an increase in autophagy, which would enhance mutant huntingtin clearance. Thus, we tested if heterozygous deletion of Igf-1r would lead to benefits in HD related phenotypes in the mouse. Surprisingly, reducing Igf-1r levels led to some beneficial effects in HD females, but also led to some detrimental effects in HD males. Interestingly, Igf-1r deficiency had no discernible effects on downstream mTOR signalling in HD mice. These results do not support a broad beneficial effect of diminishing the IIS pathway in HD pathology in a mammalian system.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Corrochano</LastName>
                    <ForeName>Silvia</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>MRC Mammalian Genetics Unit, Harwell, Oxfordshire, United Kingdom.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Renna</LastName>
                    <ForeName>Maurizio</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Medical Genetics, Cambridge Institute for Medical Research, University of Cambridge, Wellcome/MRC Building, Addenbrooke's Hospital, Cambridge, United Kingdom.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Osborne</LastName>
                    <ForeName>Georgina</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Department of Medical and Molecular Genetics, King's College London, London, United Kingdom.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Carter</LastName>
                    <ForeName>Sarah</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>MRC Mammalian Genetics Unit, Harwell, Oxfordshire, United Kingdom.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stewart</LastName>
                    <ForeName>Michelle</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>MRC Mammalian Genetics Unit, Harwell, Oxfordshire, United Kingdom.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>May</LastName>
                    <ForeName>Joel</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>MRC Mammalian Genetics Unit, Harwell, Oxfordshire, United Kingdom.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bates</LastName>
                    <ForeName>Gillian P</ForeName>
                    <Initials>GP</Initials>
                    <Affiliation>Department of Medical and Molecular Genetics, King's College London, London, United Kingdom.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brown</LastName>
                    <ForeName>Steve D M</ForeName>
                    <Initials>SD</Initials>
                    <Affiliation>MRC Mammalian Genetics Unit, Harwell, Oxfordshire, United Kingdom.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rubinsztein</LastName>
                    <ForeName>David C</ForeName>
                    <Initials>DC</Initials>
                    <Affiliation>Department of Medical Genetics, Cambridge Institute for Medical Research, University of Cambridge, Wellcome/MRC Building, Addenbrooke's Hospital, Cambridge, United Kingdom.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Acevedo-Arozena</LastName>
                    <ForeName>Abraham</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>MRC Mammalian Genetics Unit, Harwell, Oxfordshire, United Kingdom.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>12</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0105595</ArticleId>
            <ArticleId IdType="pii">PONE-D-13-52170</ArticleId>
            <ArticleId IdType="pubmed">25140802</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25140800</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Photodynamic Therapy Using Systemic Administration of 5-Aminolevulinic Acid and a 410-nm Wavelength Light-Emitting Diode for Methicillin-Resistant Staphylococcus aureus-Infected Ulcers in Mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e105173</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0105173</ELocationID>
            <Abstract>
                <AbstractText>Bacterial resistance to antibiotics has become a worldwide problem. One potential alternative for bacterial control is photodynamic therapy. 5-aminolevulinic acid is a natural precursor of the photosensitizer protoporphyrin IX. Relatively little is known about the antibacterial efficacy of photodynamic therapy using the systemic administration of 5-aminolevulinic acid; a few reports have shown that 5-aminolevulinic acid exerts photodynamic effects on methicillin-resistant Staphylococcus aureus (MRSA) in vitro. In this study, we evaluated the effectiveness of photodynamic therapy using 5-aminolevulinic acid and a 410-nm wavelength light-emitting diode in vitro and in vivo for the treatment of MRSA. We found that 5-aminolevulinic acid photodynamic therapy with the light-emitting diode had an in-vitro bactericidal effect on MRSA. In vivo, protoporphyrin IX successfully accumulated in MRSA on ulcer surfaces after intraperitoneal administration of 5-aminolevulinic acid to mice. Furthermore, 5-aminolevulinic acid photodynamic therapy accelerated wound healing and decreased bacterial counts on ulcer surfaces; in contrast, vancomycin treatment did not accelerate wound healing. Our findings indicate that 5-aminolevulinic acid photodynamic therapy may be a new treatment option for MRSA-infected wounds.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Morimoto</LastName>
                    <ForeName>Kuniyuki</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Department of Dermatology, Osaka City University Graduate School of Medicine, Osaka, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ozawa</LastName>
                    <ForeName>Toshiyuki</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Department of Dermatology, Osaka City University Graduate School of Medicine, Osaka, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Awazu</LastName>
                    <ForeName>Kunio</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Medical Beam Physics Laboratory, Osaka University Graduate School of Engineering, Osaka, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ito</LastName>
                    <ForeName>Nobuhisa</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Medical Beam Physics Laboratory, Osaka University Graduate School of Engineering, Osaka, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Honda</LastName>
                    <ForeName>Norihiro</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Medical Beam Physics Laboratory, Osaka University Graduate School of Engineering, Osaka, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Matsumoto</LastName>
                    <ForeName>Sohkichi</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Department of Bacteriology, Osaka City University Graduate School of Medicine, Osaka, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tsuruta</LastName>
                    <ForeName>Daisuke</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Department of Dermatology, Osaka City University Graduate School of Medicine, Osaka, Japan.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0105173</ArticleId>
            <ArticleId IdType="pii">PONE-D-14-18659</ArticleId>
            <ArticleId IdType="pubmed">25140800</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25140793</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1535-3907</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of proteome research</Title>
                <ISOAbbreviation>J. Proteome Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Proteomics analysis of amyloid and non-amyloid prion disease phenotypes reveals both common and divergent mechanisms of neuropathogenesis.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Prion diseases are a heterogeneous group of neurodegenerative disorders affecting various mammals including humans. Prion diseases are characterized by a misfolding of the host-encoded prion protein (PrPC) into a pathological isoform termed PrPSc. In wild-type mice, PrPC is attached to the plasma membrane by a glycosylphosphatidylinositol (GPI) anchor and PrPSc typically accumulates in diffuse non-amyloid deposits with gray matter spongiosis. By contrast, when mice lacking the GPI anchor are infected with the same prion inoculum, PrPSc accumulates in dense perivascular amyloid plaques with little or no gray matter spongiosis. In order to evaluate whether different host biochemical pathways were implicated in these two phenotypically distinct prion disease models, we utilized a proteomics approach. In both models, infected mice displayed evidence of a neuroinflammatory response and complement activation. Proteins involved in cell death and calcium homeostasis were also identified in both phenotypes. However, mitochondrial pathways of apoptosis were implicated only in the non-amyloid form while metal binding and synaptic vesicle transport were more disrupted in the amyloid phenotype. Thus, following infection with a single prion strain, PrPC anchoring to the plasma membrane correlated not only with the type of PrPSc deposition but also with unique biochemical pathways associated with pathogenesis.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Moore</LastName>
                    <ForeName>Roger A</ForeName>
                    <Initials>RA</Initials>
                </Author>
                <Author>
                    <LastName>Sturdevant</LastName>
                    <ForeName>Daniel E</ForeName>
                    <Initials>DE</Initials>
                </Author>
                <Author>
                    <LastName>Chesebro</LastName>
                    <ForeName>Bruce W</ForeName>
                    <Initials>BW</Initials>
                </Author>
                <Author>
                    <LastName>Priola</LastName>
                    <ForeName>Suzette Alise</ForeName>
                    <Initials>SA</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Proteome Res</MedlineTA>
            <NlmUniqueID>101128775</NlmUniqueID>
            <ISSNLinking>1535-3893</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1021/pr500329w</ArticleId>
            <ArticleId IdType="pubmed">25140793</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25140758</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1557-7600</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of medicinal food</Title>
                <ISOAbbreviation>J Med Food</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effect of Ganoderma applanatum Mycelium Extract on the Inhibition of Adipogenesis in 3T3-L1 Adipocytes.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Abstract Ganoderma applanatum (GA) and related fungal species have been used for over 2000 years in China to prevent and treat various human diseases. However, there is no critical research evaluating the functionality of GA grown using submerged culture technology. This study aimed to evaluate the effects of submerged culture GA mycelium (GAM) and its active components (protocatechualdehyde [PCA]) on preadipocyte differentiation of 3T3-L1 cells. Mouse-derived preadipocyte 3T3-L1 cells were treated with differentiation inducers in the presence or absence of GAM extracts. We determined triglyceride accumulations, glycerol-3-phosphate dehydrogenase (GPDH) activities, and differentiation makers. PCA, the active component of GAM extract, was also used to treat 3T3-L1 cells. The MTT assay showed that the GAM extract (0.01-1???mg/mL) was not toxic to 3T3-L1 preadipocyte. Treatment of cells with GAM extracts and its active components significantly decreased the GPDH activity and lipid accumulation, a marker of adipogenesis, in a dose-dependent manner. Western blot analysis results showed that the protein expression levels of peroxisome proliferator-activated receptor ?? (PPAR??), CCAAT/enhancer-binding protein ?? (C/EBP??), and sterol regulatory element-binding protein 1 (SREBP1) were inhibited by the GAM extract. In addition, adipogenic-specific genes such as perilipin, fatty acid synthase (FAS), fatty acid transport protein 1 (FATP1), and fatty acid-binding protein 4 (FABP4) decreased in a dose-dependent manner. Quantitative high-performance liquid chromatography analysis showed that the GAM extract contained 1.14???mg/g PCA. GAM extracts suppressed differentiation of 3T3-L1 preadipocytes, in part, through altered regulation of PPAR??, C/EBP??, and SREBP1. These results suggest that GAM extracts and PCA may suppress adipogenesis by inhibiting differentiation of preadipocytes.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Kim</LastName>
                    <ForeName>Ji-Eun</ForeName>
                    <Initials>JE</Initials>
                    <Affiliation>Department of Food Science and Technology, Keimyung University , Daegu, Korea.</Affiliation>
                </Author>
                <Author>
                    <LastName>Park</LastName>
                    <ForeName>Sung-Jin</ForeName>
                    <Initials>SJ</Initials>
                </Author>
                <Author>
                    <LastName>Yu</LastName>
                    <ForeName>Mi-Hee</ForeName>
                    <Initials>MH</Initials>
                </Author>
                <Author>
                    <LastName>Lee</LastName>
                    <ForeName>Sam-Pin</ForeName>
                    <Initials>SP</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Med Food</MedlineTA>
            <NlmUniqueID>9812512</NlmUniqueID>
            <ISSNLinking>1096-620X</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">3T3-L1 cell</Keyword>
            <Keyword MajorTopicYN="N">GPDH activity</Keyword>
            <Keyword MajorTopicYN="N">Ganoderma applanatum</Keyword>
            <Keyword MajorTopicYN="N">PPAR??</Keyword>
            <Keyword MajorTopicYN="N">anti-obesity</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1089/jmf.2013.3036</ArticleId>
            <ArticleId IdType="pubmed">25140758</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25140725</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Germ cell nuclear factor regulates gametogenesis in developing gonads.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e103985</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0103985</ELocationID>
            <Abstract>
                <AbstractText>Expression of germ cell nuclear factor (GCNF; Nr6a1), an orphan member of the nuclear receptor gene family of transcription factors, during gastrulation and neurulation is critical for normal embryogenesis in mice. Gcnf represses the expression of the POU-domain transcription factor Oct4 (Pou5f1) during mouse post-implantation development. Although Gcnf expression is not critical for the embryonic segregation of the germ cell lineage, we found that sexually dimorphic expression of Gcnf in germ cells correlates with the expression of pluripotency-associated genes, such as Oct4, Sox2, and Nanog, as well as the early meiotic marker gene Stra8. To elucidate the role of Gcnf during mouse germ cell differentiation, we generated an ex vivo Gcnf-knockdown model in combination with a regulated CreLox mutation of Gcnf. Lack of Gcnf impairs normal spermatogenesis and oogenesis in vivo, as well as the derivation of germ cells from embryonic stem cells (ESCs) in vitro. Inactivation of the Gcnf gene in vivo leads to loss of repression of Oct4 expression in both male and female gonads.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Sabour</LastName>
                    <ForeName>Davood</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Department of Cell and Developmental Biology, Max Planck Institute for Molecular Biomedicine, M??nster, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Xu</LastName>
                    <ForeName>Xueping</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chung</LastName>
                    <ForeName>Arthur C K</ForeName>
                    <Initials>AC</Initials>
                    <Affiliation>Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas, United States of America; Centre for Inflammatory Diseases and Molecular Therapies, The University of Hong Kong, Pokfulam, Hong Kong.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Le Menuet</LastName>
                    <ForeName>Damien</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas, United States of America; INSERM, U693, Facult?? de M??decine Paris-Sud, Paris, France.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ko</LastName>
                    <ForeName>Kinarm</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Center for Stem Cell Research, Institute of Biomedical Sciences and Technology, Konkuk University, Seoul, Republic of Korea; Department of Neuroscience, School of Medicine, Institute of Biomedical Sciences and Technology, Konkuk University, Seoul, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tapia</LastName>
                    <ForeName>Natalia</ForeName>
                    <Initials>N</Initials>
                    <Affiliation>Department of Cell and Developmental Biology, Max Planck Institute for Molecular Biomedicine, M??nster, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ara??zo-Bravo</LastName>
                    <ForeName>Marcos J</ForeName>
                    <Initials>MJ</Initials>
                    <Affiliation>Department of Cell and Developmental Biology, Max Planck Institute for Molecular Biomedicine, M??nster, Germany; Group of Computational Biology and Systems Biomedicine, Biodonostia Health Research Institute, San Sebasti??n, Spain.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gentile</LastName>
                    <ForeName>Luca</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Department of Cell and Developmental Biology, Max Planck Institute for Molecular Biomedicine, M??nster, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Greber</LastName>
                    <ForeName>Boris</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>Department of Cell and Developmental Biology, Max Planck Institute for Molecular Biomedicine, M??nster, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>H??bner</LastName>
                    <ForeName>Karin</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Department of Cell and Developmental Biology, Max Planck Institute for Molecular Biomedicine, M??nster, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sebastiano</LastName>
                    <ForeName>Vittorio</ForeName>
                    <Initials>V</Initials>
                    <Affiliation>Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Palo Alto, California, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Guangming</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Department of Cell and Developmental Biology, Max Planck Institute for Molecular Biomedicine, M??nster, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sch??ler</LastName>
                    <ForeName>Hans R</ForeName>
                    <Initials>HR</Initials>
                    <Affiliation>Department of Cell and Developmental Biology, Max Planck Institute for Molecular Biomedicine, M??nster, Germany; Medical Faculty, University of M??nster, M??nster, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cooney</LastName>
                    <ForeName>Austin J</ForeName>
                    <Initials>AJ</Initials>
                    <Affiliation>Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas, United States of America.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>27</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>4</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0103985</ArticleId>
            <ArticleId IdType="pii">PONE-D-14-13608</ArticleId>
            <ArticleId IdType="pubmed">25140725</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25140704</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>CRISPR/Cas9-Mediated Gene Knock-Down in Post-Mitotic Neurons.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e105584</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0105584</ELocationID>
            <Abstract>
                <AbstractText>The prokaryotic adaptive immune system CRISPR/Cas9 has recently been adapted for genome editing in eukaryotic cells. This technique allows for sequence-specific induction of double-strand breaks in genomic DNA of individual cells, effectively resulting in knock-out of targeted genes. It thus promises to be an ideal candidate for application in neuroscience where constitutive genetic modifications are frequently either lethal or ineffective due to adaptive changes of the brain. Here we use CRISPR/Cas9 to knock-out Grin1, the gene encoding the obligatory NMDA receptor subunit protein GluN1, in a sparse population of mouse pyramidal neurons. Within this genetically mosaic tissue, manipulated cells lack synaptic current mediated by NMDA-type glutamate receptors consistent with complete knock-out of the targeted gene. Our results show the first proof-of-principle demonstration of CRISPR/Cas9-mediated knock-down in neurons in vivo, where it can be a useful tool to study the function of specific proteins in neuronal circuits.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Straub</LastName>
                    <ForeName>Christoph</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Department of Neurobiology, Howard Hughes Medical Institute, Harvard Medical School, Boston, Massachusetts, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Granger</LastName>
                    <ForeName>Adam J</ForeName>
                    <Initials>AJ</Initials>
                    <Affiliation>Department of Neurobiology, Howard Hughes Medical Institute, Harvard Medical School, Boston, Massachusetts, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Saulnier</LastName>
                    <ForeName>Jessica L</ForeName>
                    <Initials>JL</Initials>
                    <Affiliation>Department of Neurobiology, Howard Hughes Medical Institute, Harvard Medical School, Boston, Massachusetts, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sabatini</LastName>
                    <ForeName>Bernardo L</ForeName>
                    <Initials>BL</Initials>
                    <Affiliation>Department of Neurobiology, Howard Hughes Medical Institute, Harvard Medical School, Boston, Massachusetts, United States of America.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0105584</ArticleId>
            <ArticleId IdType="pii">PONE-D-14-21576</ArticleId>
            <ArticleId IdType="pubmed">25140704</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25140692</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Intranasal Delivery of Influenza rNP Adjuvanted with c-di-AMP Induces Strong Humoral and Cellular Immune Responses and Provides Protection against Virus Challenge.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e104824</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0104824</ELocationID>
            <Abstract>
                <AbstractText>There is a critical need for new influenza vaccines able to protect against constantly emerging divergent virus strains. This will be sustained by the induction of vigorous cellular responses and humoral immunity capable of acting at the portal of entry of this pathogen. In this study we evaluate the protective efficacy of intranasal vaccination with recombinant influenza nucleoprotein (rNP) co-administrated with bis-(3',5')-cyclic dimeric adenosine monophosphate (c-di-AMP) as adjuvant. Immunization of BALB/c mice with two doses of the formulation stimulates high titers of NP-specific IgG in serum and secretory IgA at mucosal sites. This formulation also promotes a strong Th1 response characterized by high secretion of INF-?? and IL-2. The immune response elicited promotes efficient protection against virus challenge. These results suggest that c-di-AMP is a potent mucosal adjuvant which may significantly contribute towards the development of innovative mucosal vaccines against influenza.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Sanchez</LastName>
                    <ForeName>Maria Victoria</ForeName>
                    <Initials>MV</Initials>
                    <Affiliation>Laboratory of Virology, Institute of Experimental Medicine and Biology of Cuyo (IMBECU-CCT, CONICET), Mendoza, Argentina; Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ebensen</LastName>
                    <ForeName>Thomas</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schulze</LastName>
                    <ForeName>Kai</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cargnelutti</LastName>
                    <ForeName>Diego</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Laboratory of Virology, Institute of Experimental Medicine and Biology of Cuyo (IMBECU-CCT, CONICET), Mendoza, Argentina.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Blazejewska</LastName>
                    <ForeName>Paulina</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Boehringer Ingelheim Veterinary Research Center GmbH &amp; Co. KG, Hannover, Germany.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Scodeller</LastName>
                    <ForeName>Eduardo A</ForeName>
                    <Initials>EA</Initials>
                    <Affiliation>Laboratory of Virology, Institute of Experimental Medicine and Biology of Cuyo (IMBECU-CCT, CONICET), Mendoza, Argentina.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Guzm??n</LastName>
                    <ForeName>Carlos A</ForeName>
                    <Initials>CA</Initials>
                    <Affiliation>Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, Germany.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>17</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0104824</ArticleId>
            <ArticleId IdType="pii">PONE-D-14-16338</ArticleId>
            <ArticleId IdType="pubmed">25140692</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25140668</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1364-5528</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Analyst</Title>
                <ISOAbbreviation>Analyst</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Rapid assessment of the coenzyme Q10 redox state using ultrahigh performance liquid chromatography tandem mass spectrometry.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">An improved method for accurate and rapid assessment of the coenzyme Q10 (CoQ10) redox state using ultrahigh performance liquid chromatography tandem mass spectrometry was described, with particular attention given to the instability of the reduced form of CoQ10 during sample preparation, chromatographic separation and mass spectrometric detection. As highly lipophilic compounds in complex biological matrices, both reduced and oxidized forms of CoQ10 were extracted simultaneously from the tissue samples by methanol which is superior to ethanol and isopropanol. After centrifugation, the supernatants were immediately separated on a C18 column with isocratic elution using methanol containing 2 mM ammonium acetate as a non-aqueous mobile phase, and detected by positive electrospray ionization tandem mass spectrometry in multiple reaction monitoring (MRM) mode. Ammonium acetate as an additive in methanol provided enhanced mass spectrometric responses for both forms of CoQ10, primarily due to stable formation of adduct ions [M + NH4](+), which served as precursor ions in positive ionization MRM transitions. The assay showed a linear range of 8.6-8585 ng mL(-1) for CoQ10H2 and 8.6-4292 ng mL(-1) for CoQ10. The limits of detection (LODs) were 7.0 and 1.0 ng mL(-1) and limits of quantification (LOQs) were 15.0 and 5.0 ng mL(-1) for CoQ10H2 and CoQ10, respectively. This rapid extractive and analytical method could avoid artificial auto-oxidation of the reduced form of CoQ10, enabling the native redox state assessment. This reliable method was also successfully applied for the measurement of the CoQ10 redox state in liver tissues of mice exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin, revealing the down-regulated mitochondrial electron transport chain.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Tang</LastName>
                    <ForeName>Zhi</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>State Key Laboratory of Environmental and Biological Analysis, Department of Chemistry, Hong Kong Baptist University, Hong Kong SAR, China. zwcai@hkbu.edu.hk linshu@hkbu.edu.hk.</Affiliation>
                </Author>
                <Author>
                    <LastName>Li</LastName>
                    <ForeName>Shangfu</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author>
                    <LastName>Guan</LastName>
                    <ForeName>Xinyuan</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author>
                    <LastName>Schmitt-Kopplin</LastName>
                    <ForeName>Philippe</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author>
                    <LastName>Lin</LastName>
                    <ForeName>Shuhai</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author>
                    <LastName>Cai</LastName>
                    <ForeName>Zongwei</ForeName>
                    <Initials>Z</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Analyst</MedlineTA>
            <NlmUniqueID>0372652</NlmUniqueID>
            <ISSNLinking>0003-2654</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1039/c4an00760c</ArticleId>
            <ArticleId IdType="pubmed">25140668</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25140595</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1678-2674</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>29</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Acta cir??rgica brasileira / Sociedade Brasileira para Desenvolvimento Pesquisa em Cirurgia</Title>
                <ISOAbbreviation>Acta Cir Bras</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Copaiba oil effect under different pathways in mice subjected to sepsis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>528-31</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0102-86502014000800528</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To evaluate the effects of copaiba oil administered by different routes on survival of mices subjected to cecal ligation and puncture.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Thirty two mice were distributed into four study groups (N=8): Sham group: normal standard animals;</AbstractText>
                <AbstractText Label="CONTROL GROUP" NlmCategory="METHODS">submitted a cecal ligation and puncture (CLP); Gavage group: submitted a CLP, and treat with copaiba oil by gavage; and Subcutaneous group: submitted a CLP, and treat with copaiba oil by subcutaneous injection. After the death of the histological analysis were performed. The Kaplan-Meier curves of surviving time were realized.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">All animals that received copaiba, regardless of the route used, survived longer when compared to the control group (p&lt;0.0001), whereas the survival time ranged from 20 hours for the control group up to 32 hours for the animals of gavage group and 52 for subcutaneous group. The animals that received gavage copaiba lived about and about 20 hours unless the subcutaneous group (p=0.0042). There was no statistical difference when compared the intensity of inflammatory response (p&gt;0.05) CONCLUSION: Prophylactic subcutaneous administration of copaiba in mice subjected to severe sepsis by cecal ligation and puncture, resulted in a survival time higher than non-use or use of this oil by gavage.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Botelho</LastName>
                    <ForeName>Nara Macedo</ForeName>
                    <Initials>NM</Initials>
                    <Affiliation>Department of Integrate Health, Medical School, University State of Para, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Silveira</LastName>
                    <ForeName>Edvaldo Lima</ForeName>
                    <Initials>EL</Initials>
                    <Affiliation>UFPA, Belem, PA, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lopes</LastName>
                    <ForeName>Let??cia Nobre</ForeName>
                    <Initials>LN</Initials>
                    <Affiliation>School of Medicine, UEPA, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Santos</LastName>
                    <ForeName>Felipe Augusto Folha</ForeName>
                    <Initials>FA</Initials>
                    <Affiliation>School of Medicine, UEPA, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Teixeira</LastName>
                    <ForeName>Renan Kleber Costa</ForeName>
                    <Initials>RK</Initials>
                    <Affiliation>School of Medicine, UEPA, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Silva</LastName>
                    <ForeName>Tha??s Travassos da</ForeName>
                    <Initials>TT</Initials>
                    <Affiliation>School of Medicine, UEPA, Brazil.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Brazil</Country>
            <MedlineTA>Acta Cir Bras</MedlineTA>
            <NlmUniqueID>9103983</NlmUniqueID>
            <ISSNLinking>0102-8650</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0102-86502014000800528</ArticleId>
            <ArticleId IdType="pubmed">25140595</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25140582</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1535-4989</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>American journal of respiratory cell and molecular biology</Title>
                <ISOAbbreviation>Am. J. Respir. Cell Mol. Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Reemergence of Hedgehog Mediates Epithelial-mesenchymal Crosstalk in Pulmonary Fibrosis.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Hedgehog signaling plays important roles in development and cell differentiation. In this study, the ability of sonic Hedgehog (SHH) to induce myofibroblast differentiation was analyzed in isolated human lung fibroblasts and its in vivo significance was evaluated in rodent bleomycin induced pulmonary fibrosis. The results showed that SHH could induce myofibroblast differentiation in human lung fibroblasts in a Smo and Gli1 dependent manner. Moreover gel shift analysis, chromatin immunoprecipitation assay and site directed mutagenesis revealed that a Gli1 binding consensus in the ??-SMA promoter was important for mediating SHH-induced myofibroblast differentiation. Analysis of Hedgehog reemergence in vivo revealed that of all 3 Hedgehog isoforms, only SHH was significantly induced in bleomycin injured lung along with Gli1. The induction of SHH was only noted in epithelial cells and its expression was undetectable in lung fibroblasts or macrophages. TGF?? induced SHH significantly in cultured alveolar epithelial cells, while SHH induced TGF?? in lung fibroblasts. Moreover pulmonary fibrosis and ??-SMA expression were significantly reduced in mice that were Smo deficient only in type I collagen expressing cells. Thus the re-emergence of SHH in epithelial cells could result in induction of myofibroblast differentiation in a Smo-dependent manner and subsequent Gli1 activation of the ??-SMA promoter.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Hu</LastName>
                    <ForeName>Biao</ForeName>
                    <Initials>B</Initials>
                    <Affiliation>University of Michigan, Pathology , BSRB 4830 , 109 Zina Pitcher Place , Ann Arbor, Michigan, United States, 48109 , 734-763-5731 , 734-615-2331 ; biaohu@med.umich.edu.</Affiliation>
                </Author>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Jianhua</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author>
                    <LastName>Wu</LastName>
                    <ForeName>Zhe</ForeName>
                    <Initials>Z</Initials>
                </Author>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Tianju</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author>
                    <LastName>Ullenbruch</LastName>
                    <ForeName>Matthew R</ForeName>
                    <Initials>MR</Initials>
                </Author>
                <Author>
                    <LastName>Ding</LastName>
                    <ForeName>Lin</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author>
                    <LastName>Henke</LastName>
                    <ForeName>Craig A</ForeName>
                    <Initials>CA</Initials>
                </Author>
                <Author>
                    <LastName>Bitterman</LastName>
                    <ForeName>Peter B</ForeName>
                    <Initials>PB</Initials>
                </Author>
                <Author>
                    <LastName>Phan</LastName>
                    <ForeName>Sem H</ForeName>
                    <Initials>SH</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Am J Respir Cell Mol Biol</MedlineTA>
            <NlmUniqueID>8917225</NlmUniqueID>
            <ISSNLinking>1044-1549</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Fibrosis</Keyword>
            <Keyword MajorTopicYN="N">hedgehog</Keyword>
            <Keyword MajorTopicYN="N">myofibroblast</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1165/rcmb.2014-0108OC</ArticleId>
            <ArticleId IdType="pubmed">25140582</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25140527</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>9</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Transforming Growth Factor-??1 Signaling Represses Testicular Steroidogenesis through Cross-Talk with Orphan Nuclear Receptor Nur77.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e104812</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0104812</ELocationID>
            <Abstract>
                <AbstractText>Transforming growth factor- ??1 (TGF-??1) has been reported to inhibit luteinizing hormone (LH) mediated-steroidogenesis in testicular Leydig cells. However, the mechanism by which TGF-??1 controls the steroidogenesis in Leydig cells is not well understood. Here, we investigated the possibility that TGF-??1 represses steroidogenesis through cross-talk with the orphan nuclear receptor Nur77. Nur77, which is induced by LH/cAMP signaling, is one of major transcription factors that regulate the expression of steroidogenic genes in Leydig cells. TGF-??1 signaling inhibited cAMP-induced testosterone production and the expression of steroidogenic genes such as P450c17, StAR and 3??-HSD in mouse Leydig cells. Further, TGF-??1/ALK5 signaling repressed cAMP-induced and Nur77-activated promoter activity of steroidogenic genes. In addition, TGF-??1/ALK5-activated Smad3 repressed Nur77 transactivation of steroidogenic gene promoters by interfering with Nur77 binding to DNA. In primary Leydig cells isolated from Tgfbr2flox/flox Cyp17iCre mice, TGF-??1-mediated repression of cAMP-induced steroidogenic gene expression was significantly less than that in primary Leydig cells from Tgfbr2flox/flox mice. Taken together, these results suggest that TGF-??1/ALK5/Smad3 signaling represses the expression of steroidogenic genes via the suppression of Nur77 transactivation in testicular Leydig cells. These findings may provide a molecular mechanism involved in the TGF-??1-mediated repression of testicular steroidogenesis.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Park</LastName>
                    <ForeName>Eunsook</ForeName>
                    <Initials>E</Initials>
                    <Affiliation>Hormone Research Center, School of Biological Sciences and Technology, Chonnam National University, Gwangju, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Song</LastName>
                    <ForeName>Chin-Hee</ForeName>
                    <Initials>CH</Initials>
                    <Affiliation>Hormone Research Center, School of Biological Sciences and Technology, Chonnam National University, Gwangju, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Park</LastName>
                    <ForeName>Jae-Il</ForeName>
                    <Initials>JI</Initials>
                    <Affiliation>Korea Basic Science Institute, Gwangju Center at Chonnam National University, Gwangju, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ahn</LastName>
                    <ForeName>Ryun-Sup</ForeName>
                    <Initials>RS</Initials>
                    <Affiliation>Graduate School of Integrative Medicine, CHA Medical University, Seoul, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Choi</LastName>
                    <ForeName>Hueng-Sik</ForeName>
                    <Initials>HS</Initials>
                    <Affiliation>Hormone Research Center, School of Biological Sciences and Technology, Chonnam National University, Gwangju, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ko</LastName>
                    <ForeName>CheMyong</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Department of Comparative Biosciences, College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Urbana, Illinois, United States of America.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Keesook</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Hormone Research Center, School of Biological Sciences and Technology, Chonnam National University, Gwangju, Republic of Korea.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>2</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0104812</ArticleId>
            <ArticleId IdType="pii">PONE-D-14-19663</ArticleId>
            <ArticleId IdType="pubmed">25140527</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25140446</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>21</Day>
        </DateCreated>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1420-3049</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>19</Volume>
                    <Issue>8</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Molecules (Basel, Switzerland)</Title>
                <ISOAbbreviation>Molecules</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Cucurbitane Glycosides Derived from Mogroside IIE: Structure-Taste Relationships, Antioxidant Activity, and Acute Toxicity.</ArticleTitle>
            <Pagination>
                <MedlinePgn>12676-89</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3390/molecules190812676</ELocationID>
            <Abstract>
                <AbstractText>Mogroside IIE is a bitter triterpenoid saponin which is the main component of unripe Luo Han Guo fruit and a precursor of the commercially available sweetener mogroside V. In this study, we developed an enzymatic glycosyl transfer method, by which bitter mogroside IIE could be converted into a sweet triterpenoid saponin mixture. The reactant concentration, temperature, pH and buffer system were studied. New saponins with the ??-glucose group were isolated from the resulting mixtures, and the structures of three components of the extract were determined. The structure-taste relationships of these derivatives were also studied together with those of the natural mogrosides. The number and stereoconfiguration of glucose groups present in the mogroside molecules were found to be the main factor to determine the sweet or bitter taste of a compound. The antioxidant and food safety properties were initially evaluated by their radical scavenging ability and via 7 day mice survival tests, respectively. The results showed that the sweet triterpenoid saponin mixture has the same favorable physiological and safety characteristics as the natural mogrosides.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Lei</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Guangxi Key Laboratory of Functional Phytochemicals Research and Utilization, Institute of Botany, Guangxi Zhuang Autonomous Region and Chinese Academy of Sciences, Guilin 541006, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Ziming</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>Guangxi Key Laboratory of Functional Phytochemicals Research and Utilization, Institute of Botany, Guangxi Zhuang Autonomous Region and Chinese Academy of Sciences, Guilin 541006, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lu</LastName>
                    <ForeName>Fenglai</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Guangxi Key Laboratory of Functional Phytochemicals Research and Utilization, Institute of Botany, Guangxi Zhuang Autonomous Region and Chinese Academy of Sciences, Guilin 541006, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Jinglei</ForeName>
                    <Initials>J</Initials>
                    <Affiliation>Guangxi Key Laboratory of Functional Phytochemicals Research and Utilization, Institute of Botany, Guangxi Zhuang Autonomous Region and Chinese Academy of Sciences, Guilin 541006, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Song</LastName>
                    <ForeName>Yunfei</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Guilin Layn Natural Ingredients Corp., Guilin 541199, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Dianpeng</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Guangxi Key Laboratory of Functional Phytochemicals Research and Utilization, Institute of Botany, Guangxi Zhuang Autonomous Region and Chinese Academy of Sciences, Guilin 541006, China. ldp@gxib.cn.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Molecules</MedlineTA>
            <NlmUniqueID>100964009</NlmUniqueID>
            <ISSNLinking>1420-3049</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>06</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">molecules190812676</ArticleId>
            <ArticleId IdType="doi">10.3390/molecules190812676</ArticleId>
            <ArticleId IdType="pubmed">25140446</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25140408</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1939-6376</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Systems biology in reproductive medicine</Title>
                <ISOAbbreviation>Syst Biol Reprod Med</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Chronic alcohol administration causes expression of calprotectin and RAGE altering the distribution of zinc ions in mouse testis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1-8</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Abstract Several studies reported that chronic alcohol consumption alters the intestinal mucosa barrier, and subsequent entrance of endotoxins into the bloodstream. In many tissues endotoxin exposure causes the expression of calprotectin (CP) and the receptor for advanced glycation -end products (RAGE). In this study we investigated whether chronic alcohol administration causes expression of CP and RAGE in mouse testis. The distribution of free and loosely bound Zn(2+) (FLB-Zn(2+)) in the testicular tissues was also evaluated. Alcohol-induced testicular damage was documented by measuring testosterone blood levels and by light and electron microscope studies. Twenty mice were treated daily for three weeks with 3.0???g/kg of a 25% solution of alcohol. Ten mice were treated in the same period of time with a solution of maltose dextrins, isocaloric to alcohol. Twenty untreated mice were used as controls. Alcohol treated mice showed diffuse expression of CP and RAGE in the interstitial cells. RAGE was found also in the basal compartment of the seminiferous tubules. Depletion of FLB-Zn(2+) was observed in the adluminal compartment of the seminiferous tubules. Expression of CP and RAGE was not found in control mice and maltose dextrin treated mice. Our results indicated novel mechanisms by which alcohol acts in testis. Indeed, CP and RAGE may cause the generation of oxidants and inflammatory mediators, with negative impact on testicular functions. Depletion of FLB-Zn(2+) may contribute to the dysregulation of spermatogenesis.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Giannessi</LastName>
                    <ForeName>Francesco</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Department of Translational Research and of New Surgical and Medical Technologies, University of Pisa , Pisa , Italy .</Affiliation>
                </Author>
                <Author>
                    <LastName>Scavuzzo</LastName>
                    <ForeName>Maria C</ForeName>
                    <Initials>MC</Initials>
                </Author>
                <Author>
                    <LastName>Giambelluca</LastName>
                    <ForeName>Maria A</ForeName>
                    <Initials>MA</Initials>
                </Author>
                <Author>
                    <LastName>Fornai</LastName>
                    <ForeName>Francesco</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author>
                    <LastName>Morelli</LastName>
                    <ForeName>Girolamo</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author>
                    <LastName>Ruffoli</LastName>
                    <ForeName>Riccardo</ForeName>
                    <Initials>R</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Syst Biol Reprod Med</MedlineTA>
            <NlmUniqueID>101464963</NlmUniqueID>
            <ISSNLinking>1939-6368</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Alcohol</Keyword>
            <Keyword MajorTopicYN="N">RAGE</Keyword>
            <Keyword MajorTopicYN="N">calprotectin</Keyword>
            <Keyword MajorTopicYN="N">mice</Keyword>
            <Keyword MajorTopicYN="N">testis</Keyword>
            <Keyword MajorTopicYN="N">zinc</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.3109/19396368.2014.949905</ArticleId>
            <ArticleId IdType="pubmed">25140408</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25140394</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1945-7197</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of clinical endocrinology and metabolism</Title>
                <ISOAbbreviation>J. Clin. Endocrinol. Metab.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>SOX3 DELETION IN MOUSE AND HUMAN IS ASSOCIATED WITH PERSISTENCE OF THE CRANIOPHARYNGEAL CANAL.</ArticleTitle>
            <Pagination>
                <MedlinePgn>jc20141160</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Context: SOX3 is an early developmental transcription factor involved in pituitary development. In humans, over- and under-dosage of SOX3 is associated with X-linked hypopituitarism with variable phenotypes ranging from isolated growth hormone deficiency (GHD) to panhypopituitarism, with or without mental retardation and, in most cases with reported pituitary imaging, an ectopic/undescended posterior pituitary. Patient: We present a young patient with hemophilia B and developmental delay who had a 2.31Mb deletion on Xq27 including SOX3, F9 and eight other contiguous genes. He developed growth hormone (GH) and gonadotropin deficiency, whilst his thyroid function was in the low normal range. Magnetic resonance imaging (MRI) revealed a eutopic posterior pituitary and the unusual finding of a persistent craniopharyngeal canal that has not previously been described in patients with congenital hypopituitarism. Objective and Methods: To establish whether loss of SOX3 can account for the human phenotype, we examined in detail the hypothalamo-pituitary region of neonatal Sox3 null mice. Results: Consistent with the patient's phenotype, Sox3 null mice exhibit a ventral extension of the anterior pituitary that penetrates, and generates a mass beneath the sphenoid bone. This suggests that the defect results from abnormal induction of Rathke's pouch, leading to a persistent connection between Rathke's pouch and the oral ectoderm. Conclusions: Our observations expand the spectrum of phenotypes observed in association with altered SOX3 dosage and may affect the approach to genetic screening. Screening for SOX3 should be advised not only for hypopituitary patients with an ectopic posterior pituitary, but also for those with a structurally normal pituitary and additional findings including clefts and a persistent craniopharyngeal canal, with or without mental retardation.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Alatzoglou</LastName>
                    <ForeName>Ks</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Developmental Endocrinology Research Group, Clinical and Molecular Genetics Unit, UCL Institute of Child Health, London, UK;</Affiliation>
                </Author>
                <Author>
                    <LastName>Azriyanti</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author>
                    <LastName>Rogers</LastName>
                    <ForeName>N</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author>
                    <LastName>Ryan</LastName>
                    <ForeName>F</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author>
                    <LastName>Curry</LastName>
                    <ForeName>N</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author>
                    <LastName>Noakes</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author>
                    <LastName>Bignell</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author>
                    <LastName>Hall</LastName>
                    <ForeName>Gw</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author>
                    <LastName>Littooij</LastName>
                    <ForeName>As</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author>
                    <LastName>Saunders</LastName>
                    <ForeName>D</ForeName>
                    <Initials>D</Initials>
                </Author>
                <Author>
                    <LastName>Thomas</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author>
                    <LastName>Stewart</LastName>
                    <ForeName>H</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author>
                    <LastName>Dattani</LastName>
                    <ForeName>Mt</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>J Clin Endocrinol Metab</MedlineTA>
            <NlmUniqueID>0375362</NlmUniqueID>
            <ISSNLinking>0021-972X</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2014-1160</ArticleId>
            <ArticleId IdType="pubmed">25140394</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25140391</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1525-6073</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Chronobiology international</Title>
                <ISOAbbreviation>Chronobiol. Int.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The mouse liver displays daily rhythms in the metabolism of phospholipids and in the activity of lipid synthesizing enzymes.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1-16</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The circadian system involves central and peripheral oscillators regulating temporally biochemical processes including lipid metabolism; their disruption leads to severe metabolic diseases (obesity, diabetes, etc). Here, we investigated the temporal regulation of glycerophospholipid (GPL) synthesis in mouse liver, a well-known peripheral oscillator. Mice were synchronized to a 12:12???h light-dark (LD) cycle and then released to constant darkness with food ad libitum. Livers collected at different times exhibited a daily rhythmicity in some individual GPL content with highest levels during the subjective day. The activity of GPL-synthesizing/remodeling enzymes: phosphatidate phosphohydrolase 1 (PAP-1/lipin) and lysophospholipid acyltransferases (LPLATs) also displayed significant variations, with higher levels during the subjective day and at dusk. We evaluated the temporal regulation of expression and activity of phosphatidylcholine (PC) synthesizing enzymes. PC is mainly synthesized through the Kennedy pathway with Choline Kinase (ChoK) as a key regulatory enzyme or through the phosphatidylethanolamine (PE) N-methyltransferase (PEMT) pathway. The PC/PE content ratio exhibited a daily variation with lowest levels at night, while ChoK?? and PEMT mRNA expression displayed maximal levels at nocturnal phases. Our results demonstrate that mouse liver GPL metabolism oscillates rhythmically with a precise temporal control in the expression and/or activity of specific enzymes.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Gorn??</LastName>
                    <ForeName>Lucas D</ForeName>
                    <Initials>LD</Initials>
                    <Affiliation>Departamento de Qu??mica Biol??gica, Facultad de Ciencias Qu??micas, CIQUIBIC-CONICET, Universidad Nacional de C??rdoba , C??rdoba , Argentina and.</Affiliation>
                </Author>
                <Author>
                    <LastName>Acosta-Rodr??guez</LastName>
                    <ForeName>Victoria A</ForeName>
                    <Initials>VA</Initials>
                </Author>
                <Author>
                    <LastName>Pasquar??</LastName>
                    <ForeName>Susana J</ForeName>
                    <Initials>SJ</Initials>
                </Author>
                <Author>
                    <LastName>Salvador</LastName>
                    <ForeName>Gabriela A</ForeName>
                    <Initials>GA</Initials>
                </Author>
                <Author>
                    <LastName>Giusto</LastName>
                    <ForeName>Norma M</ForeName>
                    <Initials>NM</Initials>
                </Author>
                <Author>
                    <LastName>Guido</LastName>
                    <ForeName>Mario Eduardo</ForeName>
                    <Initials>ME</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Chronobiol Int</MedlineTA>
            <NlmUniqueID>8501362</NlmUniqueID>
            <ISSNLinking>0742-0528</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Circadian rhythm</Keyword>
            <Keyword MajorTopicYN="N">mouse liver</Keyword>
            <Keyword MajorTopicYN="N">peripheral oscillator</Keyword>
            <Keyword MajorTopicYN="N">phospholipid metabolism</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.3109/07420528.2014.949734</ArticleId>
            <ArticleId IdType="pubmed">25140391</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25140390</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1525-6073</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Chronobiology international</Title>
                <ISOAbbreviation>Chronobiol. Int.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Irradiation with X-rays phase-advances the molecular clockwork in liver, adrenal gland and pancreas.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1-10</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">The circadian clock of man and mammals shows a hierarchic organization. The master clock, located in the suprachiasmatic nuclei (SCN), controls peripheral oscillators distributed throughout the body. Rhythm generation depends on molecular clockworks based on transcriptional/translational interaction of clock genes. Numerous studies have shown that the clockwork in peripheral oscillators is capable to maintain circadian rhythms for several cycles in vitro, i.e. in the absence of signals from the SCN. The aim of the present study is to analyze the effects of irradiation with X-rays on the clockwork of liver, adrenal and pancreas. To this end organotypic slice cultures of liver (OLSC) and organotypic explant cultures of adrenal glands (OAEC) and pancreas (OPEC) were prepared from transgenic mPer2(luc) mice which express luciferase under the control of the promoter of an important clock gene, Per2, and allow to study the dynamics of the molecular clockwork by bioluminometry. The preparations were cultured in a membrane-based liquid-air interface culturing system and irradiated with X-rays at doses of 10???Gy and 50???Gy or left untreated. Bioluminometric real-time recordings show a stable oscillation of all OLSC, OAEC and OPEC for up to 12 days in vitro. Oscillations persist after irradiation with X-rays. However, a dose of 50???Gy caused a phase advance in the rhythm of the OLSC by 5???h, in the OPEC by 7???h and in the OAEC by 6???h. Our study shows that X-rays affect the molecular clockwork in liver, pancreas and adrenal leading to phase advances. Our results confirm and extend previous studies showing a phase-advancing effect of X-rays at the level of the whole animal and single cells.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>M??ller</LastName>
                    <ForeName>Mareike Hildegard</ForeName>
                    <Initials>MH</Initials>
                    <Affiliation>Dr. Senckenbergisches Chronomedizinisches Institut , Frankfurt am Main , Germany .</Affiliation>
                </Author>
                <Author>
                    <LastName>R??del</LastName>
                    <ForeName>Franz</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author>
                    <LastName>R??b</LastName>
                    <ForeName>Udo</ForeName>
                    <Initials>U</Initials>
                </Author>
                <Author>
                    <LastName>Korf</LastName>
                    <ForeName>Horst-Werner</ForeName>
                    <Initials>HW</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Chronobiol Int</MedlineTA>
            <NlmUniqueID>8501362</NlmUniqueID>
            <ISSNLinking>0742-0528</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Circadian rhythm</Keyword>
            <Keyword MajorTopicYN="N">X-rays</Keyword>
            <Keyword MajorTopicYN="N">clock gene bioluminescence</Keyword>
            <Keyword MajorTopicYN="N">phase-shift</Keyword>
            <Keyword MajorTopicYN="N">tissue culture</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.3109/07420528.2014.949735</ArticleId>
            <ArticleId IdType="pubmed">25140390</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25140386</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1535-4989</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>American journal of respiratory cell and molecular biology</Title>
                <ISOAbbreviation>Am. J. Respir. Cell Mol. Biol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Targeting of Plasminogen Activator Inhibitor 1 Improves Fibrinolytic Therapy for Tetracycline Induced Pleural Injury in Rabbits.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">Introduction: Endogenous active plasminogen activator inhibitor 1 (PAI-1) was targeted in vivo with monoclonal antibodies (mAbs) that redirect its reaction with proteinases to the substrate branch. mAbs were used as an adjunct to prourokinase (scuPA) intrapleural fibrinolytic therapy (IPFT) of tetracycline-induced pleural injury in rabbits. Methods: Outcomes of scuPA IPFT (0.25 or 0.0625 mg/kg) with 0.5 mg/kg of mouse IgG or mAbs (MA-33H1F7 and MA-8H9D4) were assessed at 24h. Pleural fluid (PF) was collected at 0, 10, 20, 40 min and 24h after IPFT and analyzed for plasminogen activating (PA), urokinase (uPA), fibrinolytic activities, levels of total plasmin/plasminogen, ??-macroglobulin (??M), mAbs/IgG antigens, free active uPA and ??M/uPA complexes. Results:Anti-PAI-1 mAbs, but not mouse IgG, delivered with an 8-fold reduction in the minimal effective dose of scuPA (from 0.5 to 0.0625 mg/kg), improved the outcome of IPFT (p&lt;0.05). mAbs and IgG were detectable in PFs at 24h. Compared to identical doses of scuPA alone or with IgG, treatment with scuPA and anti-PAI-1 mAbs generated higher PF uPA amidolytic and PA activities, faster formation of ??M/uPA complexes, and slower uPA inactivation. However, PAI-1 targeting did not significantly affect intrapleural fibrinolytic activity or levels of total plasmin/plasminogen and ??M antigens. Conclusions: Targeting PAI-1 did not induce bleeding and rendered otherwise ineffective doses of scuPA able to improve outcome in tetracycline-induced pleural injury. PAI-1 neutralizing mAbs improved IPFT by increasing the durability of intrapleural PA activity. These results suggest a novel, well-tolerated IPFT strategy that is tractable for clinical development.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Florova</LastName>
                    <ForeName>Galina</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>UTHealth Northeast, Tyler, Texas, United States ; galina.florova@uthct.edu.</Affiliation>
                </Author>
                <Author>
                    <LastName>Azghani</LastName>
                    <ForeName>Ali</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author>
                    <LastName>Karandashova</LastName>
                    <ForeName>Sophia</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author>
                    <LastName>Schaefer</LastName>
                    <ForeName>Chris</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author>
                    <LastName>Koenig</LastName>
                    <ForeName>Kathleen</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author>
                    <LastName>Stewart-Evans</LastName>
                    <ForeName>Kris</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author>
                    <LastName>Declerck</LastName>
                    <ForeName>Paul J</ForeName>
                    <Initials>PJ</Initials>
                </Author>
                <Author>
                    <LastName>Idell</LastName>
                    <ForeName>Steven</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author>
                    <LastName>Komissarov</LastName>
                    <ForeName>Andrey A</ForeName>
                    <Initials>AA</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Am J Respir Cell Mol Biol</MedlineTA>
            <NlmUniqueID>8917225</NlmUniqueID>
            <ISSNLinking>1044-1549</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Plasminogen activator inhibitor 1</Keyword>
            <Keyword MajorTopicYN="N">animal model</Keyword>
            <Keyword MajorTopicYN="N">fibrinolytic therapy</Keyword>
            <Keyword MajorTopicYN="N">mAbs</Keyword>
            <Keyword MajorTopicYN="N">prourokinase</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1165/rcmb.2014-0168OC</ArticleId>
            <ArticleId IdType="pubmed">25140386</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">25140385</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>8</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1520-6882</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2014</Year>
                        <Month>Aug</Month>
                        <Day>20</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Analytical chemistry</Title>
                <ISOAbbreviation>Anal. Chem.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>13C NMR Metabolomics: Applications at Natural Abundance.</ArticleTitle>
            <Pagination>
                <MedlinePgn/>
            </Pagination>
            <Abstract>
                <AbstractText NlmCategory="UNLABELLED">13C NMR has many advantages for a metabolomics study, including a large spectral dispersion, narrow singlets at natural abundance, and a direct measure of the backbone structures of metabolites. However, it has not had widespread use because of its relatively low sensitivity compounded by low natural abundance. Here we demonstrate the utility of high-quality 13C NMR spectra obtained using a custom 13C-optimized probe on metabolomic mixtures. A workflow was developed to use statistical correlations between replicate 1D 13C and 1H spectra, leading to composite spin systems that can be used to search publically available databases for compound identification. This was developed using synthetic mixtures and then applied to two biological samples, Drosophila melanogaster extracts and mouse serum. Using the synthetic mixtures we were able to obtain useful 13C-13C statistical correlations from metabolites with as little as 60 nmoles of material. The lower limit of 13C NMR detection under our experimental conditions is approximately 40 nmoles, slightly lower than the requirement for statistical analysis. The 13C and 1H data together led to 15 matches in the database compared to just 7 using 1H alone, and the 13C correlated peak lists had far fewer false positives than the 1H generated lists. In addi-tion, the 13C 1D data provided improved metabolite identification and separation of biologically distinct groups using multivariate statistical analysis in the D. melanogaster extracts and mouse serum.</AbstractText>
            </Abstract>
            <AuthorList>
                <Author>
                    <LastName>Clendinen</LastName>
                    <ForeName>Chaevien S</ForeName>
                    <Initials>CS</Initials>
                </Author>
                <Author>
                    <LastName>Lee-McMullen</LastName>
                    <ForeName>Brittany</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author>
                    <LastName>Williams</LastName>
                    <ForeName>Caroline</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author>
                    <LastName>Stupp</LastName>
                    <ForeName>Gregory S</ForeName>
                    <Initials>GS</Initials>
                </Author>
                <Author>
                    <LastName>Vandenborne</LastName>
                    <ForeName>Krista</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author>
                    <LastName>Hahn</LastName>
                    <ForeName>Daniel A</ForeName>
                    <Initials>DA</Initials>
                </Author>
                <Author>
                    <LastName>Walter</LastName>
                    <ForeName>Glenn A</ForeName>
                    <Initials>GA</Initials>
                </Author>
                <Author>
                    <LastName>Edison</LastName>
                    <ForeName>Arthur S</ForeName>
                    <Initials>AS</Initials>
                </Author>
            </AuthorList>
            <Language>ENG</Language>
            <PublicationTypeList>
                <PublicationType>JOURNAL ARTICLE</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <MedlineTA>Anal Chem</MedlineTA>
            <NlmUniqueID>0370536</NlmUniqueID>
            <ISSNLinking>0003-2700</ISSNLinking>
        </MedlineJournalInfo>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1021/ac502346h</ArticleId>
            <ArticleId IdType="pubmed">25140385</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25140303</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">2314-6141</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>2014</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>BioMed research international</Title>
                <ISOAbbreviation>Biomed Res Int</ISOAbbreviation>
            </Journal>
            <ArticleTitle>??-Tocotrienol Oxazine Derivative Antagonizes Mammary Tumor Cell Compensatory Response to CoCl 2 -Induced Hypoxia.</ArticleTitle>
            <Pagination>
                <MedlinePgn>285752</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1155/2014/285752</ELocationID>
            <Abstract>
                <AbstractText>In response to low oxygen supply, cancer cells elevate production of HIF-1??, a hypoxia-inducible transcription factor that subsequently acts to stimulate blood vessel formation and promote survival. Studies were conducted to determine the role of ??-tocotrienol and a semisynthetic ??-tocotrienol oxazine derivative, compound 44, on +SA mammary tumor cell hypoxic response. Treatment with 150?????M CoCl2 induced a hypoxic response in +SA mammary tumor cells as evidenced by a large increase in HIF-1?? levels, and combined treatment with compound 44 attenuated this response. CoCl2-induced hypoxia was also associated with a large increase in Akt/mTOR signaling, activation of downstream targets p70S6K and eIF-4E1, and a significant increase in VEGF production, and combined treatment with compound 44 blocked this response. Additional in vivo studies showed that intralesional treatment with compound 44 in BALB/c mice bearing +SA mammary tumors significantly decreased the levels of HIF-1??, and this effect was associated with a corresponding decrease in Akt/mTOR signaling and activation of downstream targets p70S6kinase and eIF-4E1. These findings demonstrate that treatment with the ??-tocotrienol oxazine derivative, compound 44, significantly attenuates +SA mammary tumor cell compensatory responses to hypoxia and suggests that this compound may provide benefit in the treatment of rapidly growing solid breast tumors.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ananthula</LastName>
                    <ForeName>Suryatheja</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>School of Pharmacy, University of Louisiana at Monroe, 700 University Avenue, Monroe, LA 71209-0470, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Parajuli</LastName>
                    <ForeName>Parash</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>School of Pharmacy, University of Louisiana at Monroe, 700 University Avenue, Monroe, LA 71209-0470, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Behery</LastName>
                    <ForeName>Fathy A</ForeName>
                    <Initials>FA</Initials>
                    <Affiliation>School of Pharmacy, University of Louisiana at Monroe, 700 University Avenue, Monroe, LA 71209-0470, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Alayoubi</LastName>
                    <ForeName>Alaadin Y</ForeName>
                    <Initials>AY</Initials>
                    <Affiliation>School of Pharmacy, University of Louisiana at Monroe, 700 University Avenue, Monroe, LA 71209-0470, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nazzal</LastName>
                    <ForeName>Sami</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>School of Pharmacy, University of Louisiana at Monroe, 700 University Avenue, Monroe, LA 71209-0470, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>El Sayed</LastName>
                    <ForeName>Khalid</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>School of Pharmacy, University of Louisiana at Monroe, 700 University Avenue, Monroe, LA 71209-0470, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sylvester</LastName>
                    <ForeName>Paul W</ForeName>
                    <Initials>PW</Initials>
                    <Affiliation>School of Pharmacy, University of Louisiana at Monroe, 700 University Avenue, Monroe, LA 71209-0470, USA.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>07</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Biomed Res Int</MedlineTA>
            <NlmUniqueID>101600173</NlmUniqueID>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 1999 Nov 12;274(46):32631-7</RefSource>
                <PMID Version="1">10551817</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Anticancer Res. 2014 Jun;34(6):2715-26</RefSource>
                <PMID Version="1">24922632</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Annu Rev Cell Dev Biol. 1999;15:551-78</RefSource>
                <PMID Version="1">10611972</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Haematol. 2000 Jun;109(3):477-89</RefSource>
                <PMID Version="1">10886192</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Soc Exp Biol Med. 2000 Sep;224(4):292-301</RefSource>
                <PMID Version="1">10964265</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Metastasis Rev. 2000;19(1-2):59-65</RefSource>
                <PMID Version="1">11191064</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Natl Cancer Inst. 2001 Feb 21;93(4):266-76</RefSource>
                <PMID Version="1">11181773</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Med Sci Monit. 2000 Sep-Oct;6(5):1047-52</RefSource>
                <PMID Version="1">11208453</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 2001 Apr 20;292(5516):464-8</RefSource>
                <PMID Version="1">11292862</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Cell Biol. 2001 Jun;21(12):3995-4004</RefSource>
                <PMID Version="1">11359907</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Curr Opin Genet Dev. 2001 Jun;11(3):293-9</RefSource>
                <PMID Version="1">11377966</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell Growth Differ. 2001 Jul;12(7):363-9</RefSource>
                <PMID Version="1">11457733</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell. 2001 Oct 5;107(1):1-3</RefSource>
                <PMID Version="1">11595178</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 2001 Nov 9;294(5545):1337-40</RefSource>
                <PMID Version="1">11598268</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Drug Dev Ind Pharm. 2001 Nov;27(10):1115-21</RefSource>
                <PMID Version="1">11794814</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Trends Mol Med. 2002;8(4 Suppl):S62-7</RefSource>
                <PMID Version="1">11927290</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Cell Biol. 2002 Oct;22(20):7004-14</RefSource>
                <PMID Version="1">12242281</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nutr Cancer. 2003;45(2):236-46</RefSource>
                <PMID Version="1">12881019</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Leukemia. 2003 Nov;17(11):2065-73</RefSource>
                <PMID Version="1">14523474</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genes Dev. 2004 Feb 15;18(4):423-34</RefSource>
                <PMID Version="1">15004009</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 1970 Aug 15;227(5259):680-5</RefSource>
                <PMID Version="1">5432063</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Exp Med. 1971 Feb 1;133(2):275-88</RefSource>
                <PMID Version="1">4332371</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350-4</RefSource>
                <PMID Version="1">388439</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>In Vitro. 1979 Nov;15(11):841-3</RefSource>
                <PMID Version="1">232056</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 1980 Jun;40(6):1812-9</RefSource>
                <PMID Version="1">7371012</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 1992 Oct 29;359(6398):843-5</RefSource>
                <PMID Version="1">1279431</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5510-4</RefSource>
                <PMID Version="1">7539918</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Metastasis Rev. 1996 Jun;15(2):241-5</RefSource>
                <PMID Version="1">8842497</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>FASEB J. 1999 Jan;13(1):9-22</RefSource>
                <PMID Version="1">9872925</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neurosci Lett. 2004 Nov 23;371(2-3):85-90</RefSource>
                <PMID Version="1">15519734</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2005 Feb 3;433(7025):477-80</RefSource>
                <PMID Version="1">15690031</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Surg Oncol. 2006 Aug 1;94(2):149-54</RefSource>
                <PMID Version="1">16847924</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Biol Ther. 2006 Jul;5(7):749-55</RefSource>
                <PMID Version="1">16861930</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Pharmacol. 2006 Nov;70(5):1469-80</RefSource>
                <PMID Version="1">16887934</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2007 Jul 13;282(28):20534-43</RefSource>
                <PMID Version="1">17502379</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4628-31</RefSource>
                <PMID Version="1">17671154</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pathol Int. 2009 Jan;59(1):19-27</RefSource>
                <PMID Version="1">19121088</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Cell Sci. 2009 Oct 15;122(Pt 20):3589-94</RefSource>
                <PMID Version="1">19812304</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Anticancer Res. 2010 Feb;30(2):429-37</RefSource>
                <PMID Version="1">20332450</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nutr Cancer. 2010;62(6):789-94</RefSource>
                <PMID Version="1">20661828</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Free Radic Biol Med. 2011 Sep 15;51(6):1164-74</RefSource>
                <PMID Version="1">21723941</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Rev Cancer. 2012 May;12(5):323-34</RefSource>
                <PMID Version="1">22513401</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Drug Dev Ind Pharm. 2013 Feb;39(2):363-73</RefSource>
                <PMID Version="1">22554350</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Med Chem. 2013 Jan;59:329-41</RefSource>
                <PMID Version="1">23274571</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Colloids Surf B Biointerfaces. 2013 Mar 1;103:23-30</RefSource>
                <PMID Version="1">23201715</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem J. 1999 Dec 1;344 Pt 2:427-31</RefSource>
                <PMID Version="1">10567225</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <OtherID Source="NLM">PMC4129965</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>3</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>8</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2014/285752</ArticleId>
            <ArticleId IdType="pubmed">25140303</ArticleId>
            <ArticleId IdType="pmc">PMC4129965</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25140287</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">2193-1801</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>3</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>SpringerPlus</Title>
                <ISOAbbreviation>Springerplus</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Development of a novel cellular model of Alzheimer's disease utilizing neurosphere cultures derived from B6C3-Tg(APPswe,PSEN1dE9)85Dbo/J embryonic mouse brain.</ArticleTitle>
            <Pagination>
                <MedlinePgn>161</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1186/2193-1801-3-161</ELocationID>
            <Abstract>
                <AbstractText>Increased production, oligomerization and aggregation of amyloid-?? (A??) peptides are hallmark pathologies of Alzheimer's disease (AD). Expressing familial AD mutations (amyloid precursor protein and/or presenilins mutations), the A??-pathologies of AD has been recapitulated in animal models of AD. Very few primary cell culture-based models of AD are available and they exhibit very weak A??-pathologies compared to what is seen in AD patients and animal models of AD. CNS stem/progenitor cells are present in both embryonic and adult brains. They can be isolated, grown as neurospheres and differentiated into neurons, astrocytes and oligodendrocytes. It is not yet known whether CNS stem/progenitor cells can support the production of A?? peptides in culture. In this report, we have established A??-pathologies such as production, secretion, oligomerization and aggregation of A?? peptides utilizing neurosphere cultures to create a new cellular model of AD. These cultures were developed from E15 embryonic brains of transgenic mice carrying the Swedish mutations in humanized mouse APP cDNA and the exon-9 deleted human presenilin 1 cDNA both regulated by mouse prion protein gene (Prnp) promoter. Results demonstrated the expression of transgene transcripts, APPswe protein and its processed products only in transgene positive neurosphere cultures. These cultures generate and secrete both A??40 and A??42 peptides into culture medium at levels comparable to the A?? load in the brain of AD patients and animal models of AD, and produce pathogenic oligomers of A?? peptides. The A??42/A??40 ratio in the medium of transgene positive neurosphere cultures is higher than any known cellular models of AD. Conformation dependent immunocytochemistry demonstrated the possible presence of intracellular and extracellular aggregation of A?? peptides in neurosphere cultures, which are also seen in AD brain and animal models of AD. Collectively, our neurosphere cultures provide robust A??-pathologies of AD better than existing cellular model of Alzheimer's disease.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ghate</LastName>
                    <ForeName>Pankaj S</ForeName>
                    <Initials>PS</Initials>
                    <Affiliation>National Brain Research Centre, Manesar, Haryana India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sidhar</LastName>
                    <ForeName>Himakshi</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>National Brain Research Centre, Manesar, Haryana India.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Carlson</LastName>
                    <ForeName>George A</ForeName>
                    <Initials>GA</Initials>
                    <Affiliation>McLaughlin Research Institute, Great Falls, MT USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Giri</LastName>
                    <ForeName>Ranjit K</ForeName>
                    <Initials>RK</Initials>
                    <Affiliation>National Brain Research Centre, Manesar, Haryana India ; Molecular and Cellular Neuroscience Division, National Brain Research Centre, Manesar, Haryana 122051 India.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>03</Month>
                <Day>26</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Springerplus</MedlineTA>
            <NlmUniqueID>101597967</NlmUniqueID>
        </MedlineJournalInfo>
        <OtherID Source="NLM">PMC4137416</OtherID>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">APPswe</Keyword>
            <Keyword MajorTopicYN="N">Alzheimer???s disease</Keyword>
            <Keyword MajorTopicYN="N">Amyloid-??</Keyword>
            <Keyword MajorTopicYN="N">Cellular model</Keyword>
            <Keyword MajorTopicYN="N">Neurosphere</Keyword>
            <Keyword MajorTopicYN="N">PSEN1dE9</Keyword>
            <Keyword MajorTopicYN="N">Transgenic</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>12</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1186/2193-1801-3-161</ArticleId>
            <ArticleId IdType="pii">1127</ArticleId>
            <ArticleId IdType="pubmed">25140287</ArticleId>
            <ArticleId IdType="pmc">PMC4137416</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25140216</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">2008-4633</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>6</Volume>
                    <Issue>1-2</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Season>Winter</Season>
                    </PubDate>
                </JournalIssue>
                <Title>Addiction &amp; health</Title>
                <ISOAbbreviation>Addict Health</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Selection of Variables that Influence Drug Injection in Prison: Comparison of Methods with Multiple Imputed Data Sets.</ArticleTitle>
            <Pagination>
                <MedlinePgn>36-44</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Prisoners, compared to the general population, are at greater risk of infection. Drug injection is the main route of human immunodeficiency virus ??(HIV) transmission, in particular in Iran. What would be of interest is to determine variables that govern drug injection among prisoners. However, one of the issues that challenge model building is incomplete national data sets. In this paper, we addressed the process of model development when missing data exist.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Complete data on 2720 prisoners was available. A logistic regression model was fitted and served as gold standard. We then randomly omitted 20%, and 50% of data. Missing date were imputed 10 times, applying multiple imputation by chained equations (MICE). Rubin's rule (RR) was applied to select candidate variables and to combine the results across imputed data sets. In S1, S2, and S3 methods, variables retained significant in one, five, and ten imputed data sets and were candidate for the multifactorial model. Two weighting approaches were also applied.</AbstractText>
                <AbstractText Label="FINDINGS" NlmCategory="RESULTS">Age of onset of drug use, recent use of drug before imprisonment, being single, and length of imprisonment were significantly associated with drug injection among prisoners. All variable selection schemes were able to detect significance of these variables.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">We have seen that the performances of easier variable selection methods were comparable with RR. This indicates that the screening step can be used to select candidate variables for the multifactorial model.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Haji-Maghsoudi</LastName>
                    <ForeName>Saiedeh</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>PhD Student, Regional Knowledge Hub and WHO Collaborating Centre for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Haghdoost</LastName>
                    <ForeName>Ali Akbar</ForeName>
                    <Initials>AA</Initials>
                    <Affiliation>Professor, Regional Knowledge Hub and WHO Collaborating Centre for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Baneshi</LastName>
                    <ForeName>Mohammad Reza</ForeName>
                    <Initials>MR</Initials>
                    <Affiliation>Associate Professor, Research Center for Modeling in Health, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Iran</Country>
            <MedlineTA>Addict Health</MedlineTA>
            <NlmUniqueID>101582275</NlmUniqueID>
            <ISSNLinking>2008-4633</ISSNLinking>
        </MedlineJournalInfo>
        <OtherID Source="NLM">PMC4137438</OtherID>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Drug injection</Keyword>
            <Keyword MajorTopicYN="N">Missing data</Keyword>
            <Keyword MajorTopicYN="N">Multiple imputation</Keyword>
            <Keyword MajorTopicYN="N">Prison</Keyword>
            <Keyword MajorTopicYN="N">Variable selection</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>7</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2013</Year>
                <Month>10</Month>
                <Day>09</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">25140216</ArticleId>
            <ArticleId IdType="pmc">PMC4137438</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25140191</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1743-7075</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>11</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Nutrition &amp; metabolism</Title>
                <ISOAbbreviation>Nutr Metab (Lond)</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effects and mechanisms of resveratrol on the amelioration of oxidative stress and hepatic steatosis in KKAy mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>35</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1186/1743-7075-11-35</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The exact mechanism of the protective role of Resveratrol (Res) in lipid metabolism and oxidative stress is not well elucidated. The present study aimed to investigate the potential benefits and possible mechanisms of Res on the amelioration of oxidative stress and hepatic steatosis in a KKAy mouse model.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">A total of 30 KKAy male mice were randomly divided into three groups: a normal chow group, a low resveratrol group and a high resveratrol group. After a 12-wk study period, serum levels of TG, TC, LDL-C and HDL-C, the liver content of TG and TC, ROS, GSH, GPx, SOD and MDA levels were measured. Ectopic lipid deposition was observed in sectioned frozen liver tissues. The mRNA levels of ATGL and HSL in the liver tissues were determined via real-time PCR. Furthermore, the protein expression of p47phox, gp91phox, ATGL, HSL, Sirt1, AMPK and FOXO1 were analyzed using western blotting.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Following Res supplementation, serum levels of TG and MDA were decreased, while the HDL-C and SOD levels were increased in KKAy mice. Furthermore, Res treatment increased GSH and GPx in liver tissues, while it decreased ROS. In addition, Res significantly reduced hepatic steatosis. After Res treatment, concentrations of p47phox (membrane) and gp91phox proteins were reduced, while p-HSL, HSL and ATGL protein expression levels were increased. Mechanistically, the levels of Sirt1, p-AMPK and p-FOXO1 expression in the liver tissues were up-regulated following supplementation with Res, and FOXO1 protein was released from the nucleus into the cytoplasm.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Res is able to attenuate hepatic steatosis and lipid metabolic disorder and enhance the antioxidant ability in KKAy mice, possibly by up-regulating Sirt1 expression and the phosphorylation of AMPK.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zhu</LastName>
                    <ForeName>Wei</ForeName>
                    <Initials>W</Initials>
                    <Affiliation>Guangzhou Center for Disease Control and Prevention, Guangzhou, Guangdong, People's Republic of China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Sifan</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>School of Public Health, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China ; Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Guangzhou, Guangdong, People's Republic of China ; Guangzhou Center for Disease Control and Prevention, Guangzhou, Guangdong, People's Republic of China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Zilun</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>Division of Vascular Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhao</LastName>
                    <ForeName>Xiaohong</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, People's Republic of China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Wenxue</ForeName>
                    <Initials>W</Initials>
                    <Affiliation>Guangzhou Center for Disease Control and Prevention, Guangzhou, Guangdong, People's Republic of China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sun</LastName>
                    <ForeName>Yanshuang</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>School of Public Health, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China ; Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Guangzhou, Guangdong, People's Republic of China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Zili</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>School of Public Health, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China ; Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Guangzhou, Guangdong, People's Republic of China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ling</LastName>
                    <ForeName>Wenhua</ForeName>
                    <Initials>W</Initials>
                    <Affiliation>School of Public Health, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China ; Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Guangzhou, Guangdong, People's Republic of China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Feng</LastName>
                    <ForeName>Xiang</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>School of Public Health, Sun Yat-Sen University, Guangzhou, Guangdong, People's Republic of China ; Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Guangzhou, Guangdong, People's Republic of China.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>12</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Nutr Metab (Lond)</MedlineTA>
            <NlmUniqueID>101231644</NlmUniqueID>
            <ISSNLinking>1743-7075</ISSNLinking>
        </MedlineJournalInfo>
        <OtherID Source="NLM">PMC4137107</OtherID>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">AMPK</Keyword>
            <Keyword MajorTopicYN="N">Lipid metabolic disorder</Keyword>
            <Keyword MajorTopicYN="N">NAFLD</Keyword>
            <Keyword MajorTopicYN="N">Oxidative stress</Keyword>
            <Keyword MajorTopicYN="N">Resveratrol</Keyword>
            <Keyword MajorTopicYN="N">Sirt1</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1743-7075-11-35</ArticleId>
            <ArticleId IdType="pii">1743-7075-11-35</ArticleId>
            <ArticleId IdType="pubmed">25140191</ArticleId>
            <ArticleId IdType="pmc">PMC4137107</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25140189</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">1741-427X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>2014</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Evidence-based complementary and alternative medicine : eCAM</Title>
                <ISOAbbreviation>Evid Based Complement Alternat Med</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Caffeamide 36-13 Regulates the Antidiabetic and Hypolipidemic Signs of High-Fat-Fed Mice on Glucose Transporter 4, AMPK Phosphorylation, and Regulated Hepatic Glucose Production.</ArticleTitle>
            <Pagination>
                <MedlinePgn>821569</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1155/2014/821569</ELocationID>
            <Abstract>
                <AbstractText>This study was to investigate the antidiabetic and antihyperlipidemic effects of (E)-3-[3, 4-dihydroxyphenyl-1-(piperidin-1-yl)prop-2-en-1-one] (36-13) (TS), one of caffeic acid amide derivatives, on high-fat (HF-) fed mice. The C57BL/6J mice were randomly divided into the control (CON) group and the experimental group, which was firstly fed a HF diet for 8 weeks. Then, the HF group was subdivided into four groups and was given TS orally (including two doses) or rosiglitazone (Rosi) or vehicle for 4 weeks. Blood, skeletal muscle, and tissues were examined by measuring glycaemia and dyslipidemia-associated events. TS effectively prevented HF diet-induced increases in the levels of blood glucose, triglyceride, insulin, leptin, and free fatty acid (FFA) and weights of visceral fa; moreover, adipocytes in the visceral depots showed a reduction in size. TS treatment significantly increased the protein contents of glucose transporter 4 (GLUT4) in skeletal muscle; TS also significantly enhanced Akt phosphorylation in liver, whereas it reduced the expressions of phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase). Moreover, TS enhanced phosphorylation of AMP-activated protein kinase (phospho-AMPK) both in skeletal muscle and liver tissue. Therefore, it is possible that the activation of AMPK by TS resulted in enhanced glucose uptake in skeletal muscle, contrasting with diminished gluconeogenesis in liver. TS exhibits hypolipidemic effect by decreasing the expressions of fatty acid synthase (FAS). Thus, antidiabetic properties of TS occurred as a result of decreased hepatic glucose production by PEPCK and G6Pase downregulation and improved insulin sensitization. Thus, amelioration of diabetic and dyslipidemic state by TS in HF-fed mice occurred by regulation of GLUT4, G6Pase, and FAS and phosphorylation of AMPK.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kuo</LastName>
                    <ForeName>Yueh-Hsiung</ForeName>
                    <Initials>YH</Initials>
                    <Affiliation>Department of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, China Medical University, Taichung City 40402, Taiwan ; Department of Biotechnology, Asia University, Taichung City 41354, Taiwan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lin</LastName>
                    <ForeName>Cheng-Hsiu</ForeName>
                    <Initials>CH</Initials>
                    <Affiliation>Department of Internal Medicine, Fengyuan Hospital, Ministry of Health and Welfare, Fengyuan District, Taichung City 42055, Taiwan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shih</LastName>
                    <ForeName>Chun-Ching</ForeName>
                    <Initials>CC</Initials>
                    <Affiliation>Graduate Institute of Pharmaceutical Science and Technology, College of Health Science, Central Taiwan University of Science and Technology, No. 666 Buzih Road, Beitun District, Taichung City 40601, Taiwan.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>07</Month>
                <Day>20</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Evid Based Complement Alternat Med</MedlineTA>
            <NlmUniqueID>101215021</NlmUniqueID>
            <ISSNLinking>1741-427X</ISSNLinking>
        </MedlineJournalInfo>
        <OtherID Source="NLM">PMC4130186</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>19</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>3</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2014/821569</ArticleId>
            <ArticleId IdType="pubmed">25140189</ArticleId>
            <ArticleId IdType="pmc">PMC4130186</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25140188</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">1741-427X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>2014</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Evidence-based complementary and alternative medicine : eCAM</Title>
                <ISOAbbreviation>Evid Based Complement Alternat Med</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Investigation of hepatic blood perfusion by laser speckle imaging and changes of hepatic vasoactive substances in mice after electroacupuncture.</ArticleTitle>
            <Pagination>
                <MedlinePgn>715316</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1155/2014/715316</ELocationID>
            <Abstract>
                <AbstractText>The study was conducted to observe the effect of electroacupuncture (EA) on hepatic blood perfusion (HBP) and vascular regulation. We investigated 60 male anesthetized mice under the following 3 conditions: without EA stimulation (control group); EA stimulation at Zusanli (ST36 group); EA stimulation at nonacupoint (NA group) during 30???min. The HBP was measured using the laser speckle perfusion imaging (LSPI). The level of nitric oxide (NO), endothelin-1 (ET-1), and noradrenaline (NE) in liver tissue was detected by biochemical methods. Results were as follows. At each time point, HBP increase in ST36 group was higher than that in the NA group in anesthetized mice. HBP gradually decreased during 30???min in control group. The level of NO in ST36 group was higher than that in NA group. The level of both ET-1 and NE was the highest in control group, followed by NA group and ST36 group. It is concluded that EA at ST36 could increase HBP possibly by increasing the blood flow velocity (BFV), changing vascular activity, increasing the level of NO, and inhibiting the level of ET-1 in liver tissue.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Song</LastName>
                    <ForeName>Xiao-Jing</ForeName>
                    <Initials>XJ</Initials>
                    <Affiliation>Department of Biomedical Engineering, Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, 16 Nanxiaojie, Dongzhimen, Beijing 100700, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Dong</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Department of Biomedical Engineering, Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, 16 Nanxiaojie, Dongzhimen, Beijing 100700, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wang</LastName>
                    <ForeName>Shu-You</ForeName>
                    <Initials>SY</Initials>
                    <Affiliation>Department of Biomedical Engineering, Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, 16 Nanxiaojie, Dongzhimen, Beijing 100700, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Shun-Yue</ForeName>
                    <Initials>SY</Initials>
                    <Affiliation>Department of Biomedical Engineering, Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, 16 Nanxiaojie, Dongzhimen, Beijing 100700, China.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>07</Month>
                <Day>21</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Evid Based Complement Alternat Med</MedlineTA>
            <NlmUniqueID>101215021</NlmUniqueID>
            <ISSNLinking>1741-427X</ISSNLinking>
        </MedlineJournalInfo>
        <OtherID Source="NLM">PMC4129169</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>20</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2014/715316</ArticleId>
            <ArticleId IdType="pubmed">25140188</ArticleId>
            <ArticleId IdType="pmc">PMC4129169</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25140186</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">1741-427X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>2014</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Evidence-based complementary and alternative medicine : eCAM</Title>
                <ISOAbbreviation>Evid Based Complement Alternat Med</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Moxibustion Activates Macrophage Autophagy and Protects Experimental Mice against Bacterial Infection.</ArticleTitle>
            <Pagination>
                <MedlinePgn>450623</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1155/2014/450623</ELocationID>
            <Abstract>
                <AbstractText>Moxibustion is one of main therapies in traditional Chinese medicine and uses heat stimulation on the body surface from the burning of moxa to release pain or treat diseases. Emerging studies have shown that moxibustion can generate therapeutic effects by activating a series of signaling pathways and neuroendocrine-immune activities. Here we show moxibustion promoted profound macrophage autophagy in experimental Kunming mice, with reduced Akt phosphorylation and activated eIF2?? phosphorylation. Consequently, moxibustion promoted bacterial clearance by macrophages and protected mice from mortality due to bacterial infection. These results indicate that moxibustion generates a protective response by activating autophagy against bacterial infections.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Xiaojuan</ForeName>
                    <Initials>X</Initials>
                    <Affiliation>Acupuncture and Moxibustion College, Hubei University of Chinese Medicine, Wuhan, Hubei 430061, China ; Hubei Provincial Collaborative Innovation Center of Preventive Treatment by Acupuncture and Moxibustion, Wuhan, Hubei 430061, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Guo</LastName>
                    <ForeName>Guanhua</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Acupuncture and Moxibustion College, Hubei University of Chinese Medicine, Wuhan, Hubei 430061, China ; Shanxi University of Traditional Chinese Medicine, Taiyuan, Shanxi 030024, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shen</LastName>
                    <ForeName>Feng</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Acupuncture and Moxibustion College, Hubei University of Chinese Medicine, Wuhan, Hubei 430061, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kong</LastName>
                    <ForeName>Lihong</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Acupuncture and Moxibustion College, Hubei University of Chinese Medicine, Wuhan, Hubei 430061, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liang</LastName>
                    <ForeName>Fengxia</ForeName>
                    <Initials>F</Initials>
                    <Affiliation>Acupuncture and Moxibustion College, Hubei University of Chinese Medicine, Wuhan, Hubei 430061, China ; Hubei Provincial Collaborative Innovation Center of Preventive Treatment by Acupuncture and Moxibustion, Wuhan, Hubei 430061, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sun</LastName>
                    <ForeName>Guojie</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Acupuncture and Moxibustion College, Hubei University of Chinese Medicine, Wuhan, Hubei 430061, China ; Hubei Provincial Collaborative Innovation Center of Preventive Treatment by Acupuncture and Moxibustion, Wuhan, Hubei 430061, China.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>07</Month>
                <Day>23</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Evid Based Complement Alternat Med</MedlineTA>
            <NlmUniqueID>101215021</NlmUniqueID>
            <ISSNLinking>1741-427X</ISSNLinking>
        </MedlineJournalInfo>
        <OtherID Source="NLM">PMC4129972</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>11</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>8</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>23</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2014/450623</ArticleId>
            <ArticleId IdType="pubmed">25140186</ArticleId>
            <ArticleId IdType="pmc">PMC4129972</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25140184</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">1741-427X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>2014</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Evidence-based complementary and alternative medicine : eCAM</Title>
                <ISOAbbreviation>Evid Based Complement Alternat Med</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Neuroprotective effects of cuscutae semen in a mouse model of Parkinson's disease.</ArticleTitle>
            <Pagination>
                <MedlinePgn>150153</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1155/2014/150153</ELocationID>
            <Abstract>
                <AbstractText>Parkinson's disease (PD) is a neurodegenerative movement disorder that is characterized by the progressive degeneration of the dopaminergic (DA) pathway. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) causes damage to the DA neurons, and 1-4-methyl-4-phenylpyridinium (MPP(+)) causes cell death in differentiated PC12 cells that is similar to the degeneration that occurs in PD. Moreover, MPTP treatment increases the activity of the brain's immune cells, reactive oxygen species- (ROS-) generating processes, and glutathione peroxidase. We recently reported that Cuscutae Semen (CS), a widely used traditional herbal medicine, increases cell viability in a yeast model of PD. In the present study, we examined the inhibitory effect of CS on the neurotoxicity of MPTP in mice and on the MPP+-induced cell death in differentiated PC12 cells. The MPTP-induced loss of nigral DA neurons was partly inhibited by CS-mediated decreases in ROS generation. The activation of microglia was slightly inhibited by CS, although this effect did not reach statistical significance. Furthermore, CS may reduce the MPP+ toxicity in PC12 cells by suppressing glutathione peroxidase activation. These results suggest that CS may be beneficial for the treatment of neurodegenerative diseases such as PD.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ye</LastName>
                    <ForeName>Minsook</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Department of Physiology, College of Korean Medicine, Kyung Hee University, No. 1, Hoegi-dong, Dongdaemungu, Seoul 130-701, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lee</LastName>
                    <ForeName>Seul Gi</ForeName>
                    <Initials>SG</Initials>
                    <Affiliation>Department of Physiology, College of Korean Medicine, Kyung Hee University, No. 1, Hoegi-dong, Dongdaemungu, Seoul 130-701, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chung</LastName>
                    <ForeName>Eun Sook</ForeName>
                    <Initials>ES</Initials>
                    <Affiliation>Department of Physiology, College of Korean Medicine, Kyung Hee University, No. 1, Hoegi-dong, Dongdaemungu, Seoul 130-701, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lim</LastName>
                    <ForeName>Su-Jin</ForeName>
                    <Initials>SJ</Initials>
                    <Affiliation>Department of Physiology, College of Korean Medicine, Kyung Hee University, No. 1, Hoegi-dong, Dongdaemungu, Seoul 130-701, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Won Seob</ForeName>
                    <Initials>WS</Initials>
                    <Affiliation>Department of Physiology, College of Korean Medicine, Kyung Hee University, No. 1, Hoegi-dong, Dongdaemungu, Seoul 130-701, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yoon</LastName>
                    <ForeName>Heera</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Department of Physiology, College of Korean Medicine, Kyung Hee University, No. 1, Hoegi-dong, Dongdaemungu, Seoul 130-701, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Sun Kwang</ForeName>
                    <Initials>SK</Initials>
                    <Affiliation>Department of Physiology, College of Korean Medicine, Kyung Hee University, No. 1, Hoegi-dong, Dongdaemungu, Seoul 130-701, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ahn</LastName>
                    <ForeName>Kwang Sung</ForeName>
                    <Initials>KS</Initials>
                    <Affiliation>Department of Life and Nanopharmaceutical Sciences, College of Pharmacy, Kyung Hee University, No. 1, Hoegi-dong, Dongdaemungu, Seoul 130-701, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jang</LastName>
                    <ForeName>Young Pyo</ForeName>
                    <Initials>YP</Initials>
                    <Affiliation>Department of Life and Nanopharmaceutical Sciences, College of Pharmacy, Kyung Hee University, No. 1, Hoegi-dong, Dongdaemungu, Seoul 130-701, Republic of Korea.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bae</LastName>
                    <ForeName>Hyunsu</ForeName>
                    <Initials>H</Initials>
                    <Affiliation>Department of Physiology, College of Korean Medicine, Kyung Hee University, No. 1, Hoegi-dong, Dongdaemungu, Seoul 130-701, Republic of Korea.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>07</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Evid Based Complement Alternat Med</MedlineTA>
            <NlmUniqueID>101215021</NlmUniqueID>
            <ISSNLinking>1741-427X</ISSNLinking>
        </MedlineJournalInfo>
        <OtherID Source="NLM">PMC4129928</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>3</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2014/150153</ArticleId>
            <ArticleId IdType="pubmed">25140184</ArticleId>
            <ArticleId IdType="pmc">PMC4129928</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25140174</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1678-9199</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>20</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>The journal of venomous animals and toxins including tropical diseases</Title>
                <ISOAbbreviation>J Venom Anim Toxins Incl Trop Dis</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Thalassophryne nattereri fish venom: from the envenoming to the understanding of the immune system.</ArticleTitle>
            <Pagination>
                <MedlinePgn>35</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1186/1678-9199-20-35</ELocationID>
            <Abstract>
                <AbstractText>Thalassophryne nattereri (niquim) is a venomous fish found off North and Northeast coast of Brazil, where it is known by the severity of the accidents involving humans. This review article is divided into four topics. The first one provides a brief description of the animal biology and its distribution off Brazilian coastal waters, the venom apparatus, signs and symptoms observed in envenomated humans and also describes envenomation in mice. The second topic describes the use of modern genetic approach and mass spectrometry for identification of highly expressed genes in its venom glands and the sequence of major toxins. The third chapter offers a detailed study of tissue injury induced by the venom and reveals the role of toxins that impair inflammation reduction. Finally, the fourth section expands the understanding of many extrinsic and intrinsic essential factors in maintaining survival of memory B cell compartment. Our results demonstrate the wide possibilities for research in the area of toxinology, also the necessity of interconnection among biochemistry, pharmacology and immunology areas for the expansion of knowledge and for generation of innovation.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Lopes-Ferreira</LastName>
                    <ForeName>Monica</ForeName>
                    <Initials>M</Initials>
                    <Affiliation>Unidade de Imunorregula????o, Laborat??rio Especial de Toxinologia Aplicada (CEPID/FAPESP), Instituto Butantan, Av. Vital Brazil, 1500 S??o Paulo, SP, CEP 05503-900, Brasil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Grund</LastName>
                    <ForeName>Lidiane Zito</ForeName>
                    <Initials>LZ</Initials>
                    <Affiliation>Unidade de Imunorregula????o, Laborat??rio Especial de Toxinologia Aplicada (CEPID/FAPESP), Instituto Butantan, Av. Vital Brazil, 1500 S??o Paulo, SP, CEP 05503-900, Brasil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lima</LastName>
                    <ForeName>Carla</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Unidade de Imunorregula????o, Laborat??rio Especial de Toxinologia Aplicada (CEPID/FAPESP), Instituto Butantan, Av. Vital Brazil, 1500 S??o Paulo, SP, CEP 05503-900, Brasil.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Review</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>13</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Brazil</Country>
            <MedlineTA>J Venom Anim Toxins Incl Trop Dis</MedlineTA>
            <NlmUniqueID>101201501</NlmUniqueID>
            <ISSNLinking>1678-9180</ISSNLinking>
        </MedlineJournalInfo>
        <OtherID Source="NLM">PMC4137268</OtherID>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Immunological memory</Keyword>
            <Keyword MajorTopicYN="N">Nattectin</Keyword>
            <Keyword MajorTopicYN="N">Natterin</Keyword>
            <Keyword MajorTopicYN="N">Thalassophryne nattereri</Keyword>
            <Keyword MajorTopicYN="N">Venomous fish</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>13</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1678-9199-20-35</ArticleId>
            <ArticleId IdType="pii">1678-9199-20-35</ArticleId>
            <ArticleId IdType="pubmed">25140174</ArticleId>
            <ArticleId IdType="pmc">PMC4137268</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25140151</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1663-4365</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>6</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Frontiers in aging neuroscience</Title>
                <ISOAbbreviation>Front Aging Neurosci</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Age-Dependent Modifications of AMPA Receptor Subunit Expression Levels and Related Cognitive Effects in 3xTg-AD Mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>200</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3389/fnagi.2014.00200</ELocationID>
            <Abstract>
                <AbstractText>GluA1, GluA2, GluA3, and GluA4 are the constitutive subunits of amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs), the major mediators of fast excitatory transmission in the mammalian central nervous system. Most AMPARs are Ca(2+)-impermeable because of the presence of the GluA2 subunit. GluA2 mRNA undergoes an editing process that results in a Q-R substitution, a key factor in the regulation of AMPAR Ca(2+)-permeability. AMPARs lacking GluA2 or containing the unedited subunit are permeable to Ca(2+) and Zn(2+). The phenomenon physiologically modulates synaptic plasticity while, in pathologic conditions, leads to increased vulnerability to excitotoxic neuronal death. Given the importance of these subunits, we have therefore evaluated possible associations between changes in expression levels of AMPAR subunits and development of cognitive deficits in 3xTg-AD mice, a widely investigated transgenic mouse model of Alzheimer's disease (AD). With quantitative real-time PCR analysis, we assayed hippocampal mRNA expression levels of GluA1-4 subunits occurring in young [3???months of age (m.o.a.)] and old (12 m.o.a) Tg-AD mice and made comparisons with levels found in age-matched wild type (WT) mice. Efficiency of GluA2 RNA editing was also analyzed. All animals were cognitively tested for learning short- and long-term spatial memory with the Morris Water Maze (MWM) navigation task. 3xTg-AD mice showed age-dependent decreases of mRNA levels for all the AMPAR subunits, with the exception of GluA2. Editing remained fully efficient with aging in 3xTg-AD and WT mice. A one-to-one correlation analysis between MWM performances and GluA1-4 mRNA expression profiles showed negative correlations between GluA2 levels and MWM performances in young 3xTg-AD mice. On the contrary, positive correlations between GluA2 mRNA and MWM performances were found in young WT mice. Our data suggest that increases of AMPARs that contain GluA1, GluA3, and GluA4 subunits may help in maintaining cognition in pre-symptomatic 3xTg-AD mice.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Cantanelli</LastName>
                    <ForeName>Pamela</ForeName>
                    <Initials>P</Initials>
                    <Affiliation>Molecular Neurology Unit, Center of Excellence on Aging (CeSI), &quot;G. d'Annunzio&quot; University , Chieti , Italy.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sperduti</LastName>
                    <ForeName>Samantha</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Functional Genetics Unit, Center of Excellence on Aging (CeSI), &quot;G. d'Annunzio&quot; University , Chieti , Italy ; Department of Psychological Sciences, School of Medicine and Health Sciences, &quot;G. d'Annunzio&quot; University , Chieti , Italy.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ciavardelli</LastName>
                    <ForeName>Domenico</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Molecular Neurology Unit, Center of Excellence on Aging (CeSI), &quot;G. d'Annunzio&quot; University , Chieti , Italy ; School of Human and Social Science, Kore University of Enna , Enna , Italy.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stuppia</LastName>
                    <ForeName>Liborio</ForeName>
                    <Initials>L</Initials>
                    <Affiliation>Functional Genetics Unit, Center of Excellence on Aging (CeSI), &quot;G. d'Annunzio&quot; University , Chieti , Italy ; Department of Psychological Sciences, School of Medicine and Health Sciences, &quot;G. d'Annunzio&quot; University , Chieti , Italy.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gatta</LastName>
                    <ForeName>Valentina</ForeName>
                    <Initials>V</Initials>
                    <Affiliation>Functional Genetics Unit, Center of Excellence on Aging (CeSI), &quot;G. d'Annunzio&quot; University , Chieti , Italy ; Department of Psychological Sciences, School of Medicine and Health Sciences, &quot;G. d'Annunzio&quot; University , Chieti , Italy.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sensi</LastName>
                    <ForeName>Stefano Luca</ForeName>
                    <Initials>SL</Initials>
                    <Affiliation>Molecular Neurology Unit, Center of Excellence on Aging (CeSI), &quot;G. d'Annunzio&quot; University , Chieti , Italy ; Department of Neuroscience and Imaging, &quot;G. d'Annunzio&quot; University , Chieti , Italy ; Department of Neurology, Institute for Memory Impairments and Neurological Disorders, University of California Irvine , Irvine, CA , USA ; Department of Pharmacology, Institute for Memory Impairments and Neurological Disorders, University of California Irvine , Irvine, CA , USA.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>05</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Front Aging Neurosci</MedlineTA>
            <NlmUniqueID>101525824</NlmUniqueID>
            <ISSNLinking>1663-4365</ISSNLinking>
        </MedlineJournalInfo>
        <OtherID Source="NLM">PMC4122177</OtherID>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">3xTg-AD mice</Keyword>
            <Keyword MajorTopicYN="N">AMPA receptors</Keyword>
            <Keyword MajorTopicYN="N">GluA1???4</Keyword>
            <Keyword MajorTopicYN="N">RNA editing</Keyword>
            <Keyword MajorTopicYN="N">cognitive deficits</Keyword>
            <Keyword MajorTopicYN="N">gene expression</Keyword>
            <Keyword MajorTopicYN="N">hippocampus</Keyword>
            <Keyword MajorTopicYN="N">neurotransmission</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>07</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>05</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnagi.2014.00200</ArticleId>
            <ArticleId IdType="pubmed">25140151</ArticleId>
            <ArticleId IdType="pmc">PMC4122177</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
        <PMID Version="1">25140125</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>22</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Print">1662-4548</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>8</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Frontiers in neuroscience</Title>
                <ISOAbbreviation>Front Neurosci</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Sexual attractiveness of male chemicals and vocalizations in mice.</ArticleTitle>
            <Pagination>
                <MedlinePgn>231</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.3389/fnins.2014.00231</ELocationID>
            <Abstract>
                <AbstractText>Male-female interaction is important for finding a suitable mating partner and for ensuring reproductive success. Male sexual signals such as pheromones transmit information and social and sexual status to females, and exert powerful effects on the mate preference and reproductive biology of females. Likewise, male vocalizations are attractive to females and enhance reproductive function in many animals. Interestingly, females' preference for male pheromones and vocalizations is associated with their genetic background, to avoid inbreeding. Moreover, based on acoustic cues, olfactory signals have significant effects on mate choice in mice, suggesting mate choice involves multisensory integration. In this review, we synopsize the effects of both olfactory and auditory cues on female behavior and neuroendocrine functions. We also discuss how these male signals are integrated and processed in the brain to regulate behavior and reproductive function.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Asaba</LastName>
                    <ForeName>Akari</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Department of Animal Science and Biotechnology, Graduate School of Veterinary Medicine, Azabu University Kanagawa, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hattori</LastName>
                    <ForeName>Tatsuya</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Department of Animal Science and Biotechnology, Graduate School of Veterinary Medicine, Azabu University Kanagawa, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mogi</LastName>
                    <ForeName>Kazutaka</ForeName>
                    <Initials>K</Initials>
                    <Affiliation>Department of Animal Science and Biotechnology, Graduate School of Veterinary Medicine, Azabu University Kanagawa, Japan.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kikusui</LastName>
                    <ForeName>Takefumi</ForeName>
                    <Initials>T</Initials>
                    <Affiliation>Department of Animal Science and Biotechnology, Graduate School of Veterinary Medicine, Azabu University Kanagawa, Japan.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
                <PublicationType>Review</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>05</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Switzerland</Country>
            <MedlineTA>Front Neurosci</MedlineTA>
            <NlmUniqueID>101478481</NlmUniqueID>
            <ISSNLinking>1662-453X</ISSNLinking>
        </MedlineJournalInfo>
        <OtherID Source="NLM">PMC4122165</OtherID>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">mouse</Keyword>
            <Keyword MajorTopicYN="N">multisensory integration</Keyword>
            <Keyword MajorTopicYN="N">neural circuit</Keyword>
            <Keyword MajorTopicYN="N">pheromones</Keyword>
            <Keyword MajorTopicYN="N">reproduction</Keyword>
            <Keyword MajorTopicYN="N">ultrasonic vocalizations</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ecollection">
                <Year>2014</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>05</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnins.2014.00231</ArticleId>
            <ArticleId IdType="pubmed">25140125</ArticleId>
            <ArticleId IdType="pmc">PMC4122165</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25140115</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1466-1861</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>2014</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Mediators of inflammation</Title>
                <ISOAbbreviation>Mediators Inflamm.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Tumor necrosis factor is a therapeutic target for immunological unbalance and cardiac abnormalities in chronic experimental chagas' heart disease.</ArticleTitle>
            <Pagination>
                <MedlinePgn>798078</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1155/2014/798078</ELocationID>
            <Abstract>
                <AbstractText>Background. Chagas disease (CD) is characterized by parasite persistence and immunological unbalance favoring systemic inflammatory profile. Chronic chagasic cardiomyopathy, the main manifestation of CD, occurs in a TNF-enriched milieu and frequently progresses to heart failure. Aim of the Study. To challenge the hypothesis that TNF plays a key role in Trypanosoma cruzi-induced immune deregulation and cardiac abnormalities, we tested the effect of the anti-TNF antibody Infliximab in chronically T. cruzi-infected C57BL/6 mice, a model with immunological, electrical, and histopathological abnormalities resembling Chagas' heart disease. Results. Infliximab therapy did not reactivate parasite but reshaped the immune response as reduced TNF mRNA expression in the cardiac tissue and plasma TNF and IFN?? levels; diminished the frequency of IL-17A(+) but increased IL-10(+) CD4(+) T-cells; reduced TNF(+) but augmented IL-10(+) Ly6C(+) and F4/80(+) cells. Further, anti-TNF therapy decreased cytotoxic activity but preserved IFN??-producing VNHRFTLV-specific CD8(+) T-cells in spleen and reduced the number of perforin(+) cells infiltrating the myocardium. Importantly, Infliximab reduced the frequency of mice afflicted by arrhythmias and second degree atrioventricular blocks and decreased fibronectin deposition in the cardiac tissue. Conclusions. Our data support that TNF is a crucial player in the pathogenesis of Chagas' heart disease fueling immunological unbalance which contributes to cardiac abnormalities.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Pereira</LastName>
                    <ForeName>Isabela Resende</ForeName>
                    <Initials>IR</Initials>
                    <Affiliation>Laborat??rio de Biologia das Intera????es, Instituto Oswaldo Cruz/Fiocruz, Avenida Brasil 4365, 21045-900 Rio de Janeiro, RJ, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vilar-Pereira</LastName>
                    <ForeName>Glaucia</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Laborat??rio de Biologia das Intera????es, Instituto Oswaldo Cruz/Fiocruz, Avenida Brasil 4365, 21045-900 Rio de Janeiro, RJ, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Silva</LastName>
                    <ForeName>Andrea Alice</ForeName>
                    <Initials>AA</Initials>
                    <Affiliation>Departamento de Patologia, Universidade Federal Fluminense, 24033-900 Niter??i, RJ, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Moreira</LastName>
                    <ForeName>Otacilio Cruz</ForeName>
                    <Initials>OC</Initials>
                    <Affiliation>Laborat??rio de Biologia Molecular e Doen??as End??micas, IOC/Fiocruz, 21045-900 Rio de Janeiro, RJ, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Britto</LastName>
                    <ForeName>Constan??a</ForeName>
                    <Initials>C</Initials>
                    <Affiliation>Laborat??rio de Biologia Molecular e Doen??as End??micas, IOC/Fiocruz, 21045-900 Rio de Janeiro, RJ, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sarmento</LastName>
                    <ForeName>Ellen Diana Marinho</ForeName>
                    <Initials>ED</Initials>
                    <Affiliation>Laborat??rio de Biologia das Intera????es, Instituto Oswaldo Cruz/Fiocruz, Avenida Brasil 4365, 21045-900 Rio de Janeiro, RJ, Brazil.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lannes-Vieira</LastName>
                    <ForeName>Joseli</ForeName>
                    <Initials>J</Initials>
                    <Identifier Source="ORCID">0000-0001-5503-6754</Identifier>
                    <Affiliation>Laborat??rio de Biologia das Intera????es, Instituto Oswaldo Cruz/Fiocruz, Avenida Brasil 4365, 21045-900 Rio de Janeiro, RJ, Brazil.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>07</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Mediators Inflamm</MedlineTA>
            <NlmUniqueID>9209001</NlmUniqueID>
            <ISSNLinking>0962-9351</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Microbes Infect. 2009 Feb;11(2):264-73</RefSource>
                <PMID Version="1">19100857</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Circulation. 2009 Mar 17;119(10):1386-97</RefSource>
                <PMID Version="1">19255345</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Invest. 2009 May;119(5):1167-77</RefSource>
                <PMID Version="1">19381021</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Vet Immunol Immunopathol. 2009 Jul 15;130(1-2):43-52</RefSource>
                <PMID Version="1">19211152</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Exp Immunol. 2009 Aug;157(2):291-9</RefSource>
                <PMID Version="1">19604269</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS Negl Trop Dis. 2010;4(2):e604</RefSource>
                <PMID Version="1">20169058</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lancet. 2010 Apr 17;375(9723):1388-402</RefSource>
                <PMID Version="1">20399979</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Curr Opin Pharmacol. 2010 Jun;10(3):308-15</RefSource>
                <PMID Version="1">20172761</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Expert Rev Mol Med. 2010;12:e29</RefSource>
                <PMID Version="1">20840799</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Adv Exp Med Biol. 2011;691:221-30</RefSource>
                <PMID Version="1">21153326</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Heart. 2011 Mar;97(5):357-61</RefSource>
                <PMID Version="1">21245474</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Immunity. 2011 Feb 25;34(2):149-62</RefSource>
                <PMID Version="1">21349428</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Neuroimmunol. 2011 Jun;235(1-2):84-90</RefSource>
                <PMID Version="1">21496931</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Immunol. 2012 Jan 15;188(2):649-60</RefSource>
                <PMID Version="1">22156594</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Wound Repair Regen. 2012 Jan-Feb;20(1):38-49</RefSource>
                <PMID Version="1">22151742</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS Pathog. 2012;8(4):e1002645</RefSource>
                <PMID Version="1">22532799</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS Negl Trop Dis. 2012;6(5):e1644</RefSource>
                <PMID Version="1">22590660</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Dev Immunol. 2012;2012:361730</RefSource>
                <PMID Version="1">22811738</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Brain Behav Immun. 2012 Oct;26(7):1136-49</RefSource>
                <PMID Version="1">22841695</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Immunol. 2013 Jan;33(1):151-61</RefSource>
                <PMID Version="1">22926407</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS One. 2014;9(2):e88149</RefSource>
                <PMID Version="1">24505407</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS One. 2014;9(3):e87082</RefSource>
                <PMID Version="1">24603474</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mem Inst Oswaldo Cruz. 2014 Jun;109(3):289-98</RefSource>
                <PMID Version="1">24937048</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Infect Immun. 1999 Nov;67(11):5579-86</RefSource>
                <PMID Version="1">10531203</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mem Inst Oswaldo Cruz. 1999;94 Suppl 1:253-5</RefSource>
                <PMID Version="1">10677728</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Microbes Infect. 2000 Jul;2(8):851-66</RefSource>
                <PMID Version="1">10962268</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>N Engl J Med. 2000 Nov 9;343(19):1388-98</RefSource>
                <PMID Version="1">11070105</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Circulation. 2000 Dec 12;102(24):3003-8</RefSource>
                <PMID Version="1">11113053</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Pathol. 2001 Apr;158(4):1433-40</RefSource>
                <PMID Version="1">11290561</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Parasitol. 2001 May 1;31(5-6):588-91</RefSource>
                <PMID Version="1">11334946</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Autoimmun. 2001 Aug;17(1):99-107</RefSource>
                <PMID Version="1">11488642</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Microbes Infect. 2001 Oct;3(12):971-84</RefSource>
                <PMID Version="1">11580984</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Pathol. 2001 Nov;159(5):1723-33</RefSource>
                <PMID Version="1">11696433</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arthritis Rheum. 2002 Mar;46(3):785-92</RefSource>
                <PMID Version="1">11920416</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 2002 May 31;296(5573):1634-5</RefSource>
                <PMID Version="1">12040173</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Parasitol. 2003 Mar;33(3):293-9</RefSource>
                <PMID Version="1">12670514</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mem Inst Oswaldo Cruz. 2003 Apr;98(3):407-11</RefSource>
                <PMID Version="1">12886425</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cardiovasc Res. 2003 Oct 15;60(1):96-107</RefSource>
                <PMID Version="1">14522411</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Infect Dis. 2004 Jan 15;189(2):214-20</RefSource>
                <PMID Version="1">14722885</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Circulation. 2004 Feb 17;109(6):750-5</RefSource>
                <PMID Version="1">14970111</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Infect Immun. 2004 Sep;72(9):5283-91</RefSource>
                <PMID Version="1">15322024</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Rev Soc Bras Med Trop. 1989 Jul-Sep;22(3):113-8</RefSource>
                <PMID Version="1">2518608</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Infect Immun. 1998 Jun;66(6):2960-8</RefSource>
                <PMID Version="1">9596773</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Heart. 1999 Sep;82(3):279-85</RefSource>
                <PMID Version="1">10455076</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Microbes Infect. 2007 Jul;9(9):1104-13</RefSource>
                <PMID Version="1">17644389</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Immunol. 2007 Sep 15;179(6):4135-41</RefSource>
                <PMID Version="1">17785852</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Immunol. 2008 Feb;126(2):121-36</RefSource>
                <PMID Version="1">17916444</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mem Inst Oswaldo Cruz. 2008 Jun;103(4):375-85</RefSource>
                <PMID Version="1">18660993</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Scand J Immunol. 2008 Nov;68(5):516-25</RefSource>
                <PMID Version="1">18803607</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <OtherID Source="NLM">PMC4130030</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2014/798078</ArticleId>
            <ArticleId IdType="pubmed">25140115</ArticleId>
            <ArticleId IdType="pmc">PMC4130030</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25140114</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1466-1861</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>2014</Volume>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Mediators of inflammation</Title>
                <ISOAbbreviation>Mediators Inflamm.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Rotenone remarkably attenuates oxidative stress, inflammation, and fibrosis in chronic obstructive uropathy.</ArticleTitle>
            <Pagination>
                <MedlinePgn>670106</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1155/2014/670106</ELocationID>
            <Abstract>
                <AbstractText>Mitochondrial abnormality has been shown in many kidney disease models. However, its role in the pathogenesis of chronic kidney diseases (CKDs) is still uncertain. In present study, a mitochondrial complex I inhibitor rotenone was applied to the mice subjected to unilateral ureteral obstruction (UUO). Following 7-days rotenone treatment, a remarkable attenuation of tubular injury was detected by PAS staining. In line with the improvement of kidney morphology, rotenone remarkably blunted fibrotic response as shown by downregulation of fibronectin (FN), plasminogen activator inhibitor-1 (PAI-1), collagen I, collagen III, and ??-SMA, paralleled with a substantial decrease of TGF-?? 1. Meanwhile, the oxidative stress markers thiobarbituric acid-reactive substances (TBARS) and heme oxygenase 1 (HO-1) and inflammatory markers TNF-??, IL-1??, and ICAM-1 were markedly decreased. More importantly, the reduction of mitochondrial DNA copy number and mitochondrial NADH dehydrogenase subunit 1 (mtND1) expression in obstructed kidneys was moderately but significantly restored by rotenone, suggesting an amelioration of mitochondrial injury. Collectively, mitochondrial complex I inhibitor rotenone protected kidneys against obstructive injury possibly via inhibition of mitochondrial oxidative stress, inflammation, and fibrosis, suggesting an important role of mitochondrial dysfunction in the pathogenesis of obstructive kidney disease.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Sun</LastName>
                    <ForeName>Ying</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Nanjing Key Laboratory of Pediatrics, Nanjing Children's Hospital, Nanjing Medical University, Nanjing 210008, China ; Department of Nephrology, Nanjing Children's Hospital, Nanjing Medical University, Nanjing 210008, China ; Institute of Pediatrics, Nanjing Medical University, Nanjing, China ; Division of Nephrology, Department of Medicine, New York University Langone Medical Center, New York, NY 10016, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Yue</ForeName>
                    <Initials>Y</Initials>
                    <Affiliation>Nanjing Key Laboratory of Pediatrics, Nanjing Children's Hospital, Nanjing Medical University, Nanjing 210008, China ; Department of Nephrology, Nanjing Children's Hospital, Nanjing Medical University, Nanjing 210008, China ; Institute of Pediatrics, Nanjing Medical University, Nanjing, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhao</LastName>
                    <ForeName>Daqiang</ForeName>
                    <Initials>D</Initials>
                    <Affiliation>Department of Renal Transplantation, The Third Affiliated Hospital, Sun Yat-sen University, 600 Tianhe Road, Tianhe District, Guangzhou 510630, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ding</LastName>
                    <ForeName>Guixia</ForeName>
                    <Initials>G</Initials>
                    <Affiliation>Nanjing Key Laboratory of Pediatrics, Nanjing Children's Hospital, Nanjing Medical University, Nanjing 210008, China ; Department of Nephrology, Nanjing Children's Hospital, Nanjing Medical University, Nanjing 210008, China ; Institute of Pediatrics, Nanjing Medical University, Nanjing, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>Songming</ForeName>
                    <Initials>S</Initials>
                    <Affiliation>Nanjing Key Laboratory of Pediatrics, Nanjing Children's Hospital, Nanjing Medical University, Nanjing 210008, China ; Department of Nephrology, Nanjing Children's Hospital, Nanjing Medical University, Nanjing 210008, China ; Institute of Pediatrics, Nanjing Medical University, Nanjing, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Aihua</ForeName>
                    <Initials>A</Initials>
                    <Affiliation>Nanjing Key Laboratory of Pediatrics, Nanjing Children's Hospital, Nanjing Medical University, Nanjing 210008, China ; Department of Nephrology, Nanjing Children's Hospital, Nanjing Medical University, Nanjing 210008, China ; Institute of Pediatrics, Nanjing Medical University, Nanjing, China.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jia</LastName>
                    <ForeName>Zhanjun</ForeName>
                    <Initials>Z</Initials>
                    <Affiliation>Nanjing Key Laboratory of Pediatrics, Nanjing Children's Hospital, Nanjing Medical University, Nanjing 210008, China ; Department of Nephrology, Nanjing Children's Hospital, Nanjing Medical University, Nanjing 210008, China ; Institute of Pediatrics, Nanjing Medical University, Nanjing, China.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>07</Month>
                <Day>22</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Mediators Inflamm</MedlineTA>
            <NlmUniqueID>9209001</NlmUniqueID>
            <ISSNLinking>0962-9351</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Exp Med. 2000 Oct 2;192(7):1001-14</RefSource>
                <PMID Version="1">11015441</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Kidney Dis. 2014 Feb;63(2 Suppl 2):S63-83</RefSource>
                <PMID Version="1">24461730</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Cell Biol. 2001 Dec 10;155(6):1003-15</RefSource>
                <PMID Version="1">11739410</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Leukoc Biol. 2002 Sep;72(3):530-7</RefSource>
                <PMID Version="1">12223521</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Immunol. 2003 Mar 15;170(6):3254-62</RefSource>
                <PMID Version="1">12626584</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Am Soc Nephrol. 2003 Aug;14(8 Suppl 3):S241-5</RefSource>
                <PMID Version="1">12874439</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Kidney Int Suppl. 2003 Nov;(87):S105-12</RefSource>
                <PMID Version="1">14531782</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Invest. 2003 Nov;112(10):1486-94</RefSource>
                <PMID Version="1">14617750</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Am Soc Nephrol. 2004 Mar;15(3):674-86</RefSource>
                <PMID Version="1">14978169</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Kidney Int. 2004 Aug;66(2):597-604</RefSource>
                <PMID Version="1">15253712</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Kidney Int. 1988 Oct;34(4):487-93</RefSource>
                <PMID Version="1">3264355</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 1999 Mar 5;283(5407):1482-8</RefSource>
                <PMID Version="1">10066162</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2005 Jun 10;280(23):21763-72</RefSource>
                <PMID Version="1">15826936</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nephrol Dial Transplant. 2005 Aug;20(8):1582-91</RefSource>
                <PMID Version="1">15855201</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pediatr Nephrol. 2005 Oct;20(10):1369-75</RefSource>
                <PMID Version="1">15947978</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Annu Rev Genet. 2005;39:359-407</RefSource>
                <PMID Version="1">16285865</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Circ Res. 2014 Jan 31;114(3):524-37</RefSource>
                <PMID Version="1">24481843</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Trends Mol Med. 2014 Mar;20(3):179-87</RefSource>
                <PMID Version="1">24369898</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Circ J. 2014;78(4):803-10</RefSource>
                <PMID Version="1">24647412</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pharmacol Res. 2014 Mar;81:91-102</RefSource>
                <PMID Version="1">24602801</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Kidney Int. 2005 Dec;68(6):2918-29</RefSource>
                <PMID Version="1">16316385</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Physiol Cell Physiol. 2007 Jan;292(1):C52-8</RefSource>
                <PMID Version="1">16943247</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Nephrol. 2007;27(6):545-53</RefSource>
                <PMID Version="1">17785964</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Am Soc Nephrol. 2009 Apr;20(4):807-19</RefSource>
                <PMID Version="1">19297554</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Kidney Int. 2009 Jun;75(11):1145-52</RefSource>
                <PMID Version="1">19340094</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Pathol. 2009 Aug;175(2):580-91</RefSource>
                <PMID Version="1">19590041</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Cell Mol Med. 2009 Aug;13(8B):1866-76</RefSource>
                <PMID Version="1">20141610</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hypertension. 2012 Jan;59(1):122-8</RefSource>
                <PMID Version="1">22106404</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell Tissue Res. 2012 Jan;347(1):141-54</RefSource>
                <PMID Version="1">22105921</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Cell Physiol. 2012 Jun;227(6):2297-310</RefSource>
                <PMID Version="1">21928343</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nephrology (Carlton). 2012 May;17(4):311-21</RefSource>
                <PMID Version="1">22288610</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Physiol Renal Physiol. 2012 Jun 15;302(12):F1595-605</RefSource>
                <PMID Version="1">22492946</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Mol Med. 2013 Mar;31(3):628-36</RefSource>
                <PMID Version="1">23314838</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Physiol Renal Physiol. 2013 Aug 15;305(4):F520-31</RefSource>
                <PMID Version="1">23761667</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Physiol Renal Physiol. 2013 Dec 15;305(12):F1736-46</RefSource>
                <PMID Version="1">24107422</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS One. 2013;8(12):e83593</RefSource>
                <PMID Version="1">24349535</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pediatr Nephrol. 2000 Dec;15(3-4):290-301</RefSource>
                <PMID Version="1">11149129</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <OtherID Source="NLM">PMC4130131</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2014</Year>
                <Month>5</Month>
                <Day>5</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>10</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2014</Year>
                <Month>7</Month>
                <Day>22</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2014/670106</ArticleId>
            <ArticleId IdType="pubmed">25140114</ArticleId>
            <ArticleId IdType="pmc">PMC4130131</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="In-Data-Review">
        <PMID Version="1">25140055</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateCreated>
        <Article PubModel="Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1937-9145</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>7</Volume>
                    <Issue>339</Issue>
                    <PubDate>
                        <Year>2014</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Science signaling</Title>
                <ISOAbbreviation>Sci Signal</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Manipulation of receptor oligomerization as a strategy to inhibit signaling by TNF superfamily members.</ArticleTitle>
            <Pagination>
                <MedlinePgn>ra80</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1126/scisignal.2004948</ELocationID>
            <Abstract>
                <AbstractText>Signaling by receptor activator of nuclear factor ??B (RANK) in response to its ligand RANKL, which is a member of the tumor necrosis factor (TNF) superfamily of cytokines, stimulates osteoclast formation and bone resorption. Thus, this ligand-receptor pair is a therapeutic target for various disorders, such as osteoporosis and metastasis of cancer to bone. RANKL exists as a physiological homotrimer, with each monomer recognizing a single molecule of RANK or the decoy receptor osteoprotegerin (OPG), which inhibits osteoclastogenesis. We engineered a RANKL protein in which all three monomers of RANKL were encoded as a single polypeptide chain, which enabled us to independently control receptor binding at each binding interface. To generate an effective RANK inhibitor, we used an unbiased forward genetic approach to identify mutations in RANKL that had a 500-fold increased affinity for RANK but had decreased affinity for the decoy receptor OPG. Incorporating mutations that blocked receptor binding into this high-affinity RANKL variant generated a mutant RANKL that completely inhibited wild-type RANKL-induced osteoclastogenesis in vitro and bone resorption in mice. Our approach may be generalized to enable the inhibition of other TNF receptor signaling systems, which are implicated in a wide range of pathological conditions.</AbstractText>
                <CopyrightInformation>Copyright ?? 2014, American Association for the Advancement of Science.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Warren</LastName>
                    <ForeName>Julia T</ForeName>
                    <Initials>JT</Initials>
                    <Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nelson</LastName>
                    <ForeName>Christopher A</ForeName>
                    <Initials>CA</Initials>
                    <Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Decker</LastName>
                    <ForeName>Corinne E</ForeName>
                    <Initials>CE</Initials>
                    <Affiliation>Department of Orthopaedic Surgery, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zou</LastName>
                    <ForeName>Wei</ForeName>
                    <Initials>W</Initials>
                    <Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fremont</LastName>
                    <ForeName>Daved H</ForeName>
                    <Initials>DH</Initials>
                    <Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA. Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO 63110, USA. fremont@pathology.wustl.edu teitelbs@wustl.edu.</Affiliation>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Teitelbaum</LastName>
                    <ForeName>Steven L</ForeName>
                    <Initials>SL</Initials>
                    <Affiliation>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA. Division of Bone and Mineral Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA. fremont@pathology.wustl.edu teitelbs@wustl.edu.</Affiliation>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType>Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>08</Month>
                <Day>19</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Sci Signal</MedlineTA>
            <NlmUniqueID>101465400</NlmUniqueID>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>8</Month>
                <Day>21</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">7/339/ra80</ArticleId>
            <ArticleId IdType="doi">10.1126/scisignal.2004948</ArticleId>
            <ArticleId IdType="pubmed">25140055</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
